









I declare that this thesis was composed by myself and that the work contained
therein is my own, except where explicitly stated otherwise in the text. This work




The work described in this thesis was carried out under the supervision of Prof.
Mike Tyers. I began my postgraduate studies in the Tyers lab at the University
of Toronto in March 2005. I successfully reclassified into the PhD program in
December 2006. In October/November 2007 I transferred to the University of




I would like to thank Mike for introducing me to the fascinating world of discov-
eries and big visions that is research. At times it was overwhelming, but once
things fell into place and (almost) everything made sense, it was satisfying yet
challenging to be working in science.
I am very thankful that I had the chance to collaborate with the labs of Liz
Patton and Gerry Wright. These collaborations enabled me to see how powerful
chemical biology in S. cerevisiae can be when combined with screens in zebrafish
and clinically relevant fungal pathogens. These projects widened my horizon and
I came to appreciate the budding yeast even more.
I would like to thank everyone in the Tyers lab, past (Toronto) and present
(Edinburgh), for interesting discussions, advice and encouragement. I am grateful
for advice, time and comments from Juri Rappsilber, Liz, Christine and Jan while
I was writing my thesis.
I want to thank my family for being supportive of my work even though they
probably still don’t know what exactly I am doing. A big thank you also goes out
to all my friends in Berlin, Auckland, Toronto and here in Edinburgh, especially
the non-scientist ones who were very understanding, interested in my work and
supporting. I am sure a few of them now think of me every time they hear the
word ’yeast’.
Relationships are complicated as it is. It gets even more difficult when you
iii
work together. But I think we managed somehow and we definitely both learned
a lot. So thank you Jan, for being so patient with me, especially in times when
I was down. I value the time you took to answer all my questions related to




The budding yeast S. cerevisiae is widely used as a model organism to study
biological processes that are conserved among eukaryotes. Different genomic ap-
proaches have been applied successfully to interrogate the mode of action of small
molecules and their combinations. In this thesis, these technologies were ap-
plied to different sets of chemical compounds in the context of two collaborative
projects. In addition to insight into the mode of action of these molecules, novel
approaches for analysis of chemical-genetic profiles to integrate GO annotation,
genetic interactions and protein complex data have been developed.
The first project was motivated by a pressing need to design novel therapeutic
strategies to combat infections caused by opportunistic fungal pathogens. Sys-
tematic screens of 1180 FDA approved drugs identified 148 small molecules that
exhibit synergy in combination with fluconcazole, a widely used anti-fungal drug
(Wright lab, McMaster University, Canada). Genome-wide chemical-genetic pro-
files for 6 of these drugs revealed two different modes of action of synergy. Five of
the compounds affected membrane integrity; these chemical-genetic interactions
were supported by microscopy analysis and sorbitol rescue assays. The sixth
compound targets a distinct membrane-associated pathway, sphingolipid biosyn-
thesis. These results not only give insight into the mechanism of the synergistic
interactions, they also provide starting points for the prediction of synergistic
anti-fungal combinations with potential clinical applications.
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The second project characterised compounds that affected melanocytes in a
chemical screen in zebrafish (Patton lab, Edinburgh). Chemical-genetic screens
in S.cerevisiae enabled us to show that melanocyte pigmentation reducing com-
pounds do so by interfering with copper metabolism. Further, we found that
defects in intracellular AP1 and AP3 trafficking pathways cause sensitivity to low
copper conditions. Surprisingly, we observed that the widely-used MAP-kinase
inhibitor U0126 affects copper metabolism. A nitrofuran compound was found to
specifically promote melanocyte cell death in zebrafish. This enabled us to study
off-target effects of these compounds that are used to treat trypanosome infec-
tions. Nifurtimox is a nitrofuran prodrug that is activated by pathogen-specific
nitroreductases. Using yeast and zebrafish we were able to show that nitrofurans
are also bioactivated by host-specific aldehyde dehydrogenases suggesting that a
combination therapy with an aldehyde dehydrogenase inhibitor might reduce side
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The discovery of small molecules that elicit a specific effect in the cell is of interest
for different reasons. Small molecules can be useful tools to interrogate functional
and mechanistic aspects of biological pathways. They can also be drug leads for
the development of therapeutic agents. The last twenty years have seen increased
efforts at this interface between biology and chemistry which ultimately resulted
in a community of scientists who identify themselves as chemical biologists. The
term “Chemical Biology“ came into wide use in the 1990s, but the origins of this
discipline can be traced back right to the beginnings of biology and chemistry as
distinct sciences in the 18th century. A number of journals are dedicated to the
publication of papers that aim to understand and manipulate biological systems
at the molecular level. The first of these journals, “Current Opinions in Chemical
Biology“, was launched in 1997 by Elsevier. This was followed by “BMC Chem-
ical Biology“ in 2001. Nature, ACS and Springer followed suit in 2005, 2006 and
2007, respectively. Wiley-Blackwell renamed their “Journal of Peptide Research“
into “Chemical Biology & Drug Design“ in 2006. There is still a debate if chem-
ical biology really is a new field of study or if established fields like biochemistry,
cell biology and pharmacology are simply being rebranded. Even though chemi-
cal biology integrates methodologies traditionally used in these fields, the current
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multi-disciplinarity in science has allowed them to blend into a distinct discipline
that is defined by the desire to understand and manipulate biological systems.
Chemical biology has already succeeded in changing the way biologists view small
molecules in two important ways. The definition of a compound’s mode of ac-
tion has been pushed towards greater accuracy. It also succeeded to highlight
the importance of small molecules in biological pathways and their potential to
manipulate biological systems.
One of the biggest challenges that chemical biologists face is the characteri-
sation of the mode of action of small molecules. Genomic methods in yeast have
been successfully applied to this problem (Section 1.2).
Drug discovery currently faces many challenges because target-based drug dis-
covery has reached its limit, leading to fewer new drugs being approved each year
by the U.S. Food and Drug Administration (FDA) in the last decades. Further,
developing drug resistance renders drugs ineffective, increasing the need for new
therapies. New approaches for drug discovery are urgently needed. One approach
to overcome the limitations of in vitro chemical screens is the use of model or-
ganisms in high-throughput screens (Section 1.3.3). Other strategies to speed
up the process of drug discovery include repurposing of already approved drugs
(Section 1.3.4) as well as drug combinations to develop more effective and specific
therapies (Section 1.3.5). Rational approaches for the discovery of effective drug
combinations are being developed based on functional genomics experiments to
interrogate biological systems.
1.1 Chemical Biology
Chemical Biology can be both, the use of chemistry to understand biological pro-
cesses and nature inspiring developments that advance chemistry. One of the
earliest examples of this approach must be the experiments on gases by Joseph
Priestley in the 18th century. Priestley, who was a natural philosopher among
other things, identified various gases including oxygen and nitrous oxide. He used
mice in his experiments into the effects and chemistry of these gases (Morrison
& Weiss, 2006). Another important contribution to chemical biology came from
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Friedrich Wöhler (1800 - 1882) when he managed to synthesise urea. This proved
that it is possible to synthesise biological compounds from inorganic substances
(Morrison & Weiss, 2006). Cellular imaging became possible because of the de-
velopment of chemical methods. Anna Atkins (1799 - 1871) who was a botanist
and photographer also contributed to the development of imaging techniques.
She grew up surrounded by scientists like Sir John Herschel and William Henry
Fox Talbot, because her father, John George Children, a fellow of the Royal Soci-
ety, was a British chemist, mineralogist and zoologist. Anna learned photography
from Talbot and she made use of Herschel’s cyanotype process for monochromatic
colour photography to document botanical specimen (Morrison & Weiss, 2006).
The technique that Anna developed revealed intricate details of her specimen.
Her images are still displayed in art galleries like the J Paul Getty Museum1.
Dyes continued to play an important role in the 19th and early 20th century. For
example, the development of Rudolf Virchow’s theory of cellular pathology relied
on dyes to stain fine structures within the cell. Paul Ehrlich visualised bacteria
with specific dyes and realised that this could be used to deliver toxins to bacteria
to kill them. This led to his idea of the ’magic bullet’.
These are examples of how chemicals can be used to advance biology. Chem-
ical biologists today are still interested in using small molecules to interrogate
biological processes, such as mitosis (Mayer et al., 1999), and to understand bi-
ological complexity of bacteria for example (reviewed in Falconer et al., 2011).
Probing biological systems with small molecules has many advantages over tra-
ditional genetic methods. Timing of compound treatment is a big advantage in
several aspects. Most compounds act rapidly after addition, allowing the response
to be observed by imaging and preventing cells from adapting to the perturbance
as is the case with gene deletions. Further, in in vivo studies, the time point of
drug treatment can be varied to study different aspects of development. Nor-
mally, compound treatment is reversible, allowing the study of lasting effects of
compound exposure. The time and dose of compounds can be varied to suit
the current assay. Different compounds can be easily combined to assess effects
of treatment with multiple compounds and to identify compound interactions.
1http://www.getty.edu/art/gettyguide/artMakerDetails?maker=1542
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Compounds are also not limited to a specific strain or species. Their effect can
easily be assessed in mutant strains and in other organisms. These molecular
probes can also have therapeutic value. One disadvantage of small molecular
probes compared to genetic methods is that not every protein can be targeted.
Hopkins & Groom (2002) for example estimate that only 10% of the genome of
different species are ’druggable’. Another hurdle that has to be taken is the in-
terrogation of the mode of action of small molecules. The advent of functional
genomics has played an important role in elucidating the mechanisms by which
small molecules exert their action.
1.2 Functional genomics tools in S. cerevisiae to
interrogate mode of action of small molecules.
The availability of complete genome sequences was met with great expectations
for drug discovery. The sequence of the human genome allows for novel ap-
proaches to understand and characterise diseases to develop new drugs. The
genome sequences of pathogens offer the possibility to identify pathogen-specific
drug targets for the development of antibiotic and antifungal therapies. Chemical
genomics enables the development of new strategies for drug discovery. Rather
than finding drugs for known protein targets, it is now possible to find compounds
that elicit the desired effect and to then investigate the mode of action of that
compound. Functional genomic approaches in the budding yeast Saccharomyces
cerevisiae played an important role in the development and implementation of
chemical genomic methods to elucidate the targets of known and novel com-
pounds.
1.2.1 The yeast deletion set as a resource for chemical
genomics
The publication of the genome sequence of the budding yeast (Goffeau et al., 1996)
was soon followed by collaborative efforts to generate genome-wide collections of
yeast deletion strains (Winzeler et al., 1999; Giaever et al., 2002). Each of the
4
6000 genes was individually replaced with the dominant drug resistance marker
kanMX using a PCR-based gene deletion strategy. The aim of this effort by the
Saccharomyces Genome Deletion Project was the assignment of functions to all
open reading frames (ORFs) in the yeast genome through large-scale phenotypic
analysis. The deletion project revealed that about 5000 genes are dispensable
for growth in the budding yeast. Many genome-wide screens were conducted to
interrogate the roles of these non-essential genes in various biological processes
like bud site selection (Ni & Snyder, 2001), vacuolar protein sorting (Bonangelino
et al., 2002), telomere length maintenance (Askree et al., 2004) and centromeric
cohesion (Marston et al., 2004). Tucker & Fields (2004) identified genes important
for resistance against oxidative and chemical stress in liquid cultures in 96-well
plates. In these screens, each deletion strain was assessed individually. It is
also possible to conduct competitive growth assays with pooled deletion strains.
Deletion strains in the collection are ’barcoded’, enabling quantification of each
strain in a culture of pooled deletion strains (Shoemaker et al., 1996). These
molecular tags are sets of 20 base-pairs that are unique to each deletion strain.
Two such tags were placed up- and downstream of the drug resistance marker
during deletion strain constructions. Strain abundance can be assessed with
barcode microarrays that represent the barcodes of all deletion strains (Cook
et al., 2008). This approach allows the identification of deletion strains that
are sensitive or confer resistance under specific growth conditions or in response
to compound treatment (Giaever et al., 2002). For example, this method was
used to identify genes that are required for resistance to UV radiation (Birrell et
al., 2001) and to explore the molecular basis for off-target effects of psychoactive
drugs (Ericson et al., 2008). Large-scale profiling of the deletion sets against many
different compounds and conditions revealed phenotypes for nearly all genes and
provides a rich dataset to explore the function of genes as well as the mode of
action of small molecules (Hillenmeyer et al., 2008).
Competitive growth assays have several advantages compared to approaches
that test each deletion strain individually on agar plates or in 96 well plate format.
Screening of pooled deletion mutants is much more time- and resource-effective
since the whole deletion set can be screened in culture volumes as low as 1 mL. For
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chemical genomic screens this also means that the amount of compound needed
is minimal. The pooled approach also greatly reduces experimental variance
because all strains are screened simultaneously under the same conditions.
1.2.2 Haplo-insufficiency screens to identify drug targets
The functions of essential genes can be assessed with heterozygous deletion strains
where only one copy of each gene is deleted. These strains have been used in drug-
induced haploinsufficiency profiling aimed at identifying biological targets of small
molecules (Giaever et al., 1999; Lum et al., 2004). The reasoning behind this ap-
proach is that lowering the dose of a gene encoding an essential drug target results
in hypersensitivity to treatment with that drug. Giaever et al. (1999) performed
proof of principle experiments with single deletion strains and with a pool of 223
heterozygous deletion mutants. First they showed that strains heterozygous for
the known essential drug target genes HIS3, ALG7, RNR2, TUB1/2 or ERG11
show increased sensitivity to 3-amino-triazole, tunicamycin, hydroxyurea, beno-
myl and fluconazole, respectively. They then succeeded in identifying alg7/ALG7
as one of three strains that were highly sensitive to tunicamycin treatment from
a pool of 223 heterozygous deletion strains. Lum et al. (2004) screened 78 com-
pounds against pools of 3503 heterozygous deletion strains to characterise the
cellular effects of these medically relevant small molecules. The majority of com-
pounds yielded 10 or less strains with drug-specific sensitivities. Analysis of the
results confirmed known targets for many compounds and suggested novel targets
for well described compounds. For example, the vasodilator molsidomine sensi-
tised the erg7/ERG7 strain and one of its metabolites was confirmed to inhibit
ergosterol biosynthesis at the lanosterol synthase step in the budding yeast. The
metabolite also inhibited lanosterol synthase purified from rat liver which could
explain the cholesterol lowering effects of molsidomine that have been reported
(Chassoux, 1989). In another study, 81 psychoactive drugs were found to inhibit
yeast growth and were examined for their effects on biological processes using
the heterozygous deletion set (Ericson et al., 2008). The results provided insights
into side-effects associated with drug treatment. Interestingly, Lum et al. (2004)
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and Ericson et al. (2008) identified neo1/NEO1 strains as sensitive to various
antidepressive drugs. NEO1 encodes an aminophospholipid translocase (flippase)
and Spitzer et al. (2011) subsequently showed that cationic amphiphilic drugs,
like the antidepressiva, cause membrane perturbation probably by intercalating
into one of the two layers. These and other studies (Giaever et al., 2004; Hillen-
meyer et al., 2008) confirm the utility of the heterozygous deletion set to identify
biological targets of small molecules and provide a rich data set that can be used
to uncover pathways affected by the compounds that were screened.
It is important to keep in mind that not all compounds inhibit the function of
an essential protein in the cell. In the case of compounds that target several non-
essential proteins or cause damage to cellular structures (DNA or cell membranes,
for example), induced haploinsufficiency profiling will not be able to identify the
direct target.
1.2.3 Chemical-genetic profiles reveal drug target path-
ways
Competitive growth assays with the haploid or homozygous deletion sets typically
yield larger numbers of sensitive strains than the haploinsufficiency screens. The
result of such a screen is called the chemical-genetic profile of a compound. Drug-
hypersensitivity of a deletion strain is a chemical-genetic interaction, analogous
to genetic interactions that have been explored to characterise the function of all
yeast genes (Costanzo et al., 2010). The deletion set has been used in systematic
screens to identify the functional interactions of genes (Tong et al., 2004). These
genetic interactions, such as synthetic lethality, can also be used to link bioactive
compounds to their cellular target pathways (Parsons et al., 2004; Parsons et
al., 2006). Integration of genetic and chemical-genetic interactions revealed that
there is an overlap between the chemical-genetic profiles of compounds and the
genetic interactions of their protein targets. However, this overlap is not complete,
reflecting the fact that drugs do not simply mimic deletion of the target gene and
that they have additional effects in the cell. Drug treatment also sensitises strains
deleted in proteins involved in general stress response, drug metabolism and drug
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transport.
In the same way that genes with similar functions display a similar spectrum
of genetic interactions, compounds with similar mode of actions were found to
share similar chemical-genetic profiles, allowing clustering and classification of
compounds based on these profiles (Parsons et al., 2006).
1.2.4 Dosage-suppression
Increased dosage of a target protein can confer resistance to drug treatment. Drug
targets have been successfully identified based on the dosage-dependent suppres-
sion of drug toxicity. Traditionally, wild type yeast is transformed with a random
genomic library and resistance of the resultant transformants to drug treatment
is assessed. The drug targets of cycloheximide (Fried & Warner, 1982), tuni-
camycin (Rine et al., 1983), ketoconazole (Launhardt et al., 1988) and soraphen
(Vahlensieck et al., 1994) were identified with this technique.
Advances in genome-wide techniques and the creation of genome-wide overex-
pression libraries enabled systematic overexpression screens. The method devel-
oped by Luesch et al. (2005) used a yeast genomic library, but for the resistance
screens transformants were arrayed in 384-well format. This allowed compari-
son of screen results for different compounds allowing identification of general
and specific suppressors. Other approaches monitor the abundance of transfor-
mants using microarrays to identify genes that confer resistance to drug treatment
(Butcher et al., 2006; Abruzzi et al., 2007; Hoon et al., 2008).
1.2.5 Spontaneous drug-resistant mutants
Chemical-genomic approaches discussed so far all involve reverse-genetic approaches.
Random mutagenesis and subsequent selection of mutants resistant to a com-
pound is a forward genetic approach that has also been used to identify targets
of compounds. For example, Kitamura et al. (2009) identified β-1,6-glucan syn-
thase as the target of a compound that selectively targets the fungal cell wall by
analysis of a resistant S. cerevisiae mutant.
There are different strategies for the identification of the mutations responsible
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for drug resistance. Dominant mutations can be mapped by creating a genomic
DNA library from a resistant mutant that is transformed into wild type yeast and
transformants that show resistance are isolated. Mapping of recessive mutations
is usually done by transforming the resistant mutant with a genomic library from
a wild type strain followed by identification of transformants that are not resistant
anymore, involving replica plating steps. Ho et al. (2009) developed a method
for more efficient mapping of resistant mutations. They created a molecular
barcoded yeast ORF library that can be transformed into resistant mutants and
allows rapid fitness assessment of all transformants to be done simultaneously.
The deletion set can also be used for rapid mapping of drug resistance mu-
tations. A method called synthetic genetic array mapping (SGAM) has been
described (Jorgensen et al., 2002) where every deletion strain can be considered
a marker along the genome of S. cerevisiae. Mating of a resistant mutant to the
whole deletion collection would reveal the chromosomal location of the suppressor
allele because it is impossible to obtain strains that carry the resistance allele and
the deletion marker when they are linked.
1.2.6 High-content screening
Intracellular changes in response to compound treatment can be monitored by
fluorescence microscopy. Ohnuki et al. (2010) derived 500 morphological param-
eters from yeast after treatment with compound and the obtained parameters
were compared to those of deletion mutants to identify the molecular target of
the drugs. The authors successfully recovered known targets of four different
drugs. The effect of drugs on mammalian cells has been assessed in this way, too
(Perlman et al., 2004; Young et al., 2008).
1.2.7 Expression profiling
Changes in gene expression in response to small molecule treatment have been
used to characterise the effects of small molecules on cells (Hughes et al., 2000).
Comparing gene expression profiles of deletion mutants with gene expression in
response to drug treatment allowed for Erg2 to be identified as the drug target of
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the topical anaesthetic dyclonine. Cytosolic aldehyde dehydrogenase (Ald6) was
identified as the target of compounds that suppress the toxicity of FK506 in yeast
(Butcher & Schreiber, 2004). The use of expression profiling in various species
for the interrogation of drug target pathways, a drug’s specificity and pathways
downstream of the drug target has been reviewed in Butcher & Schreiber (2005).
The “Connectivity Map” is an approach to use gene expression profiles of hu-
man cells treated with small molecules to identify functional connections among
diseases (Lamb et al., 2006).
1.2.8 Chemical-chemical interactions
The biological activity of compounds can be profiled by testing for chemical-
chemical interactions with a set of compounds with known mode of action. Farha
& Brown (2010) combined 186 bioactive compounds with 14 known antibiotics
and identified promising synergistic interactions with the known antibiotics. They
were also able to generate hypotheses about the potential mode of action for
many compounds and confirmed these predictions for two compounds. Eight
compounds that were promiscuously synergistic were found to be membrane-
active.
This approach is easily transferrable to other species because genome-wide
libraries are not required.
1.3 Challenges in drug discovery
1.3.1 A short history of drug discovery
Herbal potions and wound dressing have been used for a very long time. An-
cient Egyptian medicine dates back to 3300 BC and was well documented. The
Egyptian Ebers Papyrus (1550 BC) is the most comprehensive record of Egyptian
medicine known today. It is was bought by Georg Ebers in 1872/73 in Thebes
and is currently kept at the library of the University of Leipzig2. Chinese and An-
cient Greek medicine also have very long traditions. Traditional Chinese medicine
2http://www.ub.uni-leipzig.de/site.php?page=die ubl/sosa/scholl4
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looks back on over 2000 years of history and includes herbal medicine, acupunc-
ture, massage and diet. The first Greek medical school opened 700 BC and this
is where the practice of observing patients has been established. Hippocrates is
considered the ”Father of Medicine” and the Hippocratic Oath for physicians is
still in use today.
Despite such a long history of medicine, only a handful of drugs were available
at the beginning of the 20th century. These included cocaine and morphine
that were used as local anaesthetics, aspirin for pain and fever relief, digitalis
for the treatment of heart conditions, antipyrine, a painkiller, and quinine to
treat malaria. These drugs have been discovered based on observations resulting
from accidental exposure of animals or humans to small molecules. William
Withering learned about the use of digitalis to treat congestive heart failure from
an old folk herbalist. He succeeded in isolating digitalis as the active ingredient
in the late 18th century (Hauptman & Kelly, 1999). These discoveries provided
scientists with the knowledge that there are bioactive compounds. The discovery
of the causes of infectious diseases by Louis Pasteur and Robert Koch was also a
key development to advance medicine. Later, Louis Pasteur also discovered the
principle of immunisation.
The early 20th century saw the first systematic attempts to find drugs. Paul
Ehrlich synthesised and tested 900 arsenical compounds on mice infected with
trypanosomes which eventually led to the discovery of the syphilis treatment
salvarsan in 1909, the first man made antibiotic. Ehrlich also postulated that
parasites have ’chemoreceptors’ that are unique to them and that they could
be exploited to treat diseases by delivering toxins with ’magic bullets’. The year
1929 saw the discovery of the β-lactam antibiotic penicillin by Alexander Fleming.
While studying staphylococcal variants he noticed that one of his petri dishes was
contaminated with mould and in the vicinity of the fungus, the Staphylococcus
colonies were transparent, an indicator of bacterial lysis (Fleming, 1929). It would
take another decade before penicillin was used in hospitals. Following the success
of penicillin, many companies focused on the discovery of antibiotics (Drews,
2000) and the 1950s saw the discovery of non-lactam antibiotics (Fischbach et
al., 2009).
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The first cancer chemotherapeutics and antipsychotics were also discovered in
the 1950s. AIDS had a big influence on the drug development and research in the
field of immunology in the 1980s. In addition, this was the time when resistance to
drugs first emerged, motivating further research. The growing understanding of
human physiology and disease led to rational drug design. Robotics and automa-
tion as well as advances in combinatorial chemistry allowed for large chemical
libraries to be screened for bioactivity by pharmaceutical companies.
1.3.2 Current approaches to drug discovery
There are several approaches in drug discovery that are based on existing drugs.
Therapies can be developed that re-optimise drugs that are already used to treat
a specific disease. A method that is widely used is the combination of known
drugs. Many diseases are multi-factorial involving several genetic and environ-
mental factors and could therefore be treated more effectively with drug combina-
tions (Reich & Lander, 2001; Loktionov, 2003; Kaplan & Junien, 2000). There is
also less potential for drug resistance to develop. Treatments for HIV, cancer and
bacterial infections are often combinations of drugs. The concept of drug com-
binations is explored in more detail in Section 1.3.5. Drug replacement or drug
rotation is another approach to stem the tide of drug resistance. This method
was successfully used in Malawi, where chloroquine was replaced nationwide by
sulfadoxine-pyrimethamine because the prevalence of chloroquine resistant Plas-
modium falciparum was about 85% (Kublin et al., 2003; Laufer et al., 2006).
Eight years later, in 2000, this value was only 13% and chloroquinine can now be
used again to treat malaria. Ideally, it would be used in combination with other
drugs to prevent the re-emergence of resistant strains. There are also many drugs
that were abandoned due to unwanted side-effects. These could be reconsidered
and their dosing or formulation modified to reduce side effects. As shown in
Chapter 4, it is also possible to devise drug combinations to minimise side effects
of an otherwise effective drug.
Repurposing of known drugs is a very time and cost effective way to dis-
cover new treatments for diseases. Different approaches and resources as well as
12
advantages of drug repurposing are described in detail in Section 1.3.4.
The discovery of new compounds with bioactivity has mostly been applied in
the context of target-based approaches to drug design that are still widely used.
The advances in robotics and automation as well as combinatorial chemistry en-
abled screens of large synthetic chemical libraries against purified target proteins
to identify compounds that modulate the activity of the protein in the desired
way. Increasingly, libraries of natural products and extracts from plants or mi-
croorganisms are used in screens as well. These screens can also be done in silico
if the structure of the protein target is known. The structures of large chemical
libraries can be used by cheminformatics docking algorithms. For example, in
silico drug discovery in the context of neglected diseases is reviewed in Ekins et
al. (2011).
The exact number of unique proteins that are targeted by FDA approved drugs
has been debated (Overington et al., 2006; they stated the number as 324). It is
clear however, that it is definitely much smaller than the number of genes. The
advent of functional genomics advances the understanding of disease and enables
the identification of new potential drug targets (Hartwell et al., 1997). The
concept of synthetic lethality is applied to target discovery in cancer (reviewed
in Chan & Giaccia, 2011). RNAi screens have been successfully used to identify
pathways that can be targeted in combination therapies to treat cancer (Bauer et
al., 2010; Seyhan et al., 2011). Further, in vivo screens could be integrated with
the target-based approach to identify new targets for drug discovery (Sams-Dodd,
2005; Section 1.3.3).
There has been a steady decline in the number of new drugs approved by the
FDA in the last two decades despite increased spending on research and devel-
opment. In addition, very few new drug classes have been discovered in the last
decades to treat infections, for example (Fischbach et al., 2009). Emerging resis-
tance increases the need for new therapies (Clatworthy, 2007). Organism-based
drug discovery (Section 1.3.3), drug repurposing (Section 1.3.4) and combinations
of drugs (Section 1.3.5) are three strategies to bring much needed innovation into
the field of drug discovery to meet these demands for new drugs.
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1.3.3 Organism-based drug discovery in the zebrafish
Many of the limitations of target-based drug discovery can be overcome by screen-
ing chemical libraries in model organisms. Such screens would assess compound
activity in the physiological context and subsequent tests for effectiveness, side
effects, toxicity and pharmacokinetics of hit compounds are not necessary because
the effect of small molecules on a whole organism is observed during screening.
The use of model organisms allows the discovery of new pathways and proteins
that can be targeted to treat diseases. The range of observable phenotypes can
also be expanded to include development, physiology and behaviour. Model or-
ganisms that have been used in high-throughput chemical screens are the ne-
matode Caenorhabditis elegans, the fruitfly Drosophila melanogaster and the ze-
brafish Danio rerio (reviewed in Giacomotto & Ségalat, 2010). Kwok et al. (2006)
screened 14,000 compounds in C. elegans and identified over 300 compounds that
caused various phenotypes. They also investigated the mode of action of a com-
pound that resembles a class of widely prescribed anti-hypertension drugs. A
genetic suppressor screen in C. elegans allowed them to identify L-type calcium
channels as the target of this compound. Drosophila was shown to be amenable
to chemical screens and antiepileptic drug candidates have been identified by
Stilwell et al. (2006).
Zebrafish is a useful model to study human diseases because it is much more
similar to mammals with respect to its anatomy and physiology than the inver-
tebrates C. elegans and D. melanogaster. It is also probably best established as a
tool for high throughput screens (Patton & Zon, 2001; Taylor et al., 2010). Pio-
neering work by George Streisinger revealed the potential of zebrafish for genetic
screens (Streisinger, 1981). The first large-scale genetic screens in this vertebrate
identified many genes that are essential during development of zebrafish embryos
(Driever et al., 1996; Haffter et al., 1996). The screens also resulted in pheno-
types that resemble human genetic disease conditions and validated zebrafish as a
model for biological processes in vertebrates. These high-throughput studies were
feasible because the generation time of zebrafish is fairly short (only 3-4 months),
they have a large progeny size of 100 to 200 eggs, and recessive mutations can
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be recovered within two generations. The assessment of phenotypes is possible
because the transparent zebrafish embryos develop outside the mother and at
6 days post fertilisation most of the organs and tissues are fully developed and
clearly visible. The ease of waterborne treatment makes the zebrafish amenable
to high-throughput chemical screens. Compounds can simply be added to the
media and are absorbed through skin and gills. The small size of the embryos
allows for screens to be conducted in 96- or 384-well plates with several embryos
per well. The embryos are able to survive for days on the nutrients in the yolk
sac. The zebrafish is now established as a vertebrate model for drug discovery
screens (MacRae & Peterson, 2003; Langheinrich, 2003; Zon & Peterson, 2005;
Peal et al., 2010; Taylor et al., 2010).
The first chemical high-throughput screen in zebrafish was conducted by Pe-
terson et al. (2000). Following compound treatment, embryos were analysed for
phenotypes relating to the central nervous system, the cardiovascular system, the
ear and the skin with a dissecting microscope. Screening of only 1100 compound
yielded modifiers of all four systems. Milan et al. (2003) screened a small set of
100 compounds for effects on the cardiovascular system. In their 96-multi-well
set-up they used automated fluorescence microscopy to monitor the heart rate of
embryos expressing GFP in the myocardium. A screen for cell cycle inhibitors
emphasised the importance of organism-based screening. From a library of over
16,000 compounds (DIVERSet from Chembridge), Murphey et al. (2006) identi-
fied 14 compounds that were not found previously to have an effect on cell cycle
even though these compounds were screened for mitotic effects in mammalian cell
lines several times (for example in Haggarty, 2000). In addition, 7 of these newly
identified compounds showed activity in the developing embryos only. Murphey
and colleagues went on to show that 3 of these compounds were inactive in vitro
because of the presence of serum that is used to culture cell lines. The remaining
4 compounds are most likely activated by embryo metabolism.
Zebrafish can also be used in behaviour-based screens because touch, sight and
behavioural responses can easily be monitored. The Peterson lab was able to find
new psychoactive compounds and to identify their molecular targets using a high-
throughput approach in zebrafish (Kokel et al., 2010). The movement of zebrafish
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embryos in response to light and touch stimuli was converted into behavioural
barcodes amenable to computational analysis. Compounds with similar mode
of action elicited similar patterns of behaviour and therefore clustered together
based on their barcodes.
Zebrafish strains that model human disease conditions can be used in screens
to identify potential drug leads. Compounds that suppress the cardiovascular
phenotype in a zebrafish mutant were readily identified by Peterson et al. (2004).
Even diseases without known target pathways for which zebrafish models exist are
amenable to this approach. Zebrafish has also successfully been used to study the
progression of infections with Mycobacterium marinum (Davis et al., 2002) and
Salmonella typhimirium (Van der Sar et al., 2003). These infection models could
eventually be used for in vivo identification of novel antimicrobial compounds in
the host-pathogen context (Mukhopadhyay & Peterson, 2006).
These examples show that it is possible to assess the effect of 1000s of com-
pounds in high-content screens in zebrafish. The drug discovery assays that can
be conducted in zebrafish include drug discovery for diseases for which mod-
els exist in zebrafish like various cancers, infectious and vascular diseases. It is
also possible to screen for neuroactive compounds. Further, organism-based drug
screens can also uncover pro-drugs that rely on metabolism to be activated that
would be missed in in vitro screens.
1.3.4 Repurposing of drugs
A drug discovery strategy that has garnered considerable interest in the scien-
tific community over last few years is the repurposing or repositioning of drugs
(Ashburn & Thor, 2004; Chong & Sullivan, 2007; Boguski et al., 2009). As the
Scottish pharmacologist and Nobel laureate James W. Black famously put it ”The
most fruitful basis for the discovery of a new drug is to start with an old drug”.
Amy Patterson, NIH Associate Director for Science Policy pointed out recently
that most drugs fail during the last stages of development, not because they are
toxic, but because of lack of efficacy. She further said that the estimated success
rate of repurposed drugs is 30%.
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While there are numerous examples of serendipitous discoveries of new uses
for known drugs, the last five years saw an increase in systematic screens to un-
cover new therapeutic uses for old drugs. Repurposing of existing drugs is a very
attractive approach since it is faster and less costly than the usual route of drug
discovery because bioavailability and biosafety profiles already exist and phar-
macokinetics are known as well. Further, chemical optimisation, manufacturing
and formulation have been worked out already. The possibility to identify new
therapies rapidly, means that this approach is suited to tackle emerging diseases
like flu or resistant pathogens. Lower costs associated with this strategy makes
it applicable to neglected diseases (Section 1.3.4)
The ’promiscuous nature’ of drugs is one factor that makes the concept of
drug repurposing work. A single drug often interacts with multiple pathways or
proteins in the cell, which can lead to undesired side-effects (Keiser et al., 2009).
However, drugs that are found to be safe in human, may prove to have multiple
therapeutic uses. This is known as the ’known compound-new target’ approach.
The success of drug repurposing is also based on the fact that target proteins
or pathways might actually play a critical role in more than one disease, thus
allowing for drugs with a specific target to be used in a new indication.
Approaches for the discovery of new indications for old drugs
There are numerous repurposed drugs that are marketed for new therapeutic in-
dications already and examples are given in Ashburn & Thor (2004) as well as
Chong & Sullivan (2007, supplementary materials). Most of these new indications
for old drugs have been discovered by chance. Systematic approaches based on
large-scale screens are feasible now because various chemical libraries of known
drugs are available (see below). There are several examples of screens to identify
therapies for rare and neglected diseases (Section 1.3.4). Neuroprotective prop-
erties of β-lactam antibiotics were revealed in a screen of 1,040 FDA-approved
drugs (Rothstein et al., 2005). Ceftriaxone was one of the 15 β-lactams that
were identified as active and when administered to animals it causes increased
expression and activity of glutamate transporters which play an important role in
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glutamate toxicity. In a mouse model of amyotrophic lateral sclerosis, ceftriaxone
delayed loss of neurons and muscle strength, and lead to increased survival. In
another screen, Balgi et al. (2009) assessed the effect of more than 3500 approved
and off-patent compounds on mTORC1. They succeeded in identifying inhibitors
of mTORC1 which is indicated in diseases like tuberous sclerosis, diabetes, car-
diovascular disease and cancer.
Boguski et al. (2009) predict that the use of post marketing surveillance
information (managed by the FDA in the USA and EMA in Europe) as well as
data mining of hospital records will play an important role in the identification,
assessment and understanding of beneficial drug side effects which might lead
to new indications for known drugs (Keiser et al., 2009). Many such knowledge-
based drug repositioning approaches have been developed and have been reviewed
by Dudley et al. (2011) and Ekins et al. (2011).
Chemical libraries for systematic drug repositioning screens
There are several chemical libraries that consist of approved drugs and bioactive
compounds. The LOPAC1280 Library of Pharmacologically Active Compounds is
available from Sigma-Aldrich3 and consists of 1,280 marketed drugs and pharma-
ceutically relevant compounds that represent all major drug classes. The SPEC-
TRUM Collection4 is available from MicroSource and contains 2,000 compounds
that are marketed drugs, natural products and other bioactive compounds. The
library contains 1,000 off-patent drugs and recent ’blockbuster’ drugs. The major-
ity of these drugs are approved in the US (800) whereas the other 200 drugs are in
use in Europe and Japan. 580 natural products were selected based on structure
and chemical class. The remaining 420 compounds represent non-drug enzyme
inhibitors, membrane active compounds, cellular toxins and receptor blockers
that have either been dropped or did not reach development. Widely used herbi-
cides and pesticides are also included. The Prestwick chemical library5 contains






are bioactive alkaloids or related substances.
There are two attempts to create collections of all chemicals that have been
used in medicine, including approved drugs and the so-called ’fallen angels’, drugs
that were dropped by pharma companies because of lack of efficacy in clinical
trials. The Johns Hopkins Clinical Compound Library (JHCCL) is an ongoing
project run by the Johns Hopkins Clinical Compound Screening Initiative6 aimed
at providing resources for effective drug repurposing. The initiative was launched
as a collaboration in 2002 between Johns Hopkins Pharmacology and the Malaria
Research Institute at the Johns Hopkins Bloomberg School of Public Health.
Currently, the compound collection contains 3,100 existing drugs and the goal
is to collect all 11,000 drugs ever used in medicine. In 2007 this number was
8,850 (Chong & Sullivan, 2007) and the sources of compounds were described as
follows: 2,933 unique drugs approved by the FDA since 1938, drugs from the FDA
Orange Book (in 2006 there were 1,107), drugs from the Physician Desk reference
(888 as of 2006) and another 7,057 compounds that have either been approved
abroad or were abandoned after phase II clinical trials in the US. There are many
compounds that passed toxicology assessments but were ultimately not effective
enough to be approved. These pipeline drugs are are a valuable resource for
drug repurposing efforts. The final list of 8,850 compounds excludes antiseptics,
vaccines and therapeutic extracts.
The National Institutes of Health (NIH) Chemical Genomics Center (NCGC)
created the NCGC Pharmaceutical Collection (NPC) as an informatics and a
screening resource (Huang et al., 2011). First, a comprehensive, non-redundant
list of approved molecular entities was assembled. Through matching of com-
pounds from various data sources, a list of 9,969 molecular entities was assem-
bled. 4,034 molecular entities are currently approved by at least one regulatory
agency world wide and 4,935 unique molecular entities are registered but not
approved. The data sources included various FDA and World Health Organiza-
tion drug lists as well as the European and the Japanese pharmacopeia. 7,631 of
these compounds were considered amenable to high-throughput screening (2,750
approved and 4,881 registered molecular entities). Proteins and antibodies were
6www.jhccsi.org
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excluded as well as molecules insoluble in DMSO and only compounds with more
than 15 atoms and at least one carbon or nitrogen atom were included. The
idea is to screen these compounds in as many assays as possible to identify po-
tential drugs or drug leads. The results of all screens will be available publicly
via PubChem7 and the NPC browser. This will allow the data to be used for
drug repurposing and to define the activities of known bioactive small molecules.
The NPC browser also allows for virtual screening and docking approaches of the
collection.
Thalidomide, its fall and rise
Thalidomide, was prescribed in the 1950s to treat morning sickness in pregnant
women (Ashburn & Thor, 2004). The drug was banned just a few years later
because it led to severe skeletal birth defects. In 1964, it was used by a physician
as a last resort to treat a critically ill patient with inflammatory condition ery-
thema nodosum laprosum (ENL). Surprisingly, the patient was soon healed of his
sores and was pain free. Thalidomide was approved as a treatment for ENL in
1998 and is still the only drug to treat ENL. In the 1990s it was discovered that
thalidomide had anti-angiogenic properties (D’Amato et al., 1994) and today this
drug’s main use is in cancer treatment, primarily multiple myeloma.
Sildenafil, a PDE-5 inhibitor with many therapeutic indications
Another example where a new indication was discovered accidentally is sildenafil
(Viagra R©). Pfizer had originally developed sildenafil to treat angina. The com-
pound inhibits phosphodiesterase-5 (PDE-5) which relaxes coronary arteries and
allows greater coronary blood flow. The drug did not prove effective in a trial
in the early 1990s, but persistent and unusually strong erections were reported
as side effects by several volunteers. Since PDE-5 had been identified as a key
enzyme in mediating erections (Ignarro et al., 1990), a few small scale trials were
soon followed by a large scale trial (3700 patients in Morales et al., 1998). They
all confirmed sildenafil to be an effective treatment of erectile dysfunction. Con-
7http://pubchem.ncbi.nlm.nih.gov/
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cerns about the safety of the drug for patients with (suspected) heart disease were
voiced soon after its release as Viagra R©.
Pleiotropic effects of PDE-5 inhibitors like sildenafil were soon discovered
(Gross, 2010). Several papers have demonstrated potential for sildenafil to treat
cardiovascular conditions. It was shown to have cardioprotective properties in
rabbits (Ockaili et al., 2002) and it was successfully used in mice to treat cardiac
hypertrophy and remodelling which frequently lead to heart failure (Takimoto et
al., 2005). In 2005 it was approved for the treatment of pulmonary arterial hyper-
tension. Sildenafil also has therapeutic potential for improving vascular function
in diabetic patients (Mammi et al., 2011). Das et al. (2010) observed enhanced
antitumour activity of the chemotherapeutic doxorubucin in combination with
sildenafil while sildenafil also reduced the toxicity of doxorubicin. Recently, silde-
nafil has been described as a multidrug resistance modulating drug that enhances
the sensitivity of cancer cells to standard chemotherapeutics (Shi et al., 2011).
It has also been described as a lead compound in antimalarial drug design in a
molecular docking study (Howard et al., 2011).
Sildenafil is an example of a drug with various therapeutic indications because
its target, phosphodiesterase-5, is important in many biological processes.
A new role for metformin as anticancer drug
Metformin is probably the world’s most widely prescribed anti-diabetic drug. It
is of the biguanide class and is used to treat type 2 diabetes. Several retrospective
analyses as well as in vitro and in vivo studies have reported that metformin may
also have anti-cancer properties (reviewed in Chong & Chabner, 2009; Sahra et
al., 2010). Intriguingly, Hirsch et al. (2009) showed that metformin selectively
kills cancer stem cells in vitro and in vivo and the combination of doxorubicin
effectively wiped out tumours and prevented recurrence in mouse studies.
The effect of metformin for the treatment of diabetes is two-fold. Metformin
has been shown to facilitate the trafficking of glucose transporters in several tis-
sues which improves glucose uptake (Kozka & Holman, 1993). The drug also
partially inhibits complex 1 of the mitochondrial respiratory chain (Owen et al.,
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2000) resulting in lower ATP levels in the cells. This in turn activates AMP ki-
nase, which is a major sensor of the energy status of the cell (Zhou et al., 2001).
Once activated, AMPK phosphorylates and therefore inactivates the transcrip-
tional activator TORC2 which leads to decreased expression of genes involved in
gluconeogenesis (Koo et al., 2005). The inhibition of gluconeogenesis is thought
to be the basis for the therapeutic effect of metformin in diabetes.
The effect of metformin against breast cancer cells has been shown to depend
on AMPK (Zakikhani et al., 2006; Zhuang & Miskimins, 2008). Metabolic repro-
gramming is one of the hallmarks of cancer. The metabolic switch from oxidative
phosphorylation to glycolysis is know as the Warburg effect (Kim & Dang, 2006)
and enables cancer cells to adapt to a hypoxic environment. Metabolic states
and adaptation are probably important for understanding how metformin affects
cancer cell proliferation. Perturbation of the balance between AMP and ATP
and activation of the AMPK pathway induces stress that is similar to metabolic
stress. Depending on cell type, this leads to apoptosis, autophagy or cell cycle
arrest.
Like sildenafil, metformin shows how one target pathway can be important
for the treatment of two diseases, in this case diabetes and cancer.
Application of drug repurposing to orphan diseases
Over 6000 diseases have been classified as rare or orphan diseases by the NIH. Due
to low prevalence and/or limited commercial potential, only about 5% of orphan
diseases can be treated with 350 drugs and biological products that are available
for rare diseases (Sardana et al., 2011). Since cost is an important factor in drug
development, repurposing of drugs was early on seen as an opportunity to find
therapies for orphan diseases. In one of the first drug-repurposing screens, Chong
et al. (2006) identified 87 drugs from the Johns Hopkins Clinical Compounds
Library (it contained 2500 drugs then) that inhibited growth of the human malaria
parasite Plasmodium flaciparum. The antihistamine astemizole was found to be
highly effective against 3 different P. falciparum strains and in two mouse models
of malaria. The same library was screened by Gloeckner et al. (2010) to find new
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therapies for the neglected tropical disease Onchocerciasis, or river blindness,
which is caused by the nematode Onchocerca volvulus and affects over 37 million
people in third world countries. Closantel, a veterinary anthelmintic showed
potent and specific activity against O. volvulus larvae.
The cost-effective option of drug repurposing will hopefully boost the devel-
opment of safe and effective therapies for rare and neglected diseases.
1.3.5 Multicomponent therapies
The idea of drug combinations is not new. In fact, traditional Chinese medicine,
the Egyptian Ebers Papyrus (1550 BC) and other historical approaches to medicine
relied on mixtures of herbs and herbal extracts. In the late 19th century, inves-
tigators in Western medicine became interested in interactions between purified
compounds. The British physician and pharmacologist Thomas Richard Fraser
described the interaction between physostigma and atropia in 1871. In the early
20th century Siegfried Walter Loewe, a German pharmacologists, endocrinolo-
gists and clinical chemists, quantified the effects of drug combinations (Loewe,
1928). His work later resulted in the definition of Loewe additivity as a reference
model for drug interactions (Loewe, 1953). This model is based on the assump-
tion that a compound should only have additive interactions with itself. The
biologist Chester Ittner Bliss taught himself statistics which he used to develop,
among other things, the Bliss independence model to assess drug interactions
(Bliss, 1939). This method assumes the relative effect of a drug at a specific con-
centration to be independent of the presence of another drug. These two models
were the basis for many more methods that were devised subsequently to classify
synergistic drug combinations. These models have been discussed in Greco et al.
(1995) in the context of the debate about the definition of synergy.
Inspired by nature: effective combinations of natural compounds
There are examples in nature where mixtures of compounds result in maximal
activity. For example, medicinal plants that produce the antimicrobial agent
berberine were shown to also produce an inhibitor of multi-drug resistance pumps
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(Stermitz et al., 2000). The MDR inhibitor has no apparent activity on its own,
but this combination effectively overcomes bacterial resistance against berber-
ine. The larvae of beewolf digger wasps are constantly threatened by pathogenic
bacteria and fungi. Kroiss et al. (2010) discovered that the wasps protect their
larvae with a ’cocktail’ of nine antibiotics that is being produced by symbiotic
bacteria (Streptomyces spp.) that the wasps cultivate on their antennae. Snake
venoms are combinations of many different proteins and microbials also produce
a multitude of bioactive compounds to defend themselves against other microbial
species.
Tackling the complexity of cellular networks with drug combinations
The complexity of cellular networks as well as the multifactorial nature of many
diseases suggest that multi-component therapies might be more effective than
single agents. They contain many features such as cross talk, feedback and feed-
forward loops which systems biology is only beginning to unravel. Living systems
are characterised by an intrinsic robustness that needs to be studied to be able to
develop drugs that can control such a complex system (Kitano, 2007). Biological
networks and their structure have been studied extensively (Watts & Strogatz,
1998; Jeong et al., 2000) and theoretical considerations have resulted in the con-
clusion that weak links are just as important in biological networks as strong links
(Csermely, 2004). Drug discovery has focussed on targeting essential proteins that
correspond to strong links in a network. Csermely et al. (2005) subsequently sug-
gested that partial inhibition of a surprisingly small number of cellular targets
can have stronger effects than complete inhibition of a single target. This was
confirmed for the transcriptional regulatory networks of S. cerevisiae and E. coli
where weak inhibition of 3-5 nodes had a greater impact than complete deletion
of a single node (Ágoston et al., 2005). The interest in drug combinations has
grown in recent years. For example, the company CombinatoRx (now Zalicus)
was founded with the aim to identify synergistic combinations of approved drugs
that are effective therapies (Borisy et al., 2003). Different experimental and mod-
elling approaches were developed in the research community to find multi-target
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drugs for specific diseases. There are many potential advantages of drug combina-
tions including a reduction in side effects and reduced host toxicity. In addition,
the combination of compounds might induce effects that cannot be obtained with
a single drug resulting in higher efficacy against a disease. Attacking a system on
multiple fronts also lowers the risk of resistance and might help fight heterozy-
gous populations of tumour or pathogen cells. One important thing to keep in
mind is the fact that normal cells are affected by compound treatment as well and
therapeutic synergy is based on the selective toxicity against cancer or pathogen
cells relative to host cells. Therapeutic regimens might also have to be optimised
to improve the results of combination therapy (Berenbaum, 1990).
Drugs that were developed separately to treat a disease have been combined
based on clinical observations because they are more effective than treatment with
either agent alone. These drug combinations have been called ’congruous’ (Keith
et al., 2005). Successful examples of such ’congruous’ drug combinations are:
Combivir R© by GlaxoSmithKline for HIV treatment, Advair R© by GlaxoSmithK-
line to treat asthma and Advicor R© by Kos Pharmaceuticals to treat hypercholes-
terolaemia.
Devising higher order drug combinations is also of interest and has been at-
tempted by combining drugs that are already used to treat the target disease.
Berenbaum et al. (1983) compared the effect of double and triple antibiotic drug
combinations against Pseudonomas maltophilia and observed that triple combina-
tions usually resulted in synergy, even if the organism was resistant to one of the
drugs. First trials comparing two- and three-drug combinations in chemotherapy
generated inconclusive results about whether the higher-order drug combinations
are more effective (Pirker, 2002). Many clinical trials currently compare the
efficacy of two- and three-drug regimens.
While clinical observations have led to a number of successful drug combi-
nations, interactions with drugs that are not normally used to treat the target
disease are unlikely to be discovered. These combinations, where one of the ac-
tive ingredients was not developed to treat the target disease, have been termed
’syncretic’ drug combinations. Therefore, approaches for de novo discovery of
synergistic drug combinations are needed to explore the space of syncretic drug
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combinations.
Different mechanisms of drug interactions
The combination of two drugs might be synergistic because one compound facili-
tates the action of the other one by affecting multi drug resistance pumps or drug
metabolism. The aforementioned berberine-combination produced by plants is
a good example of this type of drug interaction. The antibiotic Augmentin R© is
another example. This drug combines the β-lactam antibiotic amoxicillin with
the β-lactamase inhibitor clavulanate to prevent the degradation of amoxcillin.
Two drugs that target the same pathway or even the same protein can also
increase pharmaceutical efficacy when combined. An example are the DNA dam-
aging chemotherapeutic agents mitomycin C and doxorubicin (Shuhendler et al.,
2007). Synergy has also been observed between the two microtubule inhibitors
discodermolide and paclitaxel (Honore et al., 2004).
Combination treatment with compounds that have separate targets can result
in synergistic drug interactions. These targets can be in the same cell or in differ-
ent tissues. Yeh at al. (2006) systematically explored the interactions between 21
antibiotics and found, that protein synthesis inhibitors synergised with inhibitors
of folic acid biosynthesis and with inhibitors of DNA synthesis. Metformin sup-
presses gluconeogenesis in the liver and also improves glucose uptake in peripheral
tissues. This drug is often combined with glyburide (Glucovance R©) which leads
to increased insulin secretion from the pancreas or rosiglitazone (Avandamet R©)
which improves insulin sensitivity. The different actions of the compound pairs
in different tissues lead to improved glucose homeostasis to treat type 2 diabetes
more effectively.
There are drug combinations where one component confines the action of the
other component to specific cells. In Section 4.2.4 (Ishizaki, Zhou et al.,, submit-
ted), the combination of nifurtimox with an aldehyde dehydrogenase inhibitor has
been suggested to reduce the side-effects of nifurtimox by inhibiting the bioacti-
vation of nifurtimox in host cells. Similarly, the effects of levodopa are confined to
the brain to treat Parkinson’s disease. It is given in combination with carbidopa
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(the combination is called Sinemet R©) which cannot cross the blood brain barrier
and therefore prevents levodopa to be converted to dopamine everywhere in the
body but the brain preventing unwanted side-effects of dopamine.
It is important to be aware of drug interactions that lead to unwanted effects
as is the case with contra-indicated drugs. These adverse effects are normally
only discovered in retrospective because complex drug interactions are hard to
predict and can often only be observed empirically. Tatonetti et al. (2011)
describe an unwanted synergistic effect of the anti-depressant paroxetine and the
lipid-lowering agent pravastatin on glucose levels in the blood of patients. Both
drugs are widely prescribed and many patients are comedicated with both drugs
to treat depression and hypercholesterolemia. Using electronic medical records,
the authors evaluated changes in blood glucose levels in response to treatment
with these drugs. Each drug on their own did not cause any changes to blood
glucose levels whereas comedication resulted in an increase of glucose levels from
110 mg/dL to 128.6 mg/dL. This increase was even larger when diabetic patients
were included in the analysis. Glucose levels changed from 115.2 mg/dL to 163.2
mg/dL.
Jia et al. (2009) have assembled a comprehensive list of drug interactions re-
ported in the literature. The authors also attempted to classify these interactions
based on their mechanism of interaction.
Systematic screens to identify effective drug combinations
A pragmatic approach to identify drug combination is their empirical discovery
through high-throughput screening of compound combinations in disease model
assays. However, the sheer number of possible combinations renders this approach
intractable. Even a small library of 1000 compounds results in nearly half a
million possible combinations.
One way to reduce the screening space is the use of an ’anchor drug’. Com-
bination therapies to treat rheumatoid arthritis were designed around ’anchor
drugs’, compounds with low toxicity and rapid, sustained action. Other drug(s)
can then be added sequentially, allowing drug combinations to be tailored to each
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patient. Sulphasalazine and methotrexate have been described as good ’anchor
drugs’ to treat rheumatoid arthritis (Farr & Bacon, 1995; Pincus, 2003). Such an
’anchor drug’ can be used in combination screens using chemical libraries to iden-
tify agents that synergise with this drug. This reduces the combinatorial space
to be screened greatly. Zhang et al. (2007) identified microbial metabolites that
synergise with the antifungal agent ketoconazole. They screened 20,000 microbial
extracts in combination with ketoconazole and then purified six natural product
compounds from the 12 extracts that were hits. Ejim et al. (2011) screened
the antibiotic minocycline in combination with previously approved drugs and
identified 41, 35 and 6 drug combinations that showed synergy in the model or-
ganism Escherichia coli and the bacterial pathogens Staphylococcus aureus and
Pseudomonas aeruginosa, respectively. Fluconazole was used as an anchor drug
to find effective antifungal combination therapies (Spitzer et al., 2011). 148 pre-
viously approved drugs were found to synergise with fluconazole in the budding
yeast and three different pathogenic fungi. Spectinomycin was successfully used
as an ’anchor drug’ by Ramón-Garćıa et al. (2011) to identify synergistic drug
combinations for tuberculosis therapies. All these screens were done at a single
concentration and hits were confirmed with concentration matrices to assess the
drug interactions further.
A more thorough approach to discover synergistic drug combinations between
previously approved drugs was taken by Borisy et al. (2003). They set up a
high-throughput screen were each drug combination was assessed in a 6x6 ma-
trix. Screening efforts were kept to a minimum by pooling drugs that did not
show activity on their own. Synergistic drug combinations against fluconazole-
resistant C. albicans were identified as well as anti-inflammatory drug combina-
tions. The most promising discovery came from a screen of 100,000 drug com-
binations against human tumour cells. The antipsychotic chlorpromazine and
the antiparasitic agent pentamidine were identified and subsequently shown to
act highly synergistic to prevent tumour growth in mice. The drug combina-
tion was patented by CombinatoRx in 2003 and Lee et al. (2007) reported that
chlorpromazine treatment results in mitotic arrest and causes monopolar spin-
dles whereas pentamidine causes chromosomal segregation defects and delayed
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progression through mitosis. The combination was also shown to synergise with
microtubule-binding agents in three-way combinations.
Computational approaches to identify effective drug combinations
A lot of data is available on cellular responses to drug treatments like gene ex-
pression profiles, chemical-genetic profiles and others. It is desirable to use com-
putational methods to assess the effect of treatment with drug combinations to
predict effective multicomponent therapies, or at least to reduce the space of pos-
sible drug combinations to test experimentally. Nelander et al., (2008) derived a
model of regulatory interactions in breast cancer cells based on results of com-
binatorial perturbation experiments. Read-outs included growth phenotype as
well as molecular states of proteins. They correctly recovered known regulatory
couplings and feed-back loops and the authors suggest that models can be built
to predict the effects of drug combinations to optimise existing combination ther-
apies and to discover new ones. A similar approach was taken by Iadevaia et al.
(2010). The authors designed optimal drug combinations against a breast cancer
cell line by focussing on the insulin-like growth (IGF) factor signalling network.
Data on protein phosphorylation after IGF-1 stimulation for mass action mod-
elling was used to predict drug combinations that minimised phosphorylation of
other proteins in the network. They confirmed their prediction that simultaneous
inhibition of MAPK and PI3K/AKT pathway decreases viability of cancer cells.
Another approach, Medicinal Algorithmic Combinatorial Screen, uses optimi-
sation strategies based on search algorithms to enrich for activity of drug cocktails
against cancer cell lines (Zinner et al., 2009). By cycling between experimental
evaluation of drug combinations and rule-based creation of new combinations of
any size, a three-way drug combination was rapidly identified as most active from
a pool of 19 drugs.
Jansen et al., 2009, used chemical genetic profiles to generate a list of 18
compounds that were predicted to synergise with fluconazole of which 11 and
10 combinations were confirmed to be synergistic against S. cerevisiae and C.
albicans, respectively.
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RNA interference (RNAi) screens in mammalian cells have also been used to
devise synergistic drug combinations. Bauer et al. (2010) identified gene products
that increase sensitivity to paclitaxel in breast cancer cells when they are targeted
with RNAi. Known drugs that target the top hits from the RNAi screen were
then tested in combination with paclitaxel and found to be synergistic in 2D and
3D cultures and in paclitaxel-resistant cell lines. A similar approach was taken
by Seyhan et al. (2011). Breast cancer cells were screened against an RNAi
library in the presence of neratinib. Various biological pathways were identified
and treatment of cells with combinations of neratinib and paclitaxel or cytarabine
resulted in synergistic effects in both cases.
1.4 Aims of this thesis
The overall aim of this thesis is the application of yeast functional genomic ap-
proaches to interrogate the mode of action of small molecules that were identified
in drug discovery screens in pathogenic fungi and zebrafish. First, I will charac-
terise known drugs that showed synergistic interactions with the antifungal flu-
conazole in a high-throughput screen to reveal mechanisms of synergy. Second,
I will present experiments in the budding yeast that complement experimental
approaches in zebrafish to understand the effects of small molecules on zebrafish
melanocytes. I also developed and implemented different approaches to analyse




2.1 General materials and methods
2.1.1 Yeast media
Tyers lab Extra YPD media (XY)
10 g Bacto yeast extract
20 g Bacto peptone
0.1 g Adenine
0.2 g Tryptophane
Synthetic complete media (SC)
1.7 g yeast nitrogen base without amino acids or ammonium sulphate
2 g amino acid master mix
5 g ammonium sulphate or 1 g L-glutamic acid potassium salt (if adding
G418 to media later)
Media was brought up to a volume of 900 mL with dH2O and autoclaved. 100 mL
20% glucose was added before use for a final sugar concentration of 2%. To pour
plates, 20 g Bacto agar was added to the medium before autoclaving. Glucose
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was added before pouring plates.
2.1.2 Chemicals
Most chemicals were ordered from Sigma Aldrich. Chemicals were dissolved in
DMSO and aliquots of mM stock solutions stored at -20◦C. Fluconazole was the
only exception in that it was dissolved in distilled water and stored at room
temperature.
Maybridge drugs
Many of the drugs in Chapter 4 were from the Maybridge Screening Collection.
For follow up experiments, 25 mg these drugs were ordered via Thermo Fisher
Scientific. They were dissolved in DMSO and aliquots stored at -20◦C.
2.1.3 Buffers and solutions
Winston-Hoffman Lysis buffer







10 mL of TRITON X-100 were poured (very slowly) into beaker with 70 ml
water and stir bar. Solution was stirred until the TRITON X-100 dissolved
completely.
Ammonium acetate, 4 M
Made with distilled water, adjusted to pH 7.0
Sodium acetate
Made with distilled water, adjusted to pH 5.2.
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TE
10 mM Tris, pH 7.5
1 mM EDTA
2.1.4 S. cerevisiae barcode microarrays
Materials
• Microarrays - were printed by the Samuel Lunenfeld Research Institute
Microarray Laboratory in Toronto, Canada1.
• Lifter slips from Thermo Scientific
• Stabilisation and Drying Solution from Agilent









Summary of chemical-genetic screening protocol
Deletion pools were subjected to compound treatment, and cell pellets were frozen
down for pool composition analysis by barcode microarray. For barcode microar-
rays, genomic DNA was extracted from drug treated as well as solvent treated cell
pellets. Barcode tags were amplified by PCR using common fluorescently labelled
UP and DN primers (OPERON Biotechnologies, Germany). The PCR products
for experimental and control samples were competitively hybridised to spotted
1http://www.mshri.on.ca/microarray/
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barcode microarrays (Cook et al., 2008) and spot intensities were analysed to
identify sensitive and resistant deletion strains.
Generation of deletion pool
The S. cerevisiae deletion collections (MATa and heterozygous deletion strains for
essential genes) were obtained from Research Genetics (Germany). Haploid and
heterozygous essential deletion pools were generated by pinning the corresponding
frozen collections onto XY plates containing glucose and 200 mg/L of G418. After
2 days colonies were condensed to 384 format on XY plates containing glucose.
Cells were then scraped into 15% glycerol after another two days of growth.
Aliquots of the deletion pool were stored at -80◦C.
DNA extraction
Genomic DNA for barcode microarrays was isolated following a protocol modified
from the Boeke lab:
1. For drug screens we normally use 2-5 ODU which will give 50 µL of DNA
with a concentration of 300-600ng/µL.
2. Spin cells down at 3600 rpm for 1 min and discard liquid.
3. Add 200 µL volume of glass beads ( 600µm), 200 µL of Winston-Hoffman
Lysis buffer and 200 µL of phenol/chloroform to each tube.
4. Vortex tubes for 10 minutes at RT. The table vortex works well if tubes are
taped onto it. Vortex on setting 7. Briefly spin down the glass beads and
liquids from the wall of the tubes.
5. Add 450 µL of 1X TE to each tube and mix well.
6. Spin at 14,000rpm for 4 minutes.
7. Transfer aqueous phase ( 600 µL) into a new tube with 300 µL of phe-
nol/chloroform. Vortex for 5 minutes.
8. Spin as in step 5.
9. Transfer aqueous phase ( 550 µL) into a new tube with 300 µL of chloroform
(chloroform: isoamyl alcohol: 24:1). Vortex for 5 minutes.
34
10. Spin as above and transfer the aqueous phase ( 500 µL) into a new tube
and add 10 µL of RNaseA (10mg/ml). Incubate at 37◦C for 30 minutes.
11. After incubation, add 300 µL phenol/chloroform. Vortex for 5 minutes.
12. Spin tubes at 14,000 rpm for 4 minutes.
13. Transfer aqueous phase ( 400 µL) into a new tube containing 300 µL chlo-
roform. Vortex for 5 minutes and spin as above.
14. Transfer aqueous phase ( 300 µL) into a new tube (normal 1.5 mL Eppendorf
tube) and precipitate with 7.5 µL of Ammonium Acetate (4M, pH7.0) and
750 µL of 100% ethanol. Mix well by inversion.
15. Spin at 14,000rpm for 10 minutes at 4◦C.
16. Wash DNA pellet with 70% ethanol.
17. Dry DNA pellet and resuspend in 50 µL of TE.
18. After quantification dilute to 50 ng/µL for microarrays.
The DTAB/CTAB (dodecyl- and cetyltrimethylammonium bromide) based
method for gDNA isolation was found to not be suitable for DNA extraction
for microarray barcode extraction. The PCR reaction to amplify and label the
barcodes was not as efficient as with DNA extracted following the protocol above
which resulted in low hybridisation intensity.
Generation of labelled DNA probe
Four PCR reactions are required per microarray since (nearly) every deletion
strain has two barcodes, the UP- and the DOWN-tag. These were amplified sep-
arately for control and experimental using the U1/U2 and D1/D2 primer pairs,
respectively. An example of the four reactions is as follows:
Control UP-tag Primers U1 and U2-Cy5
DOWN-tag Primers D1 and D2-Cy5
Experimental UP-tag Primers U1 and U2-Cy3
DOWN-tag Primers D1 and D2-Cy3
Generally, control samples were labelled with Cy5 and experimental samples with
Cy3. Dye-swap experiments were also conducted to assess dye bias.
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A PCR master mix in the following proportions was made and kept on ice:
10x PCR buffer (-Mg) 5 µL
50 mM MgCl2 1.5 µL
2 mM dNTPs 5 µL
ddH2O 30.3 µL
Taq 0.2 µL
Total volume 42 µL
These volumes were multiplied by the number of arrays, with 4 reactions per
microarray. For each reaction, the following was added to 0.2 mL PCR tubes
(with the primer and gDNA combinations as in the table above):
Master mix 42 µL
Labelled primer (25 µM) 2 µL
Unlabelled primer (25 µM) 2 µL
gDNA (25 ng/µL) 4 µL
The following PCR conditions were used for amplification and labelling of
barcode sequences:
94◦C 3 min
94◦C 30 sec )
50◦C 30 sec ) x38
72◦C 30 sec )
72◦C 5 min
4◦C forever
After completion of the PCR program, 2 µL of each PCR reaction were run on
a 2% agarose gel to assess efficiency of the PCR reactions. The 4 PCR reaction
for each microarray were then combined into one Eppendorf tube. The following
mix of blocking primers and precipitating agents was added to this:
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100 µM U1 5 µL
100 µM D1 5 µL
100 µM U2block 5 µL
100 µM D2block 5 µL
5 mg/ml linear acrylamide 1 µL
The DNA mixture was then precipitated by addition of:
3 M NaOAc, pH 5.2 22.5 µL
blocking primer mix 21 µL
95% EtOH 550 µL
Samples were placed at -20◦C for at least 1 hour.
Hybridisation of barcode microarrays
Microscope slide boxes were used as chambers for the microarrays with glass
slides as pedestals to place the microarrays onto. A small amount of chamber
hybridisation buffer (DIG Easy Hybe) was added into these boxes. Microarray
hybridisations were conducted following this protocol:
1. Spin samples at 14,000 rpm and 4◦C for 30 minutes to pellet the labeled
DNA. Wash once with 70% EtOH.
2. Dry briefly at room temperature (5 minutes).
3. Resuspend pellets in 5 µl of ddH2O
4. Add resuspended sample to 50 µL of DIG Easy Hybe.
5. Place the hybridisation buffer containing sample at 95-100◦C for 2 min.
Fast cool on ice for 5 minutes.
6. Maintain samples at 50-55◦C covered from light until ready to add to arrays.
7. Take out arrays one at a time. Add sample to the array and use a large
coverslip (24x60) to cover the surface. Be careful of bubbles.The working
surface of the arrays is quite large. When you use a 24x60 coverslip, try to
make the distance from the edges of the coverslip to the barcode or to the
end of the slide about the same. This will allow complete coverage of the
probe containing region. Immediately after completion, transfer the array
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to the chamber and keep at 25◦C. To prevent evaporation of the chamber
hybridisation buffer, wrap the edges of the chamber in parafilm.
8. Hybridise overnight at 25◦C (>12 hours).
Washing of microarrays
Washes were prepared as shown in Table 2.1 below. One extra Falcon tube with
solution 1 was prepared for each microarray. Falcon tubes with solution 1 were
pre-warmed to 30◦C. The Agilent stabilisation solution and acetonitrile were also
kept at 30◦C for 30-60 minutes before beginning the washing procedure (the
stabilisation solution sometimes forms white precipitate while it is stored at RT).
The coverslips were carefully removed one at a time for each array in the first
wash. Washes were performed as indicated in Table 2.1.
Solution Temp Procedure Container
1 6x SSPE, 0.05% Triton X-100 30◦C 5-10 dips 50 mL, in Falcon tube
- 15 mL SSPE
- 250 µL Triton
- 34.75 mL ddH2O
2 2x SSPE, 0.05% Triton X-100 RT 5-10 dips 50 mL, in Falcon tube
- 5 mL SSPE
- 250 µL Triton
- 44.75 mL ddH2O
3 0.2x SSPE, 0.05% Triton X-100 RT 5-10 dips 50 mL, in Falcon tube
- 0.5 mL SSPE
- 250 µL Triton
- 49.25 mL ddH2O
4 0.2x SSPE RT 5-10 dips 250 mL in black staining box
- 2.5 mL SSPE
- 247.5 mL ddH2O
5 Acetonitrile RT 10 sec 50 mL, in Falcon tube
6 Agilent Antioxidation solution RT 30 sec 50 mL, in Falcon tube
Table 2.1: Washing steps for barcode microarrays.
Microarrays were protected from light, scanned with a GenePix 4200AL and
hybridisation intensities were analysed with GenePix Pro 6.0 software.
38
Analysis of yeast barcode microarray data
Custom R scripts were written to store and analyse the barcode microarray data.
The database interface packages DBI and RMySQL as well as data analysis R
packages like gplots and limma were used to identify sensitive and resistant dele-
tion strains from the barcode array data. Spots with low intensity as well as
spots of low quality were excluded from further analysis. The intensities of du-
plicate spots on the arrays were averaged. Based on log2 fold change ratios (drug
treatment/solvent-only control), Z-scores were calculated for up and down bar-
code tags for each strain: Z = (x − µ)/σ where µ is the mean log2 fold change
of the whole array and σ the standard deviation. For each strain, the two Z-
scores for up and down barcode tags were averaged to get the final Z-score. Raw
data and Z-scores were stored in a custom MySQL database. Sensitive and re-
sistant deletion strains were identified with standard procedures for Z-score and
quantile-based statistics for microarray data (Quackenbush, 2002; Cheadle et al.,
2003).
2.2 Specific methods for Chapter 3
2.2.1 Fungal strains and culture conditions
The strains employed in this study were Saccharomyces cerevisiae BY4741, Can-
dida albicans Caf2-1 (from M. Whiteway), Cryptococcus neoformans H99 and
Cryptococcus gattii R265 (both from J.W. Kronstad) as well as the following
fluconazole resistant strains: Candida albicans F-1-2008 (clinical isolate), Can-
dida albicans F-07-2007 (clinical isolate), Candida parapsilosis ATCC 22019 and
Candida glabrata (all from D. Yamamura). S. cerevisiae was grown on SC agar,
Candida and Cryptococcus species were maintained on Sabauroud dextrose agar
(DifcoTM). S. cerevisiae and Cryptococcus strains were incubated at 30◦C, while
Candida strains were incubated at 37◦C.
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2.2.2 Compounds
Fluconazole (Sandoz, Quebec, Canada) was purchased as a 2 mg/mL solution in
water, sodium chloride and hydrochloric acid and/or sodium hydroxide. Alben-
dazole (Sigma, Oakville, Canada), amphotericin B (Sigma), azaperone (Prestwick
Chemical, Delaware, USA), clofazimine (Sigma), clomiphene citrate (Sigma),
daunorubicin HCL (Sigma), ebselen (Sigma), ellipticine (Sigma), hyamine (Sigma),
kawain (Sigma), ketoconazole (Sigma), L-cycloserine (Sigma), lynestrenol (Prest-
wick Chemicals), mevinolin (Sigma), mitoxantrone dihydrochloride (Sigma), ni-
trofurantoin (Sigma), sertraline (Sigma), suloctidil (Sigma), tamoxifen citrate
(Sigma), trifluoperazine dihydrochloride and zaprinast (Sigma) were purchased
as standard powders. All stock solutions were prepared in 100% dimethyl sulfox-
ide (DMSO). Fluconazole was stored at room temperature while all other stock
solutions were kept at -20◦C.
2.2.3 High-throughput screen of Prestwick library
The Prestwick Chemical library (www.prestwickchemical.com) was screened in
duplicate against Candida albicans, Cryptococcus neoformans, Cryptococcus gattii
and Saccharomyces cerevisiae at a final concentration of of 30 µM. Screens were
conducted in 384-well flat bottom microtitre plates in the presence and absence
of 1/2 MIC fluconazole. Each plate included 32 high growth and 12 low growth
control wells. Plates were incubated for 48 hours at 30◦C or 37◦C and OD600
was determined for each well. These absorbance values were then corrected using
the control values for each plate and percent residual activity was calculated for
every compound in each screen.
2.2.4 Data analysis of Prestwick library screen
Replicate screens were examined using scatterplots to assess the correlation be-
tween replicate screens. Residual activity values were averaged between duplicate
screens. Plate-wise normalisation was then conducted to remove column-, row-
and plate-bias in the data. Application of robust median absolute deviation
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(MAD; Chung et al., 2008; Birmingham et al., 2009) statistics to scatterplots of
screen data in the presence of fluconazole versus Prestwick library alone allowed
us to define hit compounds. Compounds that on their own did not affect growth
below noise levels but were more than 2 MADs away from the diagonal of the
with-versus-without-fluconazole scatterplot were identified as active. Within this
group, compounds that caused more than 80% growth inhibition in the presence
of fluconazole were defined as highly active.
2.2.5 Determination of MIC
Procedures for MIC determination were based on Clinical and Laboratory Stan-
dards Institute protocols2. Overnight cultures of the corresponding fungal strain
were set up in SC media and then diluted in 0.85% NaCl to an OD530 of 0.11, fol-
lowed by a 1:100 dilution in 0.85% NaCl and finally a 1:20 dilution in SC media.
Two-fold dilution series (0-128 µg/mL) of fluconazole and other drugs were set
up and added to 200 µL of the diluted culture in 96 well plates. After 48 hours
of growth at 30◦C or 37◦C, OD600 was measured with a microplate absorbance
reader. The minimum inhibitory concentration (MIC) for fluconazole was defined
as the lowest concentration causing 80% reduction in growth which corresponds
to 2 on the azole MIC numerical scale. MIC for other drugs was set as the
lowest concentration that inhibited growth completely. 6 different concentration
combinations of compound and fluconazole were used for time kill MIC assays
(compound at 1/4 MIC, compound at MIC, fluconazole at 1/4 MIC, flucona-
zole at MIC, fluconazole and compound both at 1/4 MIC, and fluconazole and
compound both at MIC). Dilutions from each well were spotted at 0, 24 and 48
hours onto an SC agar plate. Colonies were counted after an 48 hour incubation.
The definition of a fungicidal effect was >3*log10 reduction in CFU/mL (99.9%
killing) at synergistic concentrations after incubation for 24 hours.




Syncretic compounds and fluconazole were 2-fold serially diluted across rows and
columns of a 96 well plate (0-128 µg/mL; except for daunorubicin, terbinafine,
trifluoperazine and ellipticine which ranged from 0-64 µg/mL). The checkerboards
were incubated with fungal cultures and OD600 was determined after 48 hours.
The fractional inhibitory concentration index (FICI) of each drug combination
was determined according to standard CLSI protocols (Eliopoulos & Moellering,
1991; Odds, 2003):
FICI =
MICDrug A in combination
MICDrug A alone
+
MICDrug B in combination
MICDrug B alone
To probe chemical interactions between sertraline, trifluoperazine, L-cycloserine,
suloctidil and tamoxifen, checkerboard assays were carried out between these 5
compounds in the absence and presence of 1/2 and 1/8 MIC fluconazole (16 and
4 µg/mL, respectively).
2.2.7 Chemical-genetic screens
Concentrations that caused up to 30% growth inhibition in the deletion pools
after 12 hours incubation with a starting OD600 of 0.025 were determined for
clomiphene, L-cycloserine, sertraline, suloctidil, tamoxifen, trifluoperazine and
fluconazole. For each of the synergising drugs, a 5 x 5 matrix of increasing
concentrations of each drug (concentrations causing up to 25% growth inhibition)
and fluconazole (0-8 µg/mL, corresponding to growth inhibition of 0-25%) was
set up in 10 mL cultures. Single drug dilution series with up to 30% growth
inhibition as well as solvent-only controls (DMSO, water) were set up as well.
The final DMSO concentration was 0.2% for all screens. Deletion pools were
grown for about 10 generations, until saturation of the cultures. Cell pellets were
frozen down for DNA extraction.
The microarray data for this project is available on ArrayExpress (E-MTAB-
394).
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2.2.8 Validation of chemical-genetic interactions
Growth assays in 96 well format
Chemical-genetic interactions from barcode microarray experiments were con-
firmed with growth assays in 96-well flat-bottom polystyrene plates (Corning
Incorporated, USA) on Sunrise shaker/readers (Tecan). Single gene deletion and
wild type strains were grown in the presence of dilution series of clomiphene,
L-cycloserine, sertraline, suloctidil, tamoxifen, trifluoperazine and fluconazole.
OD600 readings were taken every 15 minutes. All assays were done in XY medium
with a starting OD of 0.0025. The final DMSO concentration was 2%. Log ratios
between deletion and wild type strains were calculated from OD values at the
time point where control wells have reached the end of log phase (with custom
R scripts). Negative log-ratios indicate sensitivity of a deletion strain to a drug
whereas positive ratios denote resistance.
2.2.9 Sorbitol rescue assay
Sorbitol rescue assays were done in 96-well plates using the Tecan Sunrise plate
readers. 100µL cultures of BY4741 were set up in XY medium with 1M sorbitol
(from 5 M stock) or with water as control. Drugs and solvent controls were added
as indicated.
2.2.10 In vivo imaging of effects of synergising compounds
Drug concentrations that affected growth of S. cerevisiae significantly were used
for imaging (64 µg/mL for fluconazole, 128 µg/mL for L-cycloserine and sertra-
line). Cells were grown to log phase, then drug was added and cultures were grown
for another 1 or 3 hours (results were the same for both incubation times). Dyes
used were Hoechst dye (Bisbenzimide H 33258, Sigma), Calcofluor White M2R
(Fluorescent Brightener 28, Sigma), FM4-64 (N-(3-triethylammoniumpropyl)-4-
(6-(4-(diethylamino)phenyl)hexatrienyl)pyridinium dibromide, Molecular Probes)
and Mitotracker Green FM (Molecular Probes). For all dyes, cells were harvested
by centrifugation at 12,000 rpm for 2 minutes. After washing and staining, cells
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were mounted on slides with 1% low melt agarose for imaging. For DNA stain-
ing, cells were resuspended in 40 µL YPD and 10 µL of 200 µM Hoechst dye
(dissolved in dH2O), grown for 15 minutes at 30
◦C, washed once with dH2O and
resuspended in 15 µL dH2O for slide mounting. Cells were resuspended in 198
µL 0.1 M Tris/HCl, pH 8 and 2 µL of 3.5 mg/mL Calcofluor White M2R (in
dH2O, 1 drop of 5M NaOH was added to stock solution to aid solubility) for cell
wall staining. Cells were then grown for 15 minutes at 30◦C, washed once with
dH2O, resuspended in 15 µL dH2O and mounted. For mitochondria labelling, cells
were resuspended in pre-warmed, Mitotracker Green containing YPD (500nM).
After 45 minutes incubation at 30◦C, cells were washed with 200 µL PBS and
resuspended in 15 µL dH2O for mounting. Vacuolar membranes were stained by
resuspending cells in 40 µL YPD with 1 µL of FM4-64 (1 mg/mL, dissolved in
DMSO). Cells were incubated for 15 minutes at 30◦C, spun down, resuspended
in 15 µL PBS and mounted. Imaging was done on a Leica DMI 6000 B micro-
scope with a Hamamatsu Orca ER-AG camera and Volocity 4 software. Images
were deconvolved with AutoDeblur Gold CWF using 2-D blind deconvolution (10
iterations per image).
2.2.11 Insect larvae assays
Per dish, ten weight matched (250-400 mg/worm) G. mellonella caterpillars were
inoculated with C. neoformans H99. 24 hours later they were injected with ser-
traline and fluconazole combined, sertraline and fluconazole alone and/or control
solutions (DMSO and PBS) (Mylonakis et al., 2005). Over 7 days, caterpillars
were examined visually for discolouration due to melanisation and for failure to
respond to touch as an inviability endpoint. Experiments were performed in
triplicate.
2.2.12 Computational analysis of gene-drug network in-
teractions
Analysis of genetic interactions between sets of genes sensitive to drug treatment
was based on genetic interaction data acquired from BioGRID (Breitkreutz et
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al., 2008; BIOGRID release 2.62 from www.thebiogrid.org). The visualisation of
bipartite graphs and simulations were performed with an online tool available at
http : //tyerslab.bio.ed.ac.uk/tools/genelookup bipartite.php.
Simulations based on chemical-genetic space (CGS) were done with a set of 1143
non-essential deletion strains that respond to various drug treatments (Hillen-
meyer et al., 2008). For each drug pair, control gene sets of the same size were
picked at random and the number of genetic interactions between the sets was
counted to generate a background distribution, which was used to calculate the
p-value for each drug pair. For parallel pathway permutation (PPP) simulations,
the chemical-genetic interactors of fluconazole and each of the synergistic drugs
were pooled, randomly assigned to two groups and genetic interactions counted
to obtain a background distribution for each drug pair. 10,000 simulations were
run for the CGS and the PPP approaches.
2.3 Specific methods for Chapter 4
2.3.1 Zebrafish methods
Phenotypic screen
Embryos were acquired by pair breedings of wild-type AB, AB* and TL zebrafish
lines. Phenotypic screens with small molecules were done in 96-well microtiter
plates. Each well contained two 4-hpf zebrafish embryos in 300 µL E3 embryo
medium. Compounds were added to a final concentration of 10 µM in 1% DMSO.
Compound libraries screened were the LOPAC Small Scale International Version
(1280 compounds; from Sigma-Aldrich) and a set of 1570 bioactive compounds (a
subset of the Maybridge screening collection from Fisher Scientific International;
described in Spitzer et al., in preparation). Embryos were imaged for phenotypic
changes at several time points: 28-hpf, 36-hpf, 48-hpf and 56-hpf.
Small molecule treatment
CI-1040 was obtained from Richard Marais (London, UK) and PD0325901 was
kindly provided by Hilary McLauchlan (University of Dundee, UK). Embryos at
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different developmental stages were treated with neocuproine and U0126 at 10 µM
or 25 µM and PD0325901at 1 µM or 2.5 µM. Inhibition of MEK pathway activity
during development was achieved by treating 4-hpf embryos with compounds
continuously until 12 hpf; immediate effects were assessed by applying a single
dose of compound from 10 hpf to 12 hpf.
Western blotting
12-hpf Embryos were frozen (at -80◦C). Lysis of samples was done in RIPA
buffer [2M Tris pH 7.5, 5M NaCl, 1% NP40, Na-deoxycholate, 10% SDS, 0.5 M
NaF, 1M β- glycosyl phosphate and protease-inhibitor cocktail tablet (Roche)].
Bradford assays were used to normalise samples which were then separated by
SDS-PAGE, transferred to a Hybond-C Extra nitrocellulose membrane (Amer-
sham Biosciences) and probed with rabbit [p44/42 MAPK (1:2000) and phospho-
MEK1/2 (Ser217/221) (1:500) (Cell Signaling Technology)] or mouse [phospho-
p44/42 MAPK (E10) (1:2000), alpha-tubulin B-5-1-2 (1:50,000) (Santa Cruz)]
antibodies. Detection was carried out with with horseradish-peroxidase- conju-
gated secondary antibodies (Roche).
Electron microscopy
Embryos were fixed with 2.5% glutaraldehyde, 2% paraformaldehyde in 100 mM
cacodylate buffer (pH 7.2) with 2 mM MgCl2 and 0.1% picric acid. After a wash
with 200mM cacodylate buffer, samples were fixed with 1% osmium tetroxide in
100mM cacodylate buffer (pH 7.0), then washed with distilled water, stained en
bloc with 0.5% aqueous uranyl acetate, and dehydrated with ethanol. Samples
were embedded in Agar 100 resin, sections were cut, stained (with lead citrate)
and viewed on a transmission electron microscope (FEI Tecnai 12).
Morpholino oligonucleotides
Gene Tools (USA) designed all four MOs. One MO was designed to block
splicing of ap3s2, a zebrafish ortholog of the yeast gene APS3. The MO se-
quence for ap3s2-MO1 was: 5’- TGCAAAAGCCTCTCCATCACCTTCC-3’. Ac-
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tivity of ap3s2-MO was confirmed by PCR with the following primers: AP3S2-
F1 [5’-TCAACAACCATGGGAAACCC-3’ (forward primer)] and AP3S2-R1 [5’-
TGACTGCAGAAACGGCTCG-3’ (reverse primer)]. Inclusion of intron 2 was
determined by sequencing of the longer cDNA product. A second MO blocked
translation of ap1s1, a zebrafish ortholog of the yeast gene APS1. The sequence
for ap1s1-MO1 was: 5’-ACAGA- AGCATAAAGCGCATCATTTC-3’. This MO
has been previously verified by Western blotting of morphant embryo extracts
with an antibody (Montpetit et al., 2008). In addition, two splice-site MOs were
used: ap3s2-MO2 (5’-TGCAGTTACGTTCACCTGTATAAGA-3’) and ap1s1-
MO2 (5’-GACTAGCATACCTACGTAAACACAC-3’) (Montpetit et al., 2008).
Activity of ap3s2-MO2 activity was confirmed by PCR with primers AP3S2-F2
[5’-TGCAGCAGCAGATCATCAGGG-3’ (forward primer)] and AP3S2-R2 [5’-
GACTGTCAGTAATGG- CAAGAGG-3’ (reverse primer)]. For each gene, re-
sults were consistent with both MOs, with increasing concentration of MO (5-10
pg) eliciting greater effects. 1 mM stock solutions were prepared for each MO with
water. For Figure 5A, we injected 1-3 pg into each one-cell stage embryo. All MOs
were labeled with a fluorescent tag to assess even MO distribution throughout
the embryo. Changes in pigmentation were assessed by at least two individuals
who scored the phenotypes blinded to the MO genotypes.
2.3.2 Yeast methods
Yeast chemical-genetic profiles
The MATa haploid and the essential heterozygous yeast deletion sets (Research
Genetics, Germany) were used to generate chemical-genetic profiles. Deletion
pools were created as described in Section 2.2.7. The growth-inhibition screens
are slightly different from the screens described in Section 2.2.7. 5-mL deletion-
pool cultures were set up with a starting OD600 of 0.025. After a 2-h pre-growth
period, compound or DMSO for solvent control samples was added. Compound
concentrations were selected such that pool growth was inhibited by 20-30% com-
pared to control cultures after 12 hours at 30◦C. Cultures were then diluted to
an OD600 of 0.025 twice and fresh compound was added both times to allow for
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competitive growth for a total of 20 generations. Each compound was screened
at two concentrations. The final DMSO concentration was 0.4% in all cultures.
The microarray data is available at ArrayExpress (accession number E-TABM-
922).
Assignment of GO biological process terms
Rather than relying on fixed cut-offs to define GO biological processes that are
enriched among the deletion mutants that were most affected by compound treat-
ment, average Z-scores were determined for all biological processes with data for
at least four genes. For each screen, we applied quartile-based statistics to iden-
tify significantly affected processes. Annotations were taken from Saccharomyces
Genome Database (http://www.yeastgenome.org, release 02/07/2009).
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CHAPTER 3
Interrogating the Mode of Action of Small Molecule
Synergies in Yeast
Most of the work presented in this chapter has been published in:
• Michaela Spitzer1, Emma Griffiths1, Kim M. Blakely, Jan Wildenhain,
Linda Ejim, Laura Rossi, Gianfranco De Pascale, Jasna Curak, Eric Brown,
Mike Tyers, and Gerard D. Wright: Syncretic Drug Combinations Potenti-
ate the Antifungal Fluconazole and Overcome Pathogen Resistance. Molec-
ular Systems Biology (2011 Jun 21).
This project was carried out in collaboration with Gerry Wright’s lab at
MacMaster University in Hamilton, Canada. The McMaster lab screened the
Prestwick library against four different fungal species. Emma Griffith and Kim
Blakely carried out the follow-up experiments in all four species to confirm drug
interactions. Emma also confirmed the synergy of sertraline with fluconazole in
fluconazole-resistant Candida strains and in the G. mellonella in vivo infection
model and she tested higher order combinations of synergising compounds. Mi-
croscopy images were taken by Laura Rossi, Jasna Curak and Gianfranco De
1The first two authors are joint first authors and contributed equally to this work.
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Pascale. Jan Wildenhain implemented the chemical-genetic space and the paral-
lel pathway permutation simulations. He also clustered the hit compounds based
on their chemical structures.
The data analysis of the screen (normalisation, identification of hit compounds
and overlap between the different species) as well as the analysis of the structural
clusters among the hits were done by me. I selected a subset of hit compounds for
the mode of action studies in S. cerevisiae, conducted the genome-wide screens,
analysed the chemical-genetic data, confirmed chemical-genetic interactions and
carried out the sorbitol rescue assay. I also worked on the integration of chemical-
genetic interactions with genetic interaction networks with Jan. All figures were
generated by me and all graphs and heatmaps were plotted with R, unless stated
otherwise. All figures except for 4.1, 4.2, 4.7A & C, 4.11, 4.13 and 4.27 were either
taken or adapted from the paper or the supplementary information of Spitzer et
al. (2011) according to the creative commons share-alike licence.
3.1 Introduction
Systemic infections caused by invasive fungi present a major threat to critically
ill patients (Gullo, 2009). In recent years, the frequency of fungal infections has
increased dramatically. Between 1979 and 2000, the number of fungal blood-
stream infections has increased by more than 200% in the United States (Pfaller
& Diekema, 2007). Immune-compromised individuals, like cancer chemotherapy,
HIV-infected and organ transplant patients, are especially susceptible to viral,
bacterial and fungal infections that are normally defeated by a healthy immune
system. The single most prevalent fungal pathogen among intensive care unit
patients is C. albicans, accounting for 17% of infections (Gullo, 2009). Infections
with other Candida species as well as the Cryptococcus and Aspergillus genera
are also increasing, especially in immune-compromised patients (Clark & Haj-
jeh, 2002; Gullo, 2009). Significant morbidity and mortality are associated with
invasive fungal infections but unfortunately therapeutic options are limited as
compared to bacterial infections.
Unlike bacteria, fungal pathogens are eukaryotes which means that their
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metabolism and cellular structures are more similar to mammalian host cells.
The first scientific breakthrough was the discovery of polyene antifungals in the
1950s. Amphotericin B is still the front line fungicide even though it causes
severe host toxicity because it non-specifically disrupts cell membrane integrity.
Continued efforts to improve this drug resulted in a less toxic liposomal formu-
lation of amphotericin B about ten years ago. The 1970s saw the development
of the synthetic azoles that target fungal ergosterol biosynthesis by inhibiting
lanosterol 14α-demethylase, the gene product of ERG11, an essential cytochrome
P450 enzyme (Groll et al., 1998; Revankar et al., 2004). Ketoconazole was the
first azole to be approved for the treatment of systemic fungal infections in 1981.
It was soon found to interact with many other drugs and to cause hepatic toxicity.
The first-generation triazoles (fluconazole and itraconazole) were introduced in
the early 1990s and represented a major improvement in the treatment of sys-
temic fungal infections because they displayed a broader spectrum of antifungal
activity. The azoles act by binding the heme Fe(III) of Erg11 which results in
depletion of ergosterol, accumulation of toxic C-14 methyl sterols and cell mem-
brane disruption. Even though the triazoles had an improved safety profile, their
cross-reactivity towards human P450 enzymes also results in toxicity. A major
clinical limitation is the fact that these drugs are fungistatic and clinical resistance
emerges (Cannon et al., 2009; Marie & White, 2009). Second-generation triazoles
have been developed and their host toxicity is still being assessed. Voriconazole,
posaconazole and ravuconazole are supposed to have greater potency and possess
increased activity against resistant and newly emerging pathogens. Allylamines,
like terbinafine, are compounds that also target the ergosterol biosynthesis path-
way, but they inhibit squalene synthase. Their antifungal specificity is based on
the fact that the fungal form of squalene synthase is much more sensitive to treat-
ment than the mammalian one. The newest class of antifungal compounds are the
echinocandins and they target one of the few structures that are fungus-specific,
the cell wall. They were introduced ten years ago and inhibit β-(1,3)-D-glucan
synthase, a cell wall biosynthesis enzyme. However, these drugs are limited in
their antifungal spectrum. The dearth of safe and effective antifungal therapies
and the threat posed by emerging clinical drug resistance make the development
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of novel antifungal strategies a necessity.
Traditional single-agent therapies require fungal-specific targets that are es-
sential for pathogen cell growth. The scarcity of essential drug targets is a major
challenge in antifungal drug discovery. One factor contributing to this problem is
the high degree of conservation of biochemical and molecular biological networks
across all eukaryotes. Another reason is the extensive buffering found in biolog-
ical networks. The systematic deletion of every single gene in the model yeast
S. cerevisiae revealed that ∼5000 of its ∼6000 genes are actually dispensable for
growth in nutrient-rich growth conditions (Winzeler et al., 1999). This problem
is aggravated by the fact that many of the essential genes can provide sufficient
function at only a fraction of wild type dosage (Yan et al., 2009). Genome-wide
genetic screens in the budding yeast have revealed that almost all non-essential
genes display synthetic genetic interactions (Tong et al., 2001). This means that
the deletion of non-essential genes becomes lethal in specific genetic backgrounds
where another non-essential gene has been deleted. It has been estimated that
the yeast genetic landscape is governed by more than 200,000 binary synthetic
lethal interactions (Costanzo et al., 2010).
The robust organisation of genetic networks as well as the success of combina-
torial therapies suggests that systematic drug design approaches should focus on
multicomponent drugs. Combinations of small molecule inhibitors of essential as
well as non-essential targets have been shown to exhibit additive or even synergis-
tic effects on cell viability (Sharom et al., 2004; Ágoston et al., 2005; Fitzgerald
et al., 2006; Lehár et al., 2007; Lehár et al., 2008). Fungal infections are of-
ten treated with ad hoc combinations of anti-infective drugs (Johnson & Perfect,
2010). This approach however, fails to exploit the complexity of the chemical-
genetic space (Sharom et al., 2004; Lehár et al., 2008). Instead, unbiased screens
for small molecule combinations that show unexpected interactions are needed
to fully explore the chemical-genetic landscape. These have been referred to as
syncretic combinations (Keith et al., 2005). As described in Section 1.3.5, focused
small molecule library screens (Borisy et al., 2003; Zhang et al., 2007; Zhai et al.,
2010) as well as computational approaches (Lehár et al., 2007; Nelander et al.,
2008; Jansen et al., 2009; Zinner et al., 2009) have successfully identified com-
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pounds that enhance the activity of known drugs in budding yeast and in cancer
cell lines. Further, direct tests of synergistic compounds have yielded drug com-
binations that are active against pathogenic fungi, including the combination of
fluconazole with chemical inhibitors of Hsp90, calcineurin or ARF (Cowen et al.,
2009; Singh et al., 2009; Epp et al., 2010) and the antibiotic polymyxin B (Zhai
et al., 2010).
The aim of the work described in this chapter was the identification of com-
pounds that potentiate the action of the antifungal drug fluconazole.
3.2 Results
3.2.1 A high-throughput screen identifies 148 compounds
that potentiate the action of fluconazole
The Prestwick Chemical library consists of 1120 bioactive compounds, 90% of
which are off-patent drugs and 10% are bioactive alkaloids or related substances.
This collection was used in cell-based high-throughput screens against the human
pathogens C. neoformans (H99), C. gattii (R265) and C. albicans (Caf2-1) as well
as the model yeast S. cerevisiae (BY4741). Screens were conducted in duplicate
at a concentration of 30 µM in the presence and absence of 1/2 MIC fluconazole
to identify compounds that have minimal antifungal activity on their own but
potentiate the anti-fungal action of fluconazole. Residual activity was determined
for each compound in each of the eight screens by normalising final OD values
for each drug against control wells within each plate.
Normalisation of HTP data
Systematic errors in HTP screen data are a well known problem and methods for
the correction of biases have been developed for a range of applications, including
microarrays (Quackenbush, 2002), in vitro screening of chemical libraries (Malo
et al., 2006) and RNA interference screens (Birmingham et al., 2009). In the
context of cell-based small molecule screens, such as this one, edge effects are
a valid concern (Lundholt et al., 2003). This means that wells along the edge
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Figure 3.1: Visualisation of row effects in HTP screen data of (i) C. gattii, (ii)
C. neoformans, (iii) C. albicans and (iv) S. cerevisiae screens with and without
fluconzole. For each of the screens, data points for each row from all 14 plates
are summarised by a boxplot to visualize the range and spread of values. The
box represents the middle 50% of the data, the black line represents the median
of the data and points outside the reach of the whiskers are considered outliers.
of a microtitre plate give higher or lower readings than the rest of the plate.
A simple way to check screen data for these effects, is to compare the range of
residual activities for each column and each row across all plates. Screen data
was analysed per column and per row for each of the eight screens. There were
no obvious column effects present in any of the screens (data not shown). In
contrast, the data points in rows A and H showed a larger spread in all four C.
gattii and C. neoformans screens than the other two screens (Figure 3.1 i,ii). In
addition, the wells in these rows had higher residual activity values. A similar
trend was observed in the C. albicans and S. cerevisiae screens, where the spread
of all columns was similar, but rows A and H showed a slight increase in residual
activity (Figure 3.1 iii, iv). A number of factors can be involved in the generation
of such effects such as a bias of the span-8 pipettor used to set up the plates for
screens, evaporation in the outer wells during incubation or uneven temperature
across the plate during incubation. These effects were removed by correction of
the row means towards the plate mean.
The identification of hit compounds is based on the comparison of screen




























































































































































































































































































































































Figure 3.2: Data variation between screens. (A) Box plot summary of the raw %
residual activity data for each of the eight screens. Values for screens of C. gattii
and C. neoformans in the presence of fluconazole (boxplots 2 and 4) are much
lower than those of the corresponding screens without fluconazole (boxplots 1 and
3). (B) Box plot summary of the % residual activity data after normalisation.
Median is now 100 for all screens and the spread of the data is similar in each
pair of screens (with and without fluconazole). This facilitates identification of
hit compounds.
the screens was summarised by a boxplot. It is obvious that there is variability
between the screens in different species. Differences in spread and values of the
residual activity can clearly be seen. The outcome of data normalisation based
on dividing the data for each plate by the corresponding plate median is shown
in Figure 3.2B. The median residual activity is 100% in all screens now. The
variation has been greatly reduced and is comparable between the two screens
for each species.
To summarise the data normalisation, Figure 3.3 visualises the correction of
plate to plate variation as well as row- and column-specific effects. In each of the
plots, all 1120 compounds of the library are represented along the x-axis whereas
the y-axis corresponds to residual activity as measured for the screen. Each row
in Figure 3.3 corresponds to one of the four fungal species. The first and third
plot in each row represent the raw data from screens without and with fluconazole
whereas the second and fourth graph show the data after normalisation. Strong



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 i)  ii)
 iii)  iv)
 v)  vi)
 viii) vii)
Figure 3.3: Normalisation of high-throughput chemical screen data. In the plots
of raw data (first plot in each of the panels i - viii) variation between plates
and spatial effects within plates can be seen. Variation between screens can also
be seen when the left plot in panels i and ii as well as in panels iii and iv are
compared. The effects of data normalisation can be seen in the plot on the right
in each panel.
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and iv displayed much lower residual activity values than any of the other screens.
In screens v to viii, variation between plates was corrected. After normalisation,
all screens have a median residual activity of 100%, indicating that the majority
of compounds did not show significant activity. The screens in C. albicans and S.
cerevisiae (Figure 3.3 v-viii) have slightly smaller standard deviations than the
other two screens.
Identification of hit compounds
A flucanazole-enhancing compound will inhibit yeast growth significantly more
in the presence of 1/2 MIC fluconazole compared to single drug application. To
identify such compounds, data from the screens with and without fluconazole was
compared for each of the four fungal species (Figure 3.4).
The data was analysed for hit compounds using robust median absolute de-
viation (MAD; Chung et al., 2008; Birmingham et al., 2009) statistics. Since the
data has been normalised and the median for each screen is 100, the diagonal
was used as a model to define hits. Therefore, data points for drugs that do not
affect growth of the fungal strains differentially in the screens with and without
fluconazole will fall along the diagonal.
The scatter plots in Figure 3.4 revealed that most compounds did not affect
growth in either condition whereas a few compounds abolished growth completely
in both screens for each fungal strain (35-45 drugs in each species). Some com-
pounds inhibited growth of the fungal strains equally in both conditions.
Potential fluconazole-interacting compounds will be more active in the screen
with fluconazole (y-axis) and will therefore be found in the lower right corner of
the scatter plots. Compounds that were at least 2 MADs below the diagonal were
considered potential fluconazole-interacting drugs. These are shown as yellow and
red filled circles in Figure 3.4. The red dots represent the most potent synergisers
from the high throughput screen since these compounds inhibited growth by more
than 80% in the presence of fluconazole compared to the effect of these drugs on
their own.











































































































































































Active (< 80% inhibition)
Not active
Active (> 80% inhibition)
Figure 3.4: Scatterplots of the Prestwick Chemical library screens. For each
of the four fungal species, residual growth percentage values for fungi treated
with compounds alone (x-axis) and in the presence of fluconazole (y-axis) are
plotted. In each plot, hit compounds are found below the diagonal, in the bottom
right corner. Hits are marked in red (very strong inhibition in the presence of
fluconazole) and yellow. Compounds above the diagonal are not marked because
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Figure 3.5: Activity of hit compounds from Prestwick Chemical library screens.
148 compounds showed activity in at least one of the fours screens against C. neo-
formans (H99), C. gattii (R265), C. albicans (Caf2-1) and S. cerevisiae (BY4741).
The colours correspond to level of activity in the screen: red indicates compounds
with 80% increase in activity in combination with fluconazole as compared to ef-
fect of single drug and yellow are all compounds that are 2 MADs away, but
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Figure 3.6: Overlap of hits between different fungal species.
ure 3.5). 91 compounds were active in C. gattii and 70 in C. neoformans. The
screens in C. albicans and S. cerevisiae only revealed 30 and 43 synergistic combi-
nations, respectively. Analysis of the overlap of hits between the different fungal
strains as displayed in Figure 3.6 revealed a striking species- or genus-specificity
of the compounds. Of the hits, only six compounds were active in all tested
species: the antidepressant sertraline which is marketed as Zoloft R©; the ally-
lamine antifungal naftifine; the monoamine oxygenase inhibitor pirlindole which
also has antidepressant activity; the antibiotic prodrug pivampicillin; the anti-
nausea drug thiethylperazine which is marketed as Torecan; and, the antipsy-
chotic drug zuclopenthixol. The latter two compounds belong to a large group
of phenothiazine-derived drugs (Figure 3.7A) that are used as antipsychotics. Of
all hits, 88 compounds showed activity in a single species or genus only. There
is little overlap between S. cerevisiae and C. albicans (12 compounds), whereas
C. gattii and C. neoformans share many hits (53 compounds). These two genera
still have a considerable number of unique hits, 37 and 17 drugs, respectively.
The screen data was also analysed for potential antagonistic drugs. There
was very little overlap between the four fungal strains, which does not reflect
the degree of overlap that was observed for the fluconazole-interacting drugs. Of
the 12, 9, 21 and 21 drugs that were classified as antagonistic in the C. gattii,
C. neoformans, C. albicans and the S. cerevisiae screens, respectively, only two
compounds are shared between C. gattii and C. neoformans, and one compound
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Flavonoid Steroid Fenamic acid Statin
Figure 3.7: Structural clusters among the 148 hit compounds. (A) Back-
bone structure of phenothiazine and thioxathene compounds. (B) Activity of
phenothiazine/thioxathene-derived compounds in different fungal species. (C)
Backbone structure of other structural clusters of compounds. Structures (A) and
(C) were drawn using Symyx Draw, now Accelrys Draw (accelrys.com/resource-
center/downloads/freeware).
antagonistic compounds (clofazimine and kawain in C. albicans and suloctidil in
C. neoformans) were tested against all four species (see Section 3.2.2) and they did
not exhibit antagonistic interactions with fluconazole. In fact, suloctidil exhibits
synergy with fluconazole in three of the tested fungal strains. This suggests that
the screen set-up is not adequate to detect antagonistic drug interactions.
Structurally distinct groups of compounds enhance activity of Flucona-
zole
The 148 compounds that potentiated the action of fluconazole are structurally
very diverse and represent a wide range of therapeutic application classes includ-
ing cardiovasculars, hormone modulators, dermatologicals, a variety of neurolep-
tic drugs, genitourinary tract anti-infectives and antiparasitics.
Clustering of all hit compounds based on their chemical structures revealed
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several groups with similar structural features (Appendix). There were 37 clus-
ters in total, 22 of which contained at least two compounds. One structural
group that stood out were the tricyclic antipsychotics of the phenothiazine and
thioxanthene type. They are spread across clusters 16 and 30 (Appendix). The
backbone structure of these two compound classes are shown in Figure 3.7A. The
Prestwick library contains 17 of these and 15 were active in the screen, espe-
cially against C. gattii and C. neoformans (Figure 3.7B). Li et al. (2008) have
shown that derivatives of tricyclic phenothiazines inhibit fatty acid synthesis and
disrupt lipid trafficking. Phenothiazine-derivatives have also been described to
have antifungal activity which might at least partially be based on the lipophilic
character of these compounds (reviewed in Pluta et al., 2011). Another clus-
ter comprises of three plant-derived flavonoids (cluster 1 in Appendix; backbone
structure shown in Figure 3.7C). Flavones have been shown to have antifungal
properties by Young et al., 2007 and Rauha et al., 2000. Further, 12 steroid-
based compounds showed drug interactions with fluconazole (cluster 7; backbone
structure shown in Figure 3.7C) as well as two synthetic estrogen compounds
(cluster 22). It is possible that these compounds interfere with ergosterol biosyn-
thesis and/or integrate into membranes, changing their composition and physical
properties. Since fluconazole targets the fungal membrane, this could explain
the observed drug interactions. Further, seven non-steroidal anti-inflammatory
drugs showed activity in the screen (clusters 13, 20 and 22). Four of these are
fenamic acid derivatives, the backbone structure of which is shown in Figure
3.7C. Three statins were also among the hits (clusters 27 and 28, backbone struc-
ture shown in Figure 3.7C). Synergy between azole antifungals and statins have
been described before (Nyilasi et al., 2010). Statins are fungal metabolites and
are prescribed to lower cholesterin levels in the blood. Their antifungal activity
and synergy with azoles are probably based on their effect on membrane fluid-
ity. Statin-treated fungal cells have been shown to have lower levels of ergosterol
and therefore exhibit decreased membrane fluidity (Gyetvai et al., 2006). Vari-
ous antimicrobial compounds with very different structures were also hits in the
screens (Appendix). Known modes of action include binding to DNA, inhibition
of translation or thiamine metabolism as well as targeting microtubules or cell
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wall processes.
3.2.2 Synergy assessment and fungicidal activity
Enhancing drug interactions can be additive or synergistic. The high-throughput
screen only generated a single data point per drug, so it is impossible to distin-
guish between these two types of interaction. To characterise the drug interactions
for a subset of hit compounds and to assess the reliability of the high-throughput
screen, standard concentration matrix (checkerboard) analysis was conducted in
all four fungal species. Based on this data, fractional inhibitory concentration in-
dices (FICIs) were calculated, which is the accepted method for drug interaction
quantification in infectious diseases (Eliopoulos & Moellering, 1991; Odds, 2003).
12 of the 148 hit compounds were selected based on criteria of commercial
availability, known mode of action and therapeutic importance to investigate
the nature of their interaction with fluconazole further. The subset of con-
taining albendazole, azaperone, clofazimine, clomiphene, L-cycloserine, kawain,
lynestrenol, mitoxantrone, sertraline, suloctidil, tamoxifen, and trifluoperazine is
representative of the structural diversity and the variety of therapeutic applica-
tion classes present in the hit set (Figure 3.8).
To this collection, five known antifungal drugs were added which would allow
us to explore potential interactions between antifungals: amphotericin B, keto-
conazole, terbinafine, fenpropidin and caspofungin (Figure 3.8). Amphotericin B
is a polyene macrolide that binds to ergosterol in the fungal membrane, effectively
creating pores which results in leaky cells with depolarised membranes. Keto-
conazole, terbinafine and fenpropidin (an agricultural fungicide) are ergosterol
biosynthesis inhibitors. Terbinafine is actually a clinically relevant allylamine
analogue of naftifine, one of the six compounds that showed activity in all four
screens. Caspofungin is the first drug of the new class of echinocandins which


































































































































































ALIMENTARY TRACT AND METABOLISM
ANTIINFECTIVES FOR SYSTEMIC USE
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
CARDIOVASCULAR SYSTEM
DERMATOLOGICALS
GENITO URINARY SYSTEM AND SEX HORMONES
NERVOUS SYSTEM
Figure 3.8: Chemical structures and application classification of 17 com-
pounds selected for synergy confirmation experiments. Approved drugs are
shown with their therapeutic application class. Structures were drawn from










































Figure 3.9: Heatmap of drug interactions with fluconazole in each species. Dark
blue indicates additive effects (FICI of 0.5 to 1); lighter shades of blue represents
synergy (FICI <0.5). Orange triangles indicate fungicidal drug combinations;
yellow triangles indicate fungistatic drug combinations.
Characterization of drug interactions
Figure 3.9 shows the FICI values for the 12 hit compounds. All compounds,
except for kawain, exhibited drug interactions with fluconazole in at least one of
the strains tested. In the case of albendazole, azaperone and lynestrenol, these
interactions are merely additive. The remaining eight compounds had rather
diverse activity profiles across the different species. Only sertraline and triflu-
operazine interacted synergistically with fluconazole in all four fungal strains,
whereas suloctidil, tamoxifen and terbinafine interact in three of the four species.
Clofazimine, clomiphene, L-cycloserine and mitoxantrone A exerted synergistic
effects exclusively in S. cerevisiae. Neither of the other three pathogens were
uniquely susceptible to any of the molecules.
Assessment of the high-throughput screen performance
Overall, most drug interactions from the high-throughput screen could be con-
firmed as synergistic interactions with fluconazole, except for albendazole, azoper-
one and kawain in S. cerevisiae, and azaperone, L-cycloserine and lynestrenol in
C. albicans (Figure 3.10). Our quantification of drug interactions revealed five
additional synergies that were not statistically significant in the screen. Tri-














































Figure 3.10: Assessment of high throughput screen performance. Heatmap rep-
resents additive (dark blue) and synergistic (light blue) drug interactions with
fluconazole as shown in Figure 3.9. The symbols indicate agreement between
confirmatory experiments and high throughput data.
fluconazole against C. gattii and C. neoformans and suloctidil exerts synergy in
C. neoformans and S. cerevisiae. The sensitivity and specificity of the primary
high throughput screen were determined based on the detailed analysis of these
12 compounds. Sensitivity of the screen indicates how many drug interactions
are correctly identified by the screen. Specificity of the screen gives an indication
of how certain we can be that a hit in the screen really represents a true drug
interaction. Table 3.1 summarises the results from the high throughput screen
and the confirmatory assays. Using this contingency table, the specificity was
calculated as follows:








Synergy No interaction HTPS total
Hit compounds True Positives False Positives 19
13 6
No interaction False Negatives True Negatives 29
5 24
Confirmation total 18 30 48
Table 3.1: Contingency table for data from primary high-throughput screen and
results of confirmatory assays. The 48 interactions of the subset of 12 compounds
in all four species are considered.
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This means that 80% of all non-interacting drug pairs were correctly classified
as such based on high-throughput screen data. Consequently, the false positive
rate α is 0.2. The sensitivity was obtained according to this formula:






This indicates that 72% of all synergistic interactions were correctly identi-
fied in the high-throughput screen. The corresponding false negative rate β is
0.28. Overall, the screen proved to be a powerful tool to identify synergistic drug
interactions.
Fungicidal potential of synergistic drug combinations
Fluconazole is a fungistatic drug because it inhibits fungal growth but does not
kill the pathogens. Drugs with fungicidal properties are desirable therapies since
they are less likely to promote the development of drug resistance. Synergistic
drug combinations were therefore tested for their fungicidal potential (Figure 3.9).
The results were species-specific for sertraline and trifluoperazine. In contrast,
all synergistic combinations with suloctidil and tamoxifen showed fungicidal ef-
fects. In total, five compounds were fungicidal in combination with fluconazole.
Further, there is species specificity in the fungicidal potential of synergistic drug
combinations.
Interactions of known antifungals with fluconazole
The five known antifungals that were included in this analysis, exhibited very
individual profiles. Like the hit compounds from the screen, the observed inter-
actions were species specific in terms of drug interactions as well as fungicidal
potential (Figure 3.11).
The cell wall-targeting drug caspofungin is only synergistic with fluconazole
against C. albicans, but this interaction is the strongest of all drug combinations
investigated and has fungicidal potential. Additive interactions with fluconazole
were seen against the two Cryptococcus species. The synergistic effect in C.


























Figure 3.11: Heatmap of interactions between known antifungals and flucona-
zole. Dark blue indicates additive effects (FICI of 0.5 to 1); lighter shades of
blue represents synergy (FICI <0.5). Orange triangles indicate fungicidal drug
combinations; yellow triangles indicate fungistatic drug combinations.
infections and synergy with fluconazole against seven out of 50 clinical isolates of
Candida glabrata has been reported in Kiraz et al. (2010).
The Erg1 inhibitor terbinafine exhibits synergy with fluconazole against three
of the fungal pathogens, but none of these interactions are fungicidal. In C. ne-
oformans the interaction is merely additive. Terbinafine and fluconazole both
inhibit ergosterol biosynthesis, but act on different steps of the pathway. Lehár
et al. (2007) investigated interactions between various drugs that target the er-
gosterol pathway in Candida glabrata and found that the terbinafine/fluconazole
combination is highly synergistic. This synergy was also confirmed in clinical
isolates of C. albicans by Barchiesi et al. (1997 and 1998). The observed syner-
gistic interactions between fenpropidin and fluconazole against S. cerevisiae and
C. neoformans are probably also based on the fact that these two drugs inhibit
ergosterol biosynthesis at different steps. It is intriguing that one interaction is
fungicidal and the other one is not.
Just like fluconazole, ketoconazole is an inhibitor of Erg11. Therefore, ad-
ditive interactions would be expected between these two drugs. This is indeed
observed in all species tested except for C. albicans where the combination is
synergistic. This is somewhat surprising, but might be due to the fact that the
triazole fluconazole and the imidazole ketoconazole are structurally different and
do not have identical effects on the cell.
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Amphotericin B was not synergistic in any of the fungal pathogens, but instead
showed additive interaction with fluconazole in all species. This is in accordance
with results from Barchiesi et al. (2000) who observed additive interactions be-
tween these two drugs in 15 clinical isolates of Cryptococcus neoformans as well
as a mouse model of systemic cryptococcosis.
3.2.3 Interrogation of the mode of action of drug synergies
by genome-wide screens in S. cerevisiae
Six compounds were selected for further studies into the molecular basis of their
synergy with fluconazole. This set included all four compounds that were fungi-
cidal in combination with fluconazole in S. cerevisiae - clomiphene, suloctidil,
tamoxifen and trifluoperazine - as well as L-cycloserine which exhibits synergy
in S. cerevisiae only and sertraline which shows synergy in all four species (Fig-
ure 3.12). For these six compounds, sensitivity profiles for the ∼ 1000 essential
genes were generated using the heterozygous deletion pool (Giaever et al. 1999).
In addition, the set of ∼5000 haploid deletion strains of non-essential genes was
also screened for drug sensitivity. Both methods have been successfully used to
identify essential drug-targets (Lum et al., 2004) as well as biological pathways
associated with drug action (Parsons et al., 2004).
Haplo-insufficiency screens
Compound action was investigated with haplo-insufficiency screens, where 1000
deletion strains that are heterozygous for essential genes were tested for drug
sensitivity to identify potential drug targets (Giaever et al., 1999). The results
of the screens for fluconazole, clomiphene, sertraline, L-cycloserine, tamoxifen
and trifluoperazine are shown in Figures 3.13. An appropriate level of growth
inhibition of the deletion pool could not be achieved with suloctidil. It was
nevertheless included in the experiments to confirm chemical-genetic interactions
of the other compounds.
As expected, deletion of one copy of the lanosterol 14α-demethylase gene






























Figure 3.12: Chemical structures of the six drugs chosen for detailed mode
of action studies. Structures were drawn from SDF files provided by
Prestwick using Symyx Draw, now Accelrys Draw (accelrys.com/resource-
center/downloads/freeware).










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.13: Sensitivity of heterozygous essential deletion strains to six different
drugs. Genes along the x-axis are sorted by their ORF name. Negative Z-scores
indicate hypersensitivity of a deletion strain in the presence of a drug. Values in
parentheses indicate drug concentration in µg/mL.
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of either LCB1 and LCB2, which encode subunits of the enzyme serine palmi-
toyltransferase that catalyzes the committed step of sphingolipid biosynthesis,
caused sensitivity to L-cycloserine. L-cycloserine is known to inhibit sphingolipid
biosynthesis and it has been shown that in yeast membrane extracts, high con-
centrations of L-cycloserine (1 mM) partially inhibit serine palmitoyltransferase
(Pinto et al., 1992).
The four remaining compounds clomiphene, sertraline, trifluoperazine and
tamoxifen conferred sensitivity to cells heterozygous in the NEO1 gene, which
encodes an essential aminophospholipid translocase required for vacuolar biogen-
esis and membrane trafficking. It has recently been shown that deletion of the
ortholog of NEO1 in C. neoformans (APT1) results in hypersensitivity to flu-
conazole and amphotericin B, as well as attenuated virulence (Hu and Kronstad,
2010). In addition, loss of one copy of TIM54, a translocase of the inner mito-
chondrial membrane, conferred sensitivity to tamoxifen and trifluoperazine in the
high throughput screen.
Growth assays that were conducted to validate the results from the haplo-
insufficiency screens confirmed the drug gene interactions observed in the screens.
Further, the specificity of these interactions was affirmed by these experiments.
Figure 3.14 shows that fluconazole sensitises ERG11/erg11∆. LCB1/lcb1∆ and
LCB2/lcb2∆ were sensitive to L-cycloserine and NEO1/neo1∆ is highly sensitive
to clomiphene, sertraline, tamoxifen and trifluoperazine as well as suloctidil. The
growth curves have also been quantified and the data for the strains shown here
is included in Figure 3.18B. For the quantification, OD measurements were taken
at the time point of control well saturation and log ratios of drug treated deletion
strains versus the untreated strains were calculated. TIM54 was also tested as
well as TIM18 and TIM22, which function in the TIM22 complex with TIM54
(Figure 3.18B). The chemical-genetic interactions of TIM54 with tamoxifen and
trifluoperazine were confirmed. Additional interactions with clomiphene and ser-
traline were identified. Testing a range of drug concentrations in the growth
curve assays, also revealed chemical-genetic interactions for TIM18 and TIM22,
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Figure 3.14: Confirmation of hits from haplo-insufficiency screen. Based
on barcode array data for the heterozygous essential genes, ERG11/erg11∆,
NEO1/neo1∆, LCB1/lcb1∆ and LCB2/lcb2∆ were selected for individual growth
curve assays in the presence of the indicated drugs. Percentage growth of the dif-
ferent deletion strains and WT compared to control wells (strains treated with
solvent control) is plotted for each drug. Values in parentheses indicate drug
concentration in µg/mL.
Chemical-genetic profiles of fluconazole and synergistic drug combina-
tions
Chemical-genetic profiles obtained by screening the haploid deletion pool against
compounds/compound combinations, point to target pathways and reveal genes
that buffer against drug toxicity. In addition, compounds with similar chemical-
genetic interaction profiles may comprise similar bioactivities (Hillenmeyer et al.,
2008). The haploid deletion pool was then subjected to the syncretic compounds
individually and in combination with fluconazole (Figure 3.15). The heatmap dis-
plays, from left to right, chemical-genetic interactions of fluconazole alone, syn-
ergiser/fluconazole combinations and the synergising drugs alone. The profiles of
the drug combinations are very similar to the profiles of fluconazole at higher con-
centrations (6-8 µM). The big clusters in the left part of the heatmap correspond
to mutants that are sensitive to fluconazole and drug combination treatment.
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Figure S6 – Global heatmap representing all haploid deletion strain chemical-genetic profiles in this study. 
The haploid deletion strain pool for ~5000 non-essential genes was screened for sensitivity to sertraline, 
clomiphene, tamoxifen, L-cycloserine, trifluoperazine and suloctidil alone and in combination with 
fluconazole. Screens are represented along the x-axis and deletion strains along the y-axis. Screens and 
deletion strains were clustered hierarchically  according to Pearson correlation between chemical-genetic 
profiles. Negative Z-scores (red) indicate sensitive deletion strains whereas positive Z-scores (green) 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.15: Heatmap representing all haploid chemical-genetic profiles generated
for this study. The haploid deletion pool of 5000 non-essential deletion strains
was screened for sensitivity to sertraline, clomiphene, tamoxifen, L-cycloserine,
trifluoperazine and suloctidil alone and in combination with fluconazole. Screens
are represented along the x-axis and deletion strains that were responsive in at
least one of the screens are represented along the y-axis (about 400 strains).
Screens and deletion strains were clustered hierarchically according to Pearson
correlation between chemical-genetic profiles. Negative Z-scores (red) indicate
sensitive deletion strains whereas positive Z-scores (green) represent resistant






















































































































































































































































































































































































































































































































































































































Figure 3.16: Haploid deletion strain sensitivity to different fluconazole con-
centrations and the syncretic drugs in the presence or absence of fluconazole.
(A) Heatmap of Z-scores for fluconazole-specific deletion strains from all hap-
loid chemical-genetic screens. GO annotations for genes involved in to vacuolar
and vesicle mediated transport are indicated. (B) Average Z-score across all
fluconazole-specific deletion strains for each screen. Different concentrations of
fluconazole are represented by red bars; blue indicates fluconazole with syncretic
drugs; green indicates syncretic drugs alone.
These fluconazole-responsive deletion strains were investigated in more detail.
Deletion strains sensitive to increasing concentrations of fluconazole alone were
associated with vesicle mediated transport and membrane organisation (Figure
3.16A), as described in previous studies (Parsons et al., 2006). For the drug
combinations, a concentration of fluconazole (6 µg/mL) that caused 20% growth
inhibition compared to control treatment was used. At this concentration, the
fluconazole-sensitive strains only have an average Z-score of around -2, whereas
a concentration of 8 µg/mL impairs growth of these deletion strains much more
resulting in an average Z-score of -4 (Figure 3.16B). Importantly, the synergis-
ing drugs alone did not impair growth of fluconazole-sensitive deletion strains.
However, they sensitised cells to lower doses of fluconazole when applied in com-
bination (Figure 3.16A and B). P-values for the increased sensitivity of these
deletion strains compared to the screen with 6 µg/mL of fluconazole confirmed
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Fluconazole 2µg/mL 9.05E-08 1.98
Fluconazole 4µg/mL 3.25E-10 1.86
Fluconazole 6µg/mL - 0.00
Fluconazole 8µg/mL 1.59E-17 -1.91
Fluconazole 8µg/mL 5.27E-14 -1.79
Fluc. 6µg/mL & Cyclos. 40µg/mL 5.85E-05 -1.00
Fluc. 7µg/mL & Tri. 1.2µg/mL 3.28E-05 -1.04
Fluc. 6µg/mL & Tam. 1µg/mL 2.39E-06 -1.09
Fluc. 6µg/mL & Sertr. 0.75µg/mL 1.36E-05 -1.22
Fluc. 6µg/mL & Sertr. 0.75µg/mL 1.71E-04 -1.12
Fluc. 6µg/mL & Clom. 0.2µg/mL 3.07E-08 -1.43
Fluc. 6µg/mL & Clom. 0.2 µg/mL 3.53E-08 -1.58
Fluc. 6µg/mL & Clom. 0.3 µg/mL 4.91E-07 -1.45
DMSO 1 (E)/ DMSO 2 (E) 4.46E-08 2.29
L-cycloserine 40µg/mL 9.21E-07 1.98
L-cycloserine 50µg/mL 7.07E-09 2.27
Trifluoperazine 1.75µg/mL 8.34E-05 1.78
Tamoxifen 1µg/mL 1.53E-05 1.75
Tamoxifen 1.2µg/mL 1.45E-04 1.51
Sertraline 0.75µg/mL 1.90E-05 1.59
Sertraline 1µg/mL 1.69E-05 1.63
Sertraline 0.75µg/mL 1.95E-06 1.77
Clomiphene 0.5µg/mL 2.27E-08 2.10
Clomiphene 0.6µg/mL 2.33E-06 1.84
Clomiphene 0.3µg/mL 9.38E-09 2.11
Suloctidil 0.15µg/mL 1.07E-07 2.31
Table 3.2: P-values for mean Z-scores of fluconazole-specific deletion strains in
each of the chemical-genetic profiles as shown in Figure 3.16B.
Chemical-genetic profiles of fluconazole synergisers
The chemical-genetic profiles of the six syncretic synergisers (Figure 3.15) were
examined in detail to gain insight into the mode of action of their interaction
with fluconazole. In Figure 3.17 the sensitivity of the 5000 deletion strains in the
presence of each drug is shown. The plot shows that some deletion strains are
sensitive or resistant to more than one of the synergisers.
The heatmap in Figure 3.18A focuses on these strains because they might help
explain the observed synergies between the compounds and fluconazole. A list
with the corresponding Z-scores can be found in Appendix Table S1. Clomiphene,




























































































































































































































Figure 3.18: Haploid deletion strains sensitive to syncretic synergisers. (A) Dele-
tion strain sensitivity to synergising drugs based on primary barcode screen data.
From duplicate profiles for each compound, strains that have a Z-score more sig-
nificant than ±3 are shown. Gene names in red indicate deletion strains that
were chosen for verification by individual growth assays. (B) Log-ratio scores
were calculated from individual growth curve assays to confirm chemical-genetic
interactions. For this, OD measurements were taken a the time point of control
well saturation and log ratios of drug treated deletion strains versus the untreated
strains were calculated. Gene names in bold indicate deletion strains that are het-
erozygous for essential genes. Negative Z-scores and log-ratios indicate sensitivity
of a strain to a specific drug, whereas positive scores represent resistance. Blue
asterisks indicate the 14 deletion strains that comprise the signature deletion
strain set for the membrane active compounds.
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a common set of deletion strains including genes that encode the non-essential
post-Golgi associated aminophospholipid translocase (flippase) DRS2 and its ac-
tivating subunit Cdc50, the protein trafficking factors Sac1 and Vps74, the cell
wall integrity MAPK kinase Slt2 and its upstream activating kinase Bck1, the
ergosterol biosynthesis enzyme Erg6 and the mitochondrial outer membrane im-
port factors Mdm10 and Mdm12. In addition, the deletion of genes involved
in downstream steps of sphingolipid metabolism, including IPT1, SKN1, SUR1,
SWH1 and YPK1 caused growth inhibition in the presence of these compounds.
The majority of deletion mutants sensitive to clomiphene, sertraline, suloctidil,
tamoxifen and trifluoperazine are involved in membrane processes and the cell
wall integrity pathway.
Interestingly, strains disrupted for non-essential genes implicated in retrograde
transport to the cis-Golgi network (YPT6, RGP1, RIC1, VPS52) and in uncoat-
ing of clathrin vesicles (SWA2) were resistant to all synergisers (Figure 3.18A),
suggesting that limited vesicle trafficking may compensate for membrane pertur-
bation. It is also possible that vesicle trafficking is required for drug import.
The chemical-genetic interactions described above were confirmed with quan-
titative growth curve assays (Figure 3.18B). With the exception of the dubious
ORF YOR072W, the quantitative growth curves corroborated the barcode mi-
croarray results. Haploid deletion strains for DNF1/2/3, the other three flippases
in S. cerevisiae, and LCB3/4/5, which function downstream of LCB1/2, were also
tested because they are functionally related to essential genes that were identi-
fied as haplo-insufficient. The only chemical-genetic interaction observed for the
LCB3/4/5 genes was one between LCB3 and L-cycloserine. Of the non-essential
flippases, deletion of DNF3 sensitised yeast to trifluoperazine, tamoxifen and
clomiphene. The lack of chemical-genetic interactions for DNF1/2 might be due
to the localisation of the different flippases in the cell: Dnf1 and Dnf2 are found in
the cell membrane whereas Neo1, Drs2 and Dnf3 localise to the Golgi membranes.
Since five of the drugs (clomiphene, sertraline, suloctidil, tamoxifen and tri-
fluoperazine) shared a number of chemical-genetic interactions, these 14 deletion
strains were defined as signature deletion strains in Figure 3.18.
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Summary
The results of these genome-wide chemical-genetic screens suggest two related
modes of action for the synergistic interactions with fluconazole. Clomiphene, ser-
traline, suloctidil, tamoxifen and trifluoperazine appear to cause general pertur-
bation of membrane, vesicle trafficking and lipid biosynthesis functions, whereas
L-cycloserine interferes with an early step in sphingolipid biosynthesis, consis-
tent with its previously established mechanism of action (Pinto et al., 1992). To
test the latter hypothesis, the effects of myriocin, another known inhibitor of the
first step of the sphingolipid biosynthesis pathway was examined (Miyake et al.,
1995). It also potentiated the antifungal action of fluconazole (FICI = 0.625),
thus confirming that the drug interaction between fluconazole and L-cycloserine
is based on the inhibition of sphingolipid biosynthesis.
3.2.4 Cell biological effects of synergistic drug combina-
tions
The effects of the syncretic synergisers alone and in combination with fluconazole
on cell physiology were assessed. The distribution of different dyes in S. cerevisiae
WT cells treated with compounds alone and in combination was visualised. The
effect of sorbitol on yeast treated with the synergisers and fluconazole was also
examined.
Microscopy images reveal effects on cell membrane
The effects of trifluoperazine, tamoxifen, sertraline, and L-cycloserine alone and
in combination with fluconazole on S. cerevisiae cell physiology was evaluated.
Different diagnostic fluorescent dyes that bind to various cellular structures were
applied to investigate cell physiological changes in response to drug treatment.
FM4-64, Calcofluor white and Mitotracker Green were used to visualise vacuolar
membranes, the cell wall and bud scars, and mitochondria, respectively. Images
shown are for cells treated with drugs for 1 hour. Staining patterns in response
to 3 hour incubation with drugs looked similar.
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FluconazoleSolvent control Sertraline FLC + SertralineA  (i)
 (ii)
 (iii)









Figure 3.19: Images of wild type S. cerevisiae grown in the presence of the indi-
cated drugs and stained with (i) Calcofluor White M2R, (ii) FM4-64 and (iii) Mi-
totracker Green FM, and imaged by fluorescence microscopy. (A) Sertraline (128
µg/mL) in the presence and absence of fluconazole (64 µg/mL). (B) L-cycloserine

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Flucon- Clomiphene Sertraline Suloctidil Tamoxifen Trifluo-L-cyclo-
1.5mg/ml128mg/ml6mg/ml 4mg/ml16mg/ml 6mg/ml7.5mg/ml
perazineserineazole
Figure 3.23: Growth of wild type S. cerevisiae treated with the syncretic syner-
gisers or fluconazole in the presence and absence of 1 M sorbitol as a percentage
of growth in control wells. The mean of four independent measurements is shown;
error bars correspond to standard error.
For each of the reporter dyes, the staining pattern in response to fluconazole
was similar to that generated with solvent controls (second column in Figures
3.19A, 3.19B, 3.20, 3.21, 3.22). In contrast, single drug treatment with trifluop-
erazine, tamoxifen, clomiphene and sertraline caused a drastic loss of dye locali-
sation and strong intracellular accumulation (Figure 3.19A, 3.20, 3.21, 3.22). In
particular, FM4-64 staining revealed the disruption of vacuolar structures. This
suggests severe loss of cell membrane integrity. The same effects were observed
when cells were treated with the synergistic drug combinations. The microscopy
images confirm an effect on membrane integrity of trifluoperazine, tamoxifen,
clomiphene and sertraline as suggested by the chemical-genetic interactions de-
scribed in Section 3.2.3. Consistent with its different chemical-genetic profile,
treatment with L-cycloserine alone or in combination with fluconazole had no
obvious effects on the localisation of any of the dyes (Figure 3.19B).
Sorbitol rescue assay
Osmotic stress caused by compromised membrane and/or cell wall structures can
often be rescued with isotonic solutions such as NaCl or sorbitol that act as
osmotic stabilisers. To test if the effect of the synergisers could be rescued by
osmotic stabilisation, a Saccharomyces cerevisiae WT strain was grown in the
presence of fluconazole, clomiphene, L-cycloserine, sertraline, suloctidil, tamox-
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ifen and trifluoperazine with and without 1 M sorbitol added to the medium.
Growth curves were obtained in 96-well plates. Addition of sorbitol was found to
relieve the growth inhibitory effects of trifluoperazine, tamoxifen, clomiphene, ser-
traline, and suloctidil (Figure 3.23). This again supported the idea of a common
membrane perturbation mechanism for these compounds. No such protective
effects were observed in cells treated with fluconazole or L-cycloserine (Figure
3.23).
3.2.5 Integration of chemical-genetic interactions with ge-
netic interaction networks
The vast number of possible drug combinations is a major challenge in the dis-
covery of synergistic drug pairs (Sharom et al., 2004; Lehár et al., 2008). As
described in Section 1.3.5, different approaches have been developed to predict
effective drug combinations computationally. Here, the chemical-genetic profiles
described in 3.2.3 were examined for their predictive power by integrating them
with genetic interaction data obtained from BIOGRID (Breitkreutz et al., 2008;
BIOGRID release 2.62). This global interaction network contains genetic inter-
actions from both, low throughput and high throughput experiments.
Genetic interactions to rationalise synergy
Analogous to genetic interactions, chemical-genetic interactions are based on the
idea of parallel pathways that converge onto an essential process in the cell.
Chemical-genetic profiles of single drugs can be interpreted as a pathway response
of the genes that are affected by drug treatment. The chemical genetic profiles
of fluconazole and the synergising drugs were investigated to see if they represent
such parallel pathways by analysing the genetic interaction space between the
respective sets of sensitive deletion strains. The 50 most sensitive deletion strains
to fluconazole were analysed in combination with the 50 most sensitive deletion
strains for each of the synergising drugs. Many genetic interactions were found
between the sets of sensitive deletion strains for all six syncretic drugs. This is
especially true for the common set of deletion strains that are sensitive to the set
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Figure 3.24: Integration of chemical-genetic and genetic networks. Bipartite
graph representing known genetic interactions between the 50 deletion strains
most sensitive to fluconazole treatment and the signature strains affected by the
five membrane active compounds. PDR5 was a member of both sets and is
therefore positioned midway between the two sets. GO categories were visualised
using GOlorize (Garcia et al., 2007).
of membrane active compounds that are referred to as ’signature’ (Figure 3.24).
Two different tests were devised to determine the significance of this enrich-
ment of genetic interactions. The first test was based on random sampling from
a chemical genetic space (CGS) that was defined based on data from Hillenmeyer
et al., 2008. 1143 non-essential genes that are responsive to drug treatment when
deleted comprised the CGS. The resulting background distributions for the num-
ber of genetic interactions between gene sets of fixed sizes randomly chosen from
CGS are shown in Figure 3.25A. The black curve represents the background dis-
tribution for the syncretic drugs because 50 deletion stains were used for analysis
of each drug. The background distribution for the signature deletion strains is
shifted to the left since this set contains only 14 strains. Arrows indicate the
actual number of genetic interactions for each drug. Calculation of p-values con-
firmed that there is a significant enrichment of interactions with tamoxifen, tri-
fluoperazine, clomiphene, sertraline, suloctidil and the signature deletion strains
sensitive to the membrane targeting compounds (p-values <0.05) whereas the
p-value for L-cycloserine was not significant (Table 3.3).
A more conservative test was also applied to look at pathway separation (Kel-
86
A































































Figure 3.25: Rationalization of synergistic interactions. (A) Results of the chemi-
cal genetic space (CGS) simulations with the 50 most sensitive deletion strains for
each synergiser as well as the signature strain set. The actual numbers of genetic
interactions between gene sets are indicated by arrows. The black curve depicts
the background distribution of genetic interactions between two random sets of 50
non-essential deletion strains chosen from 1143 strains that respond to a variety
of drug treatments (Hillenmeyer et al., 2008). The dark red curve corresponds
to the same background distribution except that the size of the second sample
set size matches the size of the signature deletion strain set. (B) Results of the
parallel pathway permutation (PPP) simulations for each of the drugs as well as
the signature strain set. Coloured curves represent background distributions for
the different drugs. Arrows indicate the actual number of interactions and colour
code is the same as in Figure 3.25A (C) Scheme of PPP simulations. * in (A)
and (B) indicate p-values <0.05.
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Tamoxifen < 10−7 0.327
Trifluoperazine < 10−7 0.001
Suloctidil 0.0006 0.2724
Signature strains < 10−7 0.0056
Table 3.3: P-values for the CGS and PPP simulations for profiles of L-cycloserine,
clomiphene, sertraline, suloctidil, tamoxifen and trifluoperazine as well as for the
signature deletion strains.
ley & Ideker, 2005). Parallel pathway permutation (PPP) was implemented,
a simulation where the chemical genetic interactors of each of the synergistic
drugs and fluconazole were pooled and randomly divided into two groups (Figure
3.25C). The background distributions and the actual values for each drug are
shown in Figure 3.25B. Using this simulation, only the set of signature deletion
strains and the top 50 most sensitive deletion strains for trifluoperazine showed
significant enrichment (p-values <0.05; Table 3.3). It is thus possible to ratio-
nalise synergism based on the genetic interactions that link the chemogenomic
profiles of compound pairs that exhibit synergy.
Assessment of predictive power of signature deletion strain set
Following on from the results with the fluconazole synergisers, the predictive
power of the signature deletion strain set (defined in Figure 3.18) was assessed.
The chemical-genetic profiles of psychoactive drugs generated by (Ericson et al.,
2008) were analysed retrospectively. Of the 81 compounds that impaired yeast
growth, 16 were represented in the Prestwick chemical library. The sensitivity
of the signature strains in these chemical genetic profiles was examined (Figure
3.26). Seven of these compounds were predicted to synergise with fluconazole and
indeed, all seven drugs showed activity in the screen. Four compounds have been
classified as hits whereas the other three exhibited weak activity. These findings
































































Figure 3.26: Chemical-genetic profiles of 11 signature deletion strains in response
to 16 previously profiled psychiatric drugs (Ericson et al., 2008) that are present
in the Prestwick chemical library. P-values indicate significance of enrichment
of signature strains. Compounds marked as active (purple) were clear hits in
our screen (80% inhibition and/or 2 MADs away from diagonal) whereas weak
activity refers to compounds that are 1 MAD away from the diagonal and show
at least 20% growth inhibition.
genetic interaction profiles.
Analysis of the profiles of all 81 compounds from the Ericson et al., 2008
dataset resulted in a list of 20 compounds that are predicted to interact with
fluconazole (Figure 3.27). Seven of these drugs were also represented in Figure
3.26 since they are present in the Prestwick chemical library. This means that an
additional 13 compounds were predicted based on the signature deletion strains
meaning that the signature was actually found in various chemical-genetic profiles.
Like sertraline, many of these drugs are inhibitors of dopamine (re-)uptake.
3.2.6 Further characterisation of drug synergies
Various additional experiments were conducted to further characterise the syn-
ergising drugs. First, potential drug interactions with other inhibitors of the er-













































































Figure 3.27: Top predictions for synergisers based on profiles of signature deletion
strains. Chemical-genetic profiles of 11 signature deletion strains in response to
all 81 profiled psychiatric drugs (Ericson et al., 2008). Compounds marked as
active (purple) were clear hits in our screen (80% inhibition and/or 2 MADs away
from diagonal) whereas weak activity refers to compounds that are 1 MAD away
from the diagonal and show at least 20% growth inhibition. Drugs with a p-value
<0.05 for enrichment of signature strains are shown.
also assessed and the antifungal effects of 3-way combinations with fluconazole
analysed. Finally, the combination of sertraline and fluconazole was tested in an
in vivo model of Cryptococcus infection and the drug combination’s efficacy was
tested against clinical isolates of Candida strains.
Fluconazole- and species-specificity of drug interactions
To investigate if the synergies are specific to fluconazole, two of the synergisers
were tested in combination with other ergosterol biosynthesis inhibitors for drug
interactions. Terbinafine, an inhibitor of the Erg1 squalene epoxidase, and ke-
toconazole, an imidazole inhibitor of ERG11 were used. To assess interactions
in different fungal species, the psychoactive drugs trifluoperazine and sertraline
were selected since they exhibited synergy with fluconazole against each of the
fungal species tested in Section 3.2.2.
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Strain Terbinafine Ketoconazole
Trifluoperazine Sertraline Trifluoperazine Sertraline
C. neoformans (H99) 2 0.75 0.25 0.38
C. albicans (Caf2-1) 2 0.5 0.38 0.16
S. cerevisiae (BY4741) 0.38 0.52 0.38 0.31
Table 3.4: FICI values for combinations of sertraline and trifluoperazine with the
ergosterol biosynthesis inhibitors terbinafine and ketoconazole in different species.
Values smaller than 0.5 indicate synergy, values between 0.5 and 1 indicate addi-
tivity and values higher than 1 indicate no interaction.
The FICI values for the combinations in Cryptococcus neoformans, Candida
albicans and Saccharomyces cerevisiae are summarised in Table 3.4. Ketocona-
zole was synergistic with both, trifluoperazine and sertraline, in all three fungal
species. The results for terbinafine were less consistent. Synergy was observed
with sertraline in Candida and Saccharomyces but not Cryptococcus. With triflu-
operazine it only synergised in Saccharomyces. These findings suggest that even
though mechanisms of synergy are conserved between different inhibitors of the
same pathways, there are species-specific differences in response to different com-
pounds. These are most likely due to differences in the genetic network structure
between species (Kuo et al., 2010).
Higher order combination of synergisers
Drugs with identical mode of actions are not expected to show synergy, but
instead should act in an additive manner. To further characterise the mode of
action of the synergisers, pairwise combinations between the membrane active
drugs sertraline, trifluoperazine, suloctidil and tamoxifen, as well as with the
sphingolipid-selective synergiser L-cycloserine were examined in an S. cerevisiae
WT strain (Table 3.5).
Despite their partially overlapping chemical-genetic profiles, synergistic inter-
actions between tamoxifen and trifluoperazine (FICI = 0.5), sertraline and triflu-
operazine (FICI = 0.4) and sertraline and tamoxifen (FICI = 0.5) were observed.
These results suggest that in addition to the effects on membrane permeability,
each compound likely elicits one or more other effects that contribute to their
overall mechanism of action. The combination of these additional effects results
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Sert Sert Tri Tri Tam Tam Suloc Suloc
(32) (64) +FLC +FLC +FLC
Trifluoperazine 0.38 0.50
Tamoxifen 0.50 0.63 0.50 0.75
Suloctidil 1.25 1.50 2.00 0.56 1.00 0.75
L-cycloserine 1.25 0.63 1.00 2.00 1.00 0.52 2.00 0.31
Table 3.5: Analysis of interactions between syncretic drugs and higher order com-
binations with fluconazole. L-Cycloserine, suloctidil (Suloc), tamoxifen (Tam)
and trifluoperazine (Tri) were combined as indicated, in the presence or absence
of 1/8 MIC fluconazole (4 µg/mL) and assayed for growth inhibition of the S.
cerevisiae strain (BY4741). FICI values smaller than 0.5 indicate synergy, val-
ues between 0.5 and 1 indicate additivity and values higher than 1 indicate no
interaction. Drug concentrations are indicated in µg/mL.
in further synergism. This means it should be possible to devise higher order
combinations between synergisers that lead to even stronger growth inhibition in
the presence of fluconazole. Thus, compound pairs were tested in the presence of
fluconazole in three-way combinations (Table 3.5). In these assays, fungal growth
was often potently inhibited. Specific sensitivity to the suloctidil/trifluoperazine,
L-cycloserine/suloctidil and L-cycloserine/tamoxifen combinations was revealed
by titration of fluconazole concentrations. The presence of just 1/8 MIC flu-
conazole showed strong effects (Table 3.5). L-cycloserine/suloctidil exhibited the
most potent synergy with fluconazole with an FICI value of 0.3. These results
demonstrate that the subtly different effects of the individual synergisers allow
to incrementally build higher order synergistic combinations.
In vivo assessment of anti-fungal synergy in an insect model of infection
The efficacy of the synergistic drug combinations in an in vivo infection model of
cryptococcal virulence, the caterpillar of the greater wax moth Galleria mellonella
was also evaluated (Mylonakis et al., 2005; Scully & Bidochka, 2006). The effect
of treatment with single drugs and drug combinations on survival rates of cater-
pillars infected with C. neoformans was assessed because this virulent pathogen
is prevalent in immune-compromised patients. Upon infection of G. mellonella
with C. neoformans, the caterpillars were injected with drug(s) or DMSO the
following day.
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Figure 3.28: Synergistic activity of fluconazole with sertraline in an in vivo infec-
tion model. (A) G. mellonella caterpillars were injected with C. neoformans H99
(8x103 cfu) on day 0 and with drugs alone or in combination (26 µg sertraline;
1 µg fluconazole) on day 1 and incubated for one week at 37◦C. Values plotted
are the mean of three independent experiments. (B) Picture of uninfected G.
mellonella caterpillars (top); melanisation of infected G. mellonella caterpillars
(bottom). Emma Griffith provided the photos of G. mellonella.
Of the five synergising drugs suloctidil, sertraline, tamoxifen, trifluperazine
and fenpropidin, only sertraline showed a significant effect on worm survival rate
in combination with fluconazole. Figure 3.28A shows the survival rates of worms
treated with fluconazole, sertraline, both drugs in combination and with solvent
control alone (DMSO). Without any drug treatment and in response to sertraline
treatment, only about 10% of the worm population was alive after seven days.
Application of fluconazole increased survival rates to 20%. Treatment with ser-
traline and fluconazole in combination, however, resulted in a significant increase
of the survival rate to 60% which confirms the synergistic action between these
two drugs in vivo (p-value < 0.02).
Synergistic activity against fluconazole-resistant Candida isolates
Since the sertraline/fluconazole combination proved effective in an in vivo infec-
tion model, it was further tested against clinically resistant isolates of Candida
species. The effect of the drug combination on the clinical isolates C. albicans
2007, C. albicans 2008 and C. glabrata as well as a resistant C. parapsilosis control
strain was assessed with checkerboard assays.




























































































































































Figure 3.29: Synergistic activity of fluconazole with sertraline against clinical
isolates of Candida strains. (A) Combination matrix assays against drug-resistant
isolates of C. albicans 2007, C. albicans 2008, C. glabrata and C. parapsilosis.
Optical density readings were plotted for the combinations of two-fold dilutions
of each drug. (B) Analysis of Bliss synergy for the combination assays in panel A.
Drug concentrations are in µg/mL. Jan Wildenhain generated the surfaces and
heatmaps.
all four strains. Calculation of Bliss synergy scores for each of the matrices re-
vealed that the sertraline/fluconazole combination has a synergistic effect in all
four Candida strains because they all have Bliss scores greater than 0.5 (Figure
3.29B). Determination of the MIC of fluconazole in combination with sertraline
shows that in the presence of sertraline, the susceptibility of the Candida strains
to fluconazole increased by up to 32-fold (Table 3.6). MIC values of the flucona-
zole resistant strains ranged from 2-8 µg/mL which is comparable to wild type
(8 µg/mL) and the drug pump-deficient strains of C. albicans (2 µg/mL). The
FICI values in Table 3.6 reveal that the combination of sertraline and fluconazole
is synergistic in both C. albicans isolates as well as the C. parapsilosis reference
strain. The FICI value for the C. glabrata isolate suggests that the drug combina-
tion has an additive effect only. This is inconsistent with the Bliss scores shown in
Figure 3.29B and is most likely due to the fact that the MIC values of the single
drugs that are used in the FICI calculation could not be determined in the C.
glabrata isolate. These experiments show that the synergistic drug interactions
in reference laboratory strains translate to drug-resistant pathogens derived from
clinical environments.
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Species MICFLC MICSertr Lowest MICFLC+Sertr FICI
C. albicans 2007 64 > 128 4 < 0.5
C. albicans 2008 64 > 128 2 < 0.5
C. glabrata > 128 > 128 8 0.625*
C. parapsilosis 32 > 128 2 0.375
Table 3.6: MIC and FICI values for drug resistant Candida strains treated with
combinations of fluconazole and sertraline. MIC values are given in µg/mL.
* indicates a FICI value based on two MICs that are > 128 and is therefore
probably unreliable.
3.2.7 Summary of Results
This project aims to extend the concept of chemical synthetic lethality from
model organisms to clinically relevant fungal pathogens. The Prestwick Chem-
ical library, which contains 1120 known drugs, was screened against Candida
albicans, Cryptococcus neoformans and Cryptococcus gattii, as well as the genet-
ically tractable budding yeast Saccharomyces cerevisiae to identify synergistic
enhancers of the fungistatic drug fluconazole. Compounds, not previously known
for their anti-fungal properties, showed potent growth inhibition in combination
with fluconazole. These interactions were often genus- or species-specific and
improved the action of fluconazole from fungistatic to fungicidal.
A subset of compounds was selected to investigate the mechanism of action
of their interaction with fluconazole in more detail. Chemical-genetic profiles
revealed two classes of compounds: one causes membrane perturbation and the
other inhibits sphingolipid biosynthesis. Integration of the chemical-genetic pro-
files with genetic interaction data allowed for prediction of further synergistic
drug combinations based on the mode of action studies. Strikingly, higher order
combinations of fluconazole and synergisers, further increased antifungal activ-
ity. Synergistic combinations were shown to be active in the in vivo infection
model of G. mellonella and efficacious against fluconazole-resistant fungal iso-
lates. Overall, this approach successfully combines the ’drug combination’ and




3.3.1 New antifungal chemical space revealed by system-
atic screens for syncretic drug combinations
In infectious disease control, the combination of known antifungal agents is an
established therapeutic approach (Johnson & Perfect, 2010). The work presented
in this chapter shows that the combination of a known antifungal with bioactive
drugs that do not have antifungal potential on their own allows for the antifungal
chemical space to easily be expanded. As described in this chapter, this also
applies to off patent drugs that have previously been approved for other indi-
cations. Systematic screens against various pathogenic fungi in the presence of
sub-therapeutic concentrations of the known antifungal fluconazole resulted in the
identification of novel syncretic drug combinations. The 148 drugs identified as
hits comprised a chemically diverse set of compounds covering a broad spectrum
of human therapeutic areas. These drugs would probably not have been tested
for their antifungal potential by infectious disease clinicians. (Section 1.3.4)
The fungicidal activity exhibited by many of the syncretic combinations, is
a highly desirable feature for infectious disease control. The combination of flu-
conazole and sertraline (the antidepressant Zoloft R© was active against all species
tested and showed fungicidal potential in two species. This combination was also
successfully tested against clinical drug-resistant Candida isolates and in an in
vivo insect model of C. neoformans infection. Fungal infections of the CNS are
a particular clinical challenge because of the requirement for drugs to pass the
blood-brain barrier. There is potential for the sertraline-fluconazole combination
to be effective in the treatment of fungal meningitis because sertraline targets
serotonin receptors in the CNS.
3.3.2 Molecular mechanisms of synergism
A subset of six fungicidal synergisers was subjected to genome-wide chemical
genetic screens in the budding yeast S. cerevisiae. Two different mechanisms
for synergy with fluconazole were revealed by these experiments. Five of the
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compounds (trifluoperazine, tamoxifen, clomiphene, sertraline and suloctidil) ex-
hibited genetic sensitivities and cell biological phenotypes that are typically as-
sociated with loss of membrane integrity. The membrane perturbation that these
compounds cause may impair fluconazole export via drug efflux pumps, increase
susceptibility of cells to the accumulation of toxic ergosterol pathway intermedi-
ates, and/or impair import of extracellular ergosterol (Kuo et al., 2010). Notably,
all five compounds are cationic amphiphilic drugs (CADs) that are known to in-
tercalate preferentially into one side of the membrane lipid bilayer. This has
previously been shown to cause membrane expansion and cell wall stress (Sheetz
& Singer, 1974), consistent with the chemical-genetic interactions with NEO1,
DRS2, SLT2 and BCK1 that were observed. Further, Rainey et al. (2010) found
genetic resistance to the CAD sertraline to be conferred by perturbation of vesic-
ular membrane biogenesis and/or trafficking. L-Cycloserine on the other hand,
exhibited a different set of genetic interactions, mostly with genes involved in
early steps of sphingolipid biosynthesis consistent with its known mode of action.
A novel potentiation effect between myriocin, another known sphingolipid biosyn-
thesis inhibitor, and fluconazole was correctly predicted based on this interaction
profile. There is further evidence that the inhibition of sphingolipid biosynthe-
sis is responsible for the fluconazole-potentiating effects seen with L-cycloserine
and myriocin. Ergosterol and sphingolipids are both essential components of the
fungal cell membrane. They are found in lipid rafts and are involved in the mod-
ulation of ABC transporter localisation and function (Klappe et al., 2009). Van
Leeuwen et al. (2008) showed that myriocin treatment in S. cerevisiae results in
decrease of ergosterol levels in the cell membrane. The gene IPT1 is involved in
the last step of sphingolipid biosynthesis, synthesis of the most abundant sphin-
golipid mannose inositol phosphorylceramide and is regulated by Pdr1 and Pdr3,
indicating that modulation of membrane composition is one component of the
pleiotropic drug response (Hallstrom et al., 2001).
New approaches to antifungal therapy might be developed based on our find-
ings that CADs and inhibition of sphingolipid biosynthesis potentiate the ac-
tion of fluconazole. In light of growing genetic and chemical-genetic interaction
networks, mechanism- or pathway-based predictive approaches should become a
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powerful tool in the discovery of synergistic drug combinations.
3.3.3 Species-specific synergistic effects
Hits from screens for fluconazole potentiation in the S. cerevisiae model system
can generally be transposed to pathogenic fungi (Borisy et al., 2003; Zhang et al.,
2007; Jansen et al., 2009; Epp et al., 2010). The primary screen data however
suggests a considerable degree of species-specificity that by definition cannot be
predicted from data generated with model organisms. While 63% (24/38) of hits
against S. cerevisiae exhibited synergistic activity against one or more fungal
pathogens in the primary screen, only 24% (24/101) of the all hits against the
pathogenic species were identified in S. cerevisiae. This observation highlights
the need to undertake primary screens in the pathogen of interest.
These genus- and species-specific syncretic interactions reflect differences in
the genetic networks that govern cellular responses to different compounds (Perl-
stein et al., 2007). Different pathogenic species diverged from a common ancestor
over 100 million years ago and have since adapted to specific host environments.
Drug susceptibility can also be affected by developmental system drift (True and
Haag, 2001) as has been documented with nikkomycin Z. This drug has differ-
ent effects on chitin synthase paralogs in Candida and Saccharomyces (Gaughran
et al., 1994; Sudoh et al., 2000). The differences in transcriptional response to
fluconazole treatment in Saccharomyces, Candida and Kluyveromyces also reflect
the distinct mechanisms by which different species respond to the same pertur-
bation (Kuo et al., 2010). More generally, the evolutionary plasticity of genetic
interaction networks might be reflected by these species-specific differences in the
response to drug treatment (Kapitzky et al., 2010). Species-selective drug combi-
nations might enable development of antifungal therapies with increased efficacy
and decreased host toxicity.
3.3.4 Devising higher order drug combinations
The structure of genetic networks predicts the existence of higher order drug
combinations that exhibit greater potency and selectivity (Sharom et al., 2004;
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Ágoston et al., 2005; Lehár et al., 2007). In particular, compounds that target a
number of genetically redundant parallel pathways may reveal n-way synergies.
Consistent with this concept, the combination of a non-synergistic drug pair (su-
loctidil and L-cycloserine, a membrane active and sphingolipid inhibiting drug,
respectively) with a low dose of fluconazole exhibited highly potent three-way
synergism. Given the similarity of their chemical-genetic profiles, pairs of mem-
brane active compounds unexpectedly showed synergistic interactions. This type
of drug-drug interaction has been observed before in bacteria and yeast (Yeh et
al., 2006; Jansen et al., 2009) and it suggests that each drug must have additional
specific cellular targets that contribute to synergism. The chemical-genetic pro-
files of drugs are complex and reflect effects on primary and secondary targets in
the cell, routes of drug metabolism and detoxification as well as genetic feedback
between different network elements (Sharom et al., 2004; Lehár et al., 2008).
Other interactions between fluconazole, Hsp90, reactive oxygen species, vesicle
trafficking and calcium metabolism that have been documented, may play a role
in these complex interactions (Cowen et al., 2009; Xu et al., 2009; Gamarra et
al., 2010; Epp et al., 2010). Even though it has been suggested that drugs with
similar chemical-genetic profiles are likely to interact synergistically (Jansen et
al., 2009), this is not very often the case (Yeh et al., 2006). Even for drugs with
well characterised mechanisms of action their genetic interaction profile can be
very different from that of their presumptive target as seen for fluconazole, for
example. Fluconazole shares many genetic interactions with ERG11, its known
target, but more than half of the chemical-genetic interactors of fluconazole are
not shared (Parsons et al., 2004).
The concept of n-way synergies will become more important as combination
therapies become more widely used. Given the complex action of small molecules
in the cell, it will be a challenge to rationally predict n-way synergies. Our results




Combinatorial anti-infective therapies have various benefits including lower effi-
cient doses of individual drugs, lower rate of selection for drug resistant strains,
enhanced antimicrobial activity and a decrease in host toxicity (Sharom et al.,
2004; Hopkins, 2008; Lehár et al., 2008). This study and others (Zhang et al.,
2007; Jansen et al., 2009; Epp et al., 2010) have shown that syncretic drug com-
binations with increased antifungal potential can be readily identified in both
model fungal species and pathogenic clinical isolates. While synergistic combi-
nations have been shown to result in enhanced selectivity without adverse side
effects (Lehár et al., 2009) it is important to note that undesirable side effects
may arise from these drug combinations as occurs with known contraindicated
drugs, for example. In addition, the original therapeutic use of repurposed drugs
can potentially lead to unwanted side effects.
Another important benefit may be improved activity in therapeutically recal-
citrant tissues, such as the CNS. These combinatorial principles are also applica-
ble to viral and bacterial pathogens as well as cancer and other genetic diseases
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wood, and E. Elizabeth Patton: Off-target toxicity of 5-nitrofurans is me-
diated by ALDH2.
The work described in this chapter is the results of a collaboration with the
Patton lab at the MRC Human Genetics Unit, Edinburgh. Dr. Hironori Ishizaki
conducted the chemical screen in zebrafish and carried out many of the zebrafish
experiments in collaboration with members of the lab. I designed and carried out
experiments in S. cerevisiae to characterise ’interesting’ compounds further.
4.1 Introduction
One of the advantages of chemical biology is that small molecules are likely to
have the same mode of action in different species (see section introduction). This
allows for interesting compounds identified in one species to be followed up in
other model organisms. This chapter describes experiments I carried out in S.
cerevisiae on compounds that were hits in a chemical high-throughput screen
in zebrafish (Danio rerio) that was conducted in the lab of Liz Patton at the
MRC Human Genetics Unit. The Patton lab studies melanocyte and melanoma
biology. The introduction of this chapter is very specific to the collaborative
zebrafish-yeast studies. The next two sections give background information about
skin cancer (Section 4.1.1) and explain why zebrafish is a useful model to study
melanocyte biology (Section 4.1.2). Sections 4.1.3 and 4.1.3 describe results from
the chemical screen that was performed by the Patton lab in zebrafish to identify
compounds that affect melanocyte development.
4.1.1 Skin cancer
The skin, consists of different cell types and skin cancers are classified by the
types of cells involved. Basal cell carcinoma is the most common type of skin ma-
lignancy, followed by squamous cell carcinoma. They are both highly curable by
local excision, radiotherapy and chemotherapy. Melanoma occurs in melanocytes,
the pigment producing cells. It is far less common than the other two skin ma-
lignancies (∼5%), but survival rates are very low, making melanoma the leading
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cause of death from skin disease. Metastatic melanoma has a survival rate of less
than one year. The primary cause of basal and squamous cell carcinoma is chronic
accumulation of UV-induced skin damage. Melanoma, however, is thought to be
promoted by multiple, intermittent severe burns, especially during early years of
life. Pale skin pigmentation and hereditary factors are risk factors for melanoma,
such that people with reduced skin melanin are highly susceptible to melanoma.
Notably, in the Scottish population, many people have a polymorphism in an
Mc1r gene that causes the production of red hair and freckling, which are also
risk factors for melanoma.
The incidence of skin cancer has increased significantly over the last decades,
especially in Western nations. This is presumably due to an increase in sunlight
exposure caused by the reduction in the ozone layer as well as increased travel to
warmer regions for holidays and social acceptance of tanned skin. In Scotland and
northern England, melanoma incidence continues to increase in young women due
to an increase in sun bed use. Malignant melanoma is ten times more common
in Australasia than in Europe, but its frequency is increasing up to 7% per year
in some parts of Europe. Scotland has the highest rise in incidence in the world.
Annual incidence is 5-7 per 100,000 in Europe and the US, especially among
Caucasians with fair skin and red hair.
Depending on the stage of the disease, treatment usually involves excision
of the tumour together with a margin of skin. Malignant melanoma is highly
resistant to radiotherapy and standard chemotherapy and is highly metastatic.
The most commonly used drug is dacarbazine, an alkylating agent. Early promise
of immunotherapy with interleukin-2, interferons and various vaccines was not
followed by significant improvement of survival rates. The only exception is
Ipilimumab, a recombinant human monoclonal antibody, that was approved by
the FDA in March this year for immunotherapeutic treatment of unresectable or
metastatic melanoma (Sondak et al., 2011).
The rapid rise in skin cancer rates and the fact that it does not respond to
well to available therapy options make melanoma a very challenging disease to
treat. Studies of the development, proliferation, differentiation and migration of
melanocytes might help answer the question why it is so difficult to treat and
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might reveal starting points for new treatment options (Ko & Fisher, 2011).
4.1.2 Zebrafish as a model to study melanocyte biology
The zebrafish is an attractive model for the study of melanocytes as well as
melanoma formation and progression for various reasons. As in other vertebrates,
zebrafish body melanocytes are derived from the neural crest. Importantly, ze-
brafish embryos are easy to study because they develop outside the mother and
are semi-transparent. This enables observation of melanocytes through all stages
of development. Several studies have established melanoma models in the ze-
brafish. Patton et al. (2005) found that activating mutations in the BRAF gene,
encoding a a serine/threonine kinase involved in cell growth, led to development
of nevi in fish and together with p53 pathway inactivation produces melanoma.
Other genes that have been found to be involved in melanoma are conserved
between mammals and zebrafish. These are melanocyte-specific genes like Mitf,
Kit, endothelins and Snail/Slug as well as general genes like receptor tyrosine
kinases, Ras family GTPases, BRAF, CDKN2A and the p53 pathway (reviewed
in Ceol et al., 2008 and Patton et al., 2010).
4.1.3 A chemical screen identified compounds that affect
melanocytes and pigmentation in D. rerio
As described in section 1.3.3, zebrafish are very well suited for chemical screens
(Taylor et al., 2010). The Patton lab screened the 1280-member Library of
Pharmacologically Active Compounds (LOPAC) and a chemical library of 1570
bioactive compounds (Spitzer et al., in preparation) in zebrafish to identify com-
pounds that cause developmental or melanocyte-specific phenotypes. The screen
was conducted in 96-well format at a final compound concentration of 10 µM
with two zebrafish embryos per well. Nearly 200 compounds had an effect on
melanocyte development and pigmentation. 45 of these compounds elicited a
phenotype characteristic of copper depletion by causing hypopigmentation, an
undulating notochord and an expanded hindbrain in the 2- to 3-day-old fish (Fig-
ure 4.1B). The group of copper metabolism compounds included known copper-
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Excess exogenous copper can restore pigmentation to BLOC-1-
deficient melanocytes in vitro (Setty et al., 2008). Components of
BLOC-1 are mutated in Hermansky-Pudlak syndrome (HPS), a
disorder characterized by defects in lysosome-related organelles,
particularly melanosomes and platelet-dense granules (Wei, 2006).
Aberrant transport of ATP7A might be responsible for the HPS
pathology of melanocytes from BLOC-1-deficient individuals (Setty
et al., 2008). In zebrafish, mutation of atp7a or treatment with the
copper-chelator neocuproine causes a phenotype with features of
Menkes disease, including hypopigmentation, neurological
disorders, and loss of lysyl oxidase cuproenzyme activity in the
developing notochord (Mendelsohn et al., 2006). In zebrafish,
hypomorphic alleles of atp7a and the vacuolar ATPase (v-ATPase)
cause hypopigmentation at low copper concentrations,
demonstrating that genetic mutations can result in copper-
deficiency symptoms in suboptimal nutrient conditions (Madsen
and Gitlin, 2008).
We have developed a coupled zebrafish phenotypic and yeast
chemical-genetic screening approach to identify novel genetic
pathways that underlie copper-nutrient sensitivity in the developing
vertebrate melanocyte (Fig. 1A). Phenotypic chemical screens in
zebrafish enable the identification of novel biological pathways by
virtue of chemically induced phenotypes (Zon and Peterson, 2005).
Such zebrafish screens are typically carried out by treating
developing embryos with libraries of small molecules to identify
compounds that elicit a specific phenotype. The small size and
transparency of the embryo, which can be arrayed in 96-well plates,
coupled with tractable genetic tools for target validation and
disease modelling make the zebrafish a highly effective system for
phenotype-driven small-molecule screens. However, despite its
tractability, identification of the target pathways in zebrafish is
usually arduous (Peterson, 2008). Chemical-genetic approaches in
the budding yeast Saccharomyces cerevisiae can provide rich
functional information on the mechanism of action of compounds
dmm.biologists.org640
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Fig. 1. A combined zebrafish and yeast approach to probe chemical-genetic interactions in melanocyte pigmentation. (A)Overview of work flow.
Phenotypic screening in zebrafish informs as to the developmental and physiological target pathway. Small molecules that promote similar phenotypes in
zebrafish are then tested in genome-wide chemical-genetic screens in yeast to reveal potential target genetic pathways. Conserved target pathways are then
directly re-tested for chemical-genetic interactions in the zebrafish system using genetic mutant lines, morpholino oligonucleotides or small molecules known to
impinge on the same target. (B)Phenotypic screening of a >1500-compound yeast-bioactive library (S.D., J.W., M. Spitzer and M.T., unpublished data) and the
Sigma LOPAC library for altered pigmentation in zebrafish embryos revealed a copper-metabolism phenotype characterized by hypopigmentation, an expanded
hindbrain and an undulating notochord (Mendelsohn et al., 2006). Representative phenotype caused by 10M JFD00692 was rescued by treatment with
exogenous copper chloride (5M or 15M) during development. (C)Examples of the copper-metabolism phenotype induced by some of the compounds
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Figure 4.1: Phenotypic screen to identify compounds that affect melanocytes.
(A) Overview of combin d zebrafish and yeas approac . Phenotypic creens
in zebrafish allow identification of compounds that target specific developmen-
tal and physi logical pathways. Small molecul s of interest are then su jec ed
to genome-wide chemical-genetic screens in the budding yeast to identify poten-
tial target pathways based on genetics. Conserved genetic target pathways can
then be directly tested in zebrafish using genetic mutant lines, blocking target
gene expression with morpholino oligonucleotides or using small molecules known
to act on the same cellular target. (B) Representative example of the copper-
metabolism phenotype as caused by 10 µM JFD00692. The characteristics of the
copper-metabolism are clearly visible in the JFD00692 treated embryo: hypopig-
mentation, an undulating notochord and an expanded hindbrain (Mendelsohn
et al., 2006). Rescue was observed with addition of 5 µM or 15 µM exogenous
copper. (C) Further examples of compounds that induce the copper-metabolism
phenotype identified in the screen. This figure was taken from Ishizaki, Spitzer
et al., 2010.
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binding molecules like 1-phenyl-3-(2-thiazolyl)-2-thiourea (PTT) (Mendelsohn
et al., 2006) as well as metal-binding thiourea derivates, thiosemicarbazones,
pyridin-pyrimidinones and phenanthrolines (Table 4.1). Surprisingly, the widely
used MEK inhibitor U0126 was identified as a copper-metabolism compound (Ta-
ble 4.1). Further characterisation of all compounds listed in Table 4.1 revealed
that the copper-metabolism phenotype could be rescued completely by the ad-
dition of 5 µM exogenous copper for the majority of compounds. The effects
of five of the compounds could only partially be rescued by addition of copper
(15 µM) and for three compounds the addition of exogenous copper was lethal.
Compounds that cause hypersensitivity to additional copper could be interfering
with detoxification of excess copper ions in the cell. Copper levels are tightly
regulated in the cell and controlled by copper chaperones and metallothionein
levels (Rae et al., 1999; Wegner et al., 2011).
Identification of two compounds that selectively kill melanocytes in
Danio rerio
The phenotypic screen in zebrafish also yielded a number of compounds that
seemed to specifically affect melanocytes. Two of these compounds were RF
03928 and BTB 05727 (Figure 4.2A). Zebrafish embryos normally have black
melanocytes in the eyes and pattering on the body. Treatment with each of the
two compounds greatly reduced the number of melanocytes (first row in Figure
4.2B). Some compounds that are melanocyte-specific are pro-drugs that are ac-
tivated by enzymes expressed in melanocytes. Tyrosinase is an enzyme that
is expressed specifically in melanocytes and tyrosinase-dependent compounds
have been of limited interest for melanoma treatment so far. Tyrosinase and
other pigmentation enzymes are copper-dependent and addition of the copper-
chelating PTU (4-hydroxy-2-mercapto-6-propylpyrimidine) prevents pigmenta-
tion of melanocytes. To test if RF 03928 and BTB 05727 required the activ-
ity of pigmentation enzymes for melanocyte specific activity, zebrafish embryos
were treated with RF 03928 and BTB 05727 in combination with PTU. These
experiments showed RF 03928 to be a tyrosinase-dependent drug since addition
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RF 03928 BTB 05727
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NFN1.1
Figure 4.2: Compounds that are melanocytotoxic in zebrafish. (A) Structures of
RF 03928, BTB 05727 (NFN1) and NFN1.1 (B) Examples of the effects of RF
03928 and BTB 05727 alone and in combination with the copper chelator PTU on
zebrafish embryos. Three day old zebrafish embryos were treated with compound
or DMSO for two days and images were taken at five days pf. Images in (B) were
taken by Dr. Hironori Ishizaki in the Patton laboratory.
of PTU resulted in normal melanocyte development (second row in Figure 4.2B).
In contrast, the effect of BTB 05727 on zebrafish melanocytes was not rescued
by PTU, indicating that it is not a tyrosinase dependent drug.
In the first part of this chapter, I will present experiments that applied the
genome-wide tools available in the model organism S. cerevisiae to investigate
the mode of action of some of the compounds that caused melanocyte-specific
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phenotypes in zebrafish. These experiments proved the budding yeast to be
very useful to inform about pathways and proteins that are conserved in higher
organisms. Sections 4.2.1, 4.2.2 and 4.2.3 focus on the compounds that affect
copper metabolism. The two small molecules that specifically affect melanocyte
viability were also studied in more detail (sections 4.2.4 and 4.2.5).
4.2 Results
4.2.1 Chemical-genetic profiles in S. cerevisiae reveal po-
tential copper-metabolism pathways
To identify pathways affected by perturbation of copper metabolism, six of the
copper metabolism compounds identified in the chemical screen in zebrafish (Sec-
tion 4.1.3) as well as the known copper chelator neocuproine were subjected to
genome-wide chemical-genetic screens in S. cerevisiae. The compounds selected
represent the different structural groups and three of them cause hypersensitivity
to exogenous copper (U0126, SEW01049 and SPB07427) while the other three
can be rescued by copper (DP00477, JFD00692 and RJF01649).
This copper-metabolism subset (CM subset) contains neocuproine, U0126,
DP00477, SEW01049, SPB07427, JFD00692 and RJF01649 (Table 4.1). Pools
of 5000 haploid deletion strains in non-essential genes as well as the 1000 diploid
deletion strains heterozygous for essential genes were screened against all seven
drugs. Compounds were screened at concentrations that inhibited growth of the
deletion pools by 20-30%. Pools were grown in the presence of drug or 0.4%
DMSO for 20 generations. The response of the deletion strains to compound
treatment at two different concentrations was assessed by spotted oligonucleotide
microarrays (Cook et al., 2008). Strains sensitive and resistant to the compounds
were identified using quantile statistics as shown in Figure 4.3. The quantile
statistics were similar for all experiments; only the two screens with JFD00692
displayed a different distribution of Z-scores.
Even though all drugs in the CM subset elicit a similar developmental pheno-
type in the zebrafish embryo, distinct and common pathways were identified with
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Maybridge Phenotype Copper addition Compound structure
Code
Neocuproine Copper metabolism Rescue (5 µM) Phenanthroline
U0126 Copper metabolism Lethal (5 µM) Sulfanylmethylidene-butanedinitrile
PTT Copper metabolism not determined 1-Phenyl-3-(2-thiazolyl)-2-thiourea
DP00477 Copper metabolism Partial rescue (15 µM) Thiocarbamoyl-acetamide derivative
DP00750 Copper metabolism Rescue (5 µM) Thiosemicarbazone
CD00707 Copper metabolism Rescue (5 µM) Thio-urea
CD02745 Copper metabolism Rescue (5 µM) Thiosemicarbazone
CD02044 Copper metabolism Partial rescue (15 µM) Thiosemicarbazone
HR00030 Copper metabolism Rescue (5 µM) Thio-urea derivate
FM00217 No pigmentation Rescue (5 µM) Thiosemicarbazone
PD00357 No pigmentation Rescue (5 µM) Thiosemicarbazone
RDR00803 Copper metabolism Rescue (15 µM) Thiosemicarbazone
KM09752 Copper metabolism Rescue (5 µM) Thio-urea derivate
RJC00588 Copper metabolism Rescue (5 µM) Carbamic acid
RH01646 Copper metabolism Rescue (5 µM) Thiosemicarbazone
RH01676 No pigmentation Rescue (5 µM) Triazole-thiol
SEW02973 No pigmentation Rescue (5 µM) Pyridin-pyrimidinone
SEW01049 Copper metabolism Lethal (5 µM) Thiosemicarbazone
RJF01673 Wavy notochord Rescue (5 µM) Pyridin-pyrminidinone
S02347 Copper metabolism Partial rescue (15 µM) 2,4-Diphenyl-2,3-dihydro-1,5-benzothiazepine
RJF01809 Copper metabolism Rescue (5 µM) Pyridin-pyrimidinone
S02850 Copper metabolism Rescue (5 µM) Carbamothioyl benzamide
SJC00393 Copper metabolism Rescue (5 µM) Thiosemicarbazone
SPB02722 Copper metabolism Partial rescue (15 µM) Benzoxazole derivate
SPB00258 Copper metabolism Rescue (5 µM) Thiosemicarbazone
SPB05679 Copper metabolism Rescue (5 µM) Pyridin-pyrimidinone
SPB07427 Copper metabolism Lethal (5 µM) Thiadiazole derivate
SPB07119 No pigmentation Rescue (15 µM) Thiosemicarbazone
SEW06186 Copper metabolism Rescue (5 µM) Urea derivative (carboline-carboxamide)
SEW01792 No pigmentation Rescue (15 µM) N-Hydroxy-benzamidine derivative
SPB01039 Copper metabolism Rescue (5 µM) Triazole-thiol derivate
SPB07027 Copper metabolism Rescue (5 µM) Thiosemicarbazone
SPB07028 Copper metabolism Rescue (5 µM) Thiosemicarbazone
SPB00779 No pigmentation Rescue (5 µM) Triazole-thiol
CD02543 Copper metabolism Rescue (5 µM) Thiosemicarbazone
CD03007 Copper metabolism Rescue (5 µM) Thiosemicarbazone
CD06646 Copper metabolism Rescue (5 µM) Pyridin-pyrimidinone
DFP00275 Copper metabolism Rescue (5 µM) Thio-urea derivate (carbamothioyl benzamide)
JFD00692 Copper metabolism Rescue (5 µM) Phenanthroline (cisplatin analogues)
RF01893 Copper metabolism Rescue (5 µM) N-Hydroxy-benzamidine derivative
RDR00093 No pigmentation Rescue (5 µM) Thiourea derivate
RDR00691 Copper metabolism Rescue (5 µM) Thiosemicarbazone
S04201 Copper metabolism Rescue (5 µM) Thio-urea/Quinazolinone derivative
RJF01649 Copper metabolism Rescue (5 µM) Pyridin-pyrimidinone
S09668 Copper metabolism Partial rescue (15 µM) Thiourea derivates
S14458 Copper metabolism Rescue (5 µM) Thiosemicarbazone
Table 4.1: Characterisation of small molecules that cause copper-metabolism
phenotypes. The table was taken from Ishizaki, Spitzer et al., 2010.
109
Figure 4.3: Boxplots of Z-scores for each of the microarrays visualise quantile
statistics for all arrays. Boxplots visualise the distribution of Z-scores using quan-
tiles: the box contains 50% of the data points (called interquartile range) and the
black line represents the median. The hinges extend for 1.5 interquartile ranges
from the box and data points that lie beyond this range are considered outliers.
the genome-wide chemical-genetic screens in yeast, reflecting differences in the
molecular effects of each compound. The sensitivity of strains deleted for genes
known to be involved in copper transport and homeostasis was examined in more
detail (Figure 4.4A). Deletion strains defective in copper metabolism are rarely
affected in chemical-genetic screens (Hillenmeyer et al., 2008) probably because
yeast is typically grown in rich medium that provides sufficient exogenous copper.
Figure 4.4A reveals unique profiles of the strains defective in copper metabolism
for each compound. Deletion strains that showed sensitivity include the copper
transporter Ctr1, the copper-transporting ATPase Ccc2, the copper chaperones
Atx1 and Atx2, copper-dependent transcription factor CUP2 and the copper-
zinc superoxide dismutase Sod1. Copper is transported into cells by high-affinity
transporters that require copper to be in the reduced Cu(I) state, which is depen-
dent on the cupric and ferric reductases Fre1 and Fre2 (De Freitas et al., 2003).
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Iron and copper homeostasis are intimately linked in the budding yeast and in
human disease (De Freitas et al., 2003; van Bakel et al., 2005; Madsen and Gitlin,
2007). Strains deleted for FRE1 and FRE2, the major cell surface reductases in S.
cerevisiae were sensitive to copper starvation caused by different compounds. Fi-
nally, of the iron transporters Fet3 and Fet5, both copper-dependent enzymes, the
fet3∆ strain also displayed sensitivity to some of the compounds. The chemical-
genetic profiles of the CM subset thus reflected effects on copper homeostasis, as
well as iron homeostasis (van Bakel et al., 2005; Rustici et al., 2007).
To link the action of the CM subset to cellular pathways, the effect of com-
pound treatment on all genes of each GO categories was assessed. In Figure
4.4 groups of GO categories that are affected by each compound are visualised.
Several biological processes were affected by several compounds. These shared
processes, many of which can be linked to copper metabolism, included tubulin-
complex assembly, the Swr1 histone-remodelling complex, vacuolar organisation
and intracellular transport, mitochondrial translation initiation and peroxisome
formation. For example, copper plays an important role in mitochondrial func-
tion, such as in cytochrome C oxidase activity (Madsen and Gitlin, 2007). The
sensitivity of the Swr1 histone-exchange complex (Zilberman et al., 2008) might
reflect inappropriate levels of metallothionein (CUP1-1 and CUP1-2) since ex-
pression of the copper metallothionein gene in S. cerevisiae is regulated by chro-
matin modification (Kuo et al., 2005). Deletion of genes involved in the threonine
biosynthesis pathway resulted in sensitivity to some of the CM subset compounds.
Sensitivity of deletion strains in genes involved in the biosynthesis of amino acids
has been observed before, also in response to high-copper concentrations. The
threonine-biosynthesis pathway genes, however, were not among these known
pleiotropic genes (Ericson et al., 2008; Hillenmeyer et al., 2008; Jo et al., 2008).
The findings in this study might highlight a novel relationship between copper
metabolism and threonine biosynthesis in yeast. Alternatively, it is possible that
the threonine pathway is required for detoxification of some of the CM subset
compounds.
Strains deleted for proteins involved in tubulin binding and tubulin assembly
displayed resistance to a few of the compounds. Microtubule assembly is complex
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Figure 4.4: Chemical-genetic interactions of compounds that affect copper
metabolism. (A) Response of deletion strains in copper-pathway genes to treat-
ment with U0126, neocuproine or the copper metabolism compounds. Data from
two screens at different drug concentrations is shown. Genes for proteins that
contain copper as well as proteins involved in copper and/or iron transport
and homeostasis were compiled from Saccharomyces Genome Database (SGD,
http://www.yeastgenome.org). Colour scale indicates sensitivity (red) or resis-
tance (green) of a deletion strain to a specific drug treatment; white indicates no
data available in a given experiment. (B) Heatmap indicating GO categories that
showed sensitivity (red) or resistance (green) in response to treatment with dif-
ferent compounds. Two concentrations were screened for each compound. Scores
were calculated for each GO category that contained at least four genes by av-
eraging the Z-scores of all deletion strains annotated in the category. Categories
shown in the heatmap are the top 2% of affected GO categories. GO categories
are grouped by overlap in their gene sets (see also Table 2).
112
and requires proper folding of α- and β-tubulins and formation of heterodimers.
Excess copper has been shown to cause microtubules to disassemble in vitro and
in cell-based studies (Liliom et al., 1999; Liliom et al., 2000; Pribyl et al., 2008;
Liu et al., 2009).
The peroxisome was identified as an organelle that is important when cells are
treated with CM subset compounds. This dependency might arise because the
cytosolic copper-zinc superoxide dismutase is targeted to peroxisomes by its inter-
action partner ’copper chaperone of SOD1’ (CCS) in mammalian cells (Islinger et
al., 2009). In yeast, deletions in peroxisomal genes have been shown to sensitise
cells to low-iron conditions which could be due to the fact that the requirement
for peroxisomal β-oxidation is elevated when iron-dependent mitochondrial en-
ergy production is impaired (Jo et al., 2009). Copper deficiency might cause a
similar effect because copper is required for iron homeostasis and mitochondrial
functions. Notably, high levels of copper and iron in tissues and blood are char-
acteristics of human disorders of peroxisome biogenesis (Wanders & Waterham,
2005).
Copper concentrations and transport are highly regulated in the cell. Path-
ways involved in copper homeostasis include transport into the endoplasmic
reticulum and through secretory and vacuolar pathways for delivery to copper-
dependent enzymes as well as for excretion and detoxification of copper (Yuan et
al., 1997; González et al., 2008; Jo et al., 2008; Jo et al., 2009). Deletion mutants
in the AP1, the AP3 and the clathrin adaptor complexes, the HOPS complex and
the Golgi-to-vacuole transport pathway were identified as sensitive in low-copper
conditions (Figure 4.4). Disruption of these complexes has not been associated
with sensitivity to low-copper conditions, but intracellular transport and vacuolar
pathways have been shown to be sensitive to perturbations of iron homeostasis.
For example, disruption of the AP3 adaptor complex in apm3∆ and aps3∆ strains
causes sensitivity to low-copper and low-iron conditions (Jo et al., 2009). These
pathways might be required in low-copper conditions because copper is not able
to reach essential copper-dependent proteins.
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4.2.2 The MEK inhibitor U0126 elicits an unexpected
copper-metabolism phenotype
The identification of U0126 as a compound that affects copper-metabolism in ze-
brafish is consistent with the phenotype described in a recent paper. Hawkins et
al. (2008) who report that treatment with the MEK inhibitor produces zebrafish
embryos without pigmentation, with a shorter tail and an undulated notochord.
The authors explained this observation by suggesting a potential link between
the MAPK-pathway and copper-dependent processes during notochord differen-
tiation, although this speculative link has not been investigated further. The
following experiments in zebrafish and yeast were devised to distinguish if the
copper-metabolism phenotype caused by U0126 is due to it inhibition of MEK
or if U0126 has additional targets in the cell that affect copper homeostasis,
independent of its action on the MAPK pathway.
First of all, the phenotype induced by U0126 in the developing zebrafish was
compared to that caused by the selective MEK inhibitor PD0325901 and the
known copper chelator neocuproine. Figure 4.5A shows that treatment with
U0126 and neocuproine caused the typical copper depletion phenotype. The
2-day-old fish exhibited hypopigmentation, an undulating notochord and an ex-
panded hindbrain. Embryos treated with PD0325901 prevented development of
posterior features but had not effect on pigmentation.
Even though the RAS-RAF-MEK-ERK signalling pathway is important in
melanoma development in zebrafish, mice and humans, neither PD0325901 nor
CI-1040 (another highly selective MEK inhibitor) affected melanocyte pigmenta-
tion in zebrafish (Figure 4.5A and data not shown). This observation suggests
that U0126 has a previously undetected additional target in copper metabolism
since selective inhibition of the MAPK-pathway does not affect pigmentation of
zebrafish melanocytes.
U0126 also prevents blood development in zebrafish embryos as indicated by
o-dianisidine staining (Figure 4.5B) and causes an undulating notochord (Figure
4.5A). A colour-change assay revealed that U0126, just like neocuproine, directly
binds copper in aqueous solution whereas CI-1040 does not seem to interact with
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Figure 4.5: Phenotype caused by U0126 treatment in the developing zebrafish
embryo. (A) Comparison of phenotypes elicited by treatment with the copper
chelator neocuproine (neo), U0126 and the selective MEK inhibitor PD03259. (B)
Neocuproine and U0126 treated embryos as well as control embryos were stained
with o-dianisidine (red) to visualise red blood cells. (C) U0126 and neocuproine
were added to aqueous copper chloride solution. A significant change in colour
of the solution indicates that a compound form complexes with copper. (D)
Phospho-ERK and phospho-MEK levels were assessed in lysates of 12-hpf ze-
brafish embryos that were treated with neocuproine (Neo), PD0325901 (PD) and
U0126 (U0) as well as DMSO (solvent control). (E) Schematic that visualises
the relationship between timing and outcome of U0126 treatment. Each barline
represents a U0126 treatment (starting at different times post fertilisation). The
colour of each barline corresponds to the level of pigmentation of the zebrafish
melanocytes. Asterisks indicate time point when unpigmented 33 hpf zebrafish
embryos were shifted to fresh embryo medium. (F) Electron microscopy of 2-
day-old control and U0126-treated (5 µM) zebrafish embryos. Dark organelles




Figure 4.5D shows the effects of neocuproine (Neo), U0126 (U0) and PD0325901
(PD) on phospho-ERK and phospho-MEK levels. Probing lysates from compound-
treated zebrafish embryos with an anti-phospho-ERK antibody revealed that
U0126 and PD0325901 both inhibit MEK activity as seen by decreased phospho-
ERK and increased phospho-MEK levels. These effects were much stronger with
PD0325901 treatment, confirming its higher potency. Neocuproine had no obvi-
ous effects on reducing the phospho-ERK or phospho-MEK levels in zebrafish.
Mapping the timing of U0126 action during development revealed more de-
tails about the U0126-induced pigmentation phenotype (Figure 4.5E). Zebrafish
melanocytes develop from the neural crest and start making pigment at about 28
hpf. Treatment with 10 µM U0126 before 21 hpf prevented normal melanocyte
pigmentation whereas addition of compound after 21 hpf did not affect pigmen-
tation. The effect of U0126 in unpigmented zebrafish was easily reversible by
placing the embryos into fresh medium without compound. Electron microscopy
showed that melanocytes of embryos treated with 5 µM U0126 have fewer and
less-dense melanosomes (Figure 4.5F; Ishizaki, Spitzer et al., 2010).
Yeast deletion pools were subjected to U0126, CI-1040 and neocuproine treat-
ment for the generation of genome-wide chemical-genetic profiles to characterise
potential target pathways for U0126. Analysis of the overlap between these pro-
files revealed that 13 deletion strains exhibited sensitivity to both U0126 and
neocuproine, and that 12 deletion strains showed sensitivity to U0126 and CI-
1040 (Figure 4.6A). In contrast, the chemical-genetic profiles of CI-1040 and
neocuproine share only one sensitive deletion strain, the pex10∆ strain, and only
the yaf9∆ strain was sensitive to treatment with each of the three compounds.
Therefore, even though the profile of U0126 partially overlaps with those of CI-
1040 and neocuproine, CI-1040 and neocuproine have different activities. These
profiles fully corroborate the shared molecular phenotype of U0126 and CI-1040
(inhibition of ERK phosphorylation in zebrafish lysates) as well as the shared
developmental and chemical phenotype of U0126 and neocuproine.
Comparison of GO biological processes affected by all three compounds re-
vealed a complex network of shared and distinct processes. The genes affected
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Figure 4.6: Novel target pathways for U0126, a MEK inhibitor. (A) Heat map
shows S. cerevisiae deletion strains that are sensitive (red) or resistant (green)
in response to treatment with U0126, neocuproine and CI-1040. (B) Z-scores
of deletion strains annotated with GO categories that are affected by treatment
with neocuproine (yellow), U0126 (green) and CI-1040 (purple) are represented as
boxplots. Only GO categories with data for more than four genes were analysed.
GO category Genes
Histone H3-K4 methylation BRE2, SDC1, SHG1, SPP1, SWD1, SWD3
Protein import into DJP1, PEX1, PEX2, PEX4, PEX5, PEX6, PEX7, PEX10, PEX12,
peroxisome matrix PEX13, PEX14, PEX15, PEX17, PEX18, PEX21, PEX22, PEX25
Tubulin-complex assembly GIM3, GIM4, GIM5, PAC10, RBL2, YKE2
Golgi-to-vacuole transport APL2, APL4, APL5, APL6, APM1, APM2, APM3, APS1, APS3,
GGA1, GGA2, PEP7, PEP12, TLG2, VAM3, VAM7, VPS52, VPS53,
VTH1, YPT7
Swr1 complex ARP6, SWC3, SWC5, SWC7, SWR1, VPS71, VPS72, YAF9
GID complex FYV10, GID7, GID8, RMD5, VID24, VID30
alpha-subunit complex PRE10, PRE5, PRE6, PRE8, PRE9, PUP2, SCL1
(proteasome core complex)
Lid subcomplex (proteasome RPN3, RPN5, RPN6, RPN7, RPN8, RPN9, RPN10, RPN11, RPN12,
regulatory particle) RPN13, SEM1
Base subcomplex (proteasome RPT1, RPT2, RPT3, RPT4, RPT5, RPT6, RPN1, RPN10, RPN12
regulatory particle)
Table 4.2: Genes in the GO categories shown in Figure 4.6B. The table was taken
from Ishizaki, Spitzer et al., 2010.
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by compound treatment in each of the GO categories are listed in Table 4.2. As
already seen in Figure 4.4B, the peroxisome and the Swr1 histone-exchange com-
plexes are required for resistance to both U0126 and neocuproine (Figure 4.6B).
Intracellular transport and the proteasome 19S regulatory particle were required
for growth only in the presence of neocuproine whereas disruption of histone H3-
K4 methylation rendered cells resistant to the drug. Disruption of tubulin-binding
processes led to U0126-resistance, an effect that was not seen with neocuproine
or CI-1040. Most of the CM subset compounds, however, caused the same re-
sponse and which indicates that U0126 affects microtubule-associated processes
by perturbing copper homeostasis.
Intriguingly, the GID ubiquitin ligase complex was required for growth in the
presence of U0126. The GID complex is an E3 ubiquitin ligase that targets fruc-
tose 1,6-bisphosphatase (FBPase), a key enzyme in gluconeogenesis, for proteaso-
mal degradation (Santt et al., 2008). Deletion of the GID complex caused slight
sensitivity with all compounds in the CM subset except for neocuproine, but the
effect was strongest in the presence of U0126. The GID complex might therefore
either represent a new copper-dependent target or U0126 might have yet another
function in addition to MEK inhibition and effects on copper-homeostasis.
4.2.3 Knockdown of trafficking proteins identified in yeast
screens sensitises zebrafish to copper-dependent hy-
popigmentation
Intracellular transport pathways are essential for all cells, but have an impor-
tant role in melanosome biogenesis. The copper transporter ATP7A as well as
pigmentation enzymes are selectively transported from the trans-Golgi network
to maturing melanosomes. Two genes, that when deleted sensitised yeast to
perturbations in copper-homeostasis caused by CM compound treatment, were
selected to test whether they might inform about relevant copper pathways in
zebrafish melanocytes. Two such genes with orthologs in zebrafish were the yeast
genes APS1 and APS3 encoding components of the AP1 and AP3 transport
complexes, respectively. A splicesite Morpholino antisense Oligonucleotide (MO)
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(supplementary material Fig. S5). We separately injected a splice-
site MO designed against ap3s2 (ap3s2-MO1) and a translation-
blocking MO designed against ap1s1 (ap1s2-MO1) (Montpetit et
al., 2008) into single-celled zebrafish embryos and monitored
development in low-neocuproine conditions. Splice-site MOs were
verified by PCR analysis (supplementary material Fig. S6). At low
MO concentrations (1-3 pg), the ap1s1 and ap3s2 morphants
developed normally to at least 2 days pf (Fig. 5A). Next, we treated
4-6 hpf morphants with a range of neocuproine concentrations (1
M, 2 M and 5 M) and followed the development of the treated
animals over 2 days. Without neocuproine, neither the uninjected
controls nor the morphant animals displayed any of the principal
features of developmental copper deficiency, including reduced
pigmentation, a buckling notochord or an expanded hindbrain (Fig.
5A). This result suggests that under optimal nutrition conditions,
partial reduction of ap1s1 or ap3s2 function does not affect
development of the zebrafish embryo. At 5 M neocuproine,
developing wild-type and morphant embryos exhibited features of
developmental copper-metabolism deficiency, which could be
prevented with the addition of exogenous copper chloride at a
concentration of 5 M (Fig. 5A). At intermediate neocuproine
concentrations (1 M, 2 M), we often observed severe
hypopigmentation in the ap3s2 morphants (n37/71 embryos),
whereas control animals exhibited only a mild (at 1 M) to
moderate (at 2 M) reduction in melanocyte pigmentation (n>100).
The ap1s1 morphants also displayed melanocyte pigmentation
sensitivity at 1 M neocuproine (n13/39) compared with the
control-treated animals. A similar effect was seen using the splice-
site MOs ap3s2 (ap3s2-MO2) and ap1s1 (ap1s1-MO2) (see
Methods). Thus, at least two of the yeast intracellular transport
pathways that affected sensitivity to the CM subset compounds
proved to be physiologically relevant in the developing vertebrate.
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Fig. 5. Identification of two new gene-nutrient interactions in melanocyte pigmentation. Morpholino oligonucleotides (1-3 pg) directed against ap1s1 and
ap3s2 result in morphants with normal development and pigmentation. Higher concentrations of ap1s1-MO have been reported to cause pigmentation
phenotypes (Montpetit et al., 2008). Treatment with 5M neocuproine caused a copper-deficiency phenotype in all animals that could be rescued with the
addition of 15M copper chloride. At a concentration of 1.0M neocuproine, copper limitation caused a loss of pigmentation in the ap3s2 morphants compared
with control-treated embryos, and a severe loss of pigmentation at 2M neocuproine, compared with mild (1M) to moderate (2M) loss of pigmentation in
control animals. A milder pigmentation phenotype was also visible in the ap1s1 morphants treated with 1M neocuproine. Experiments were repeated multiple
times (more than three times for each morpholino; n>20 per treatment), and similar results could be obtained with an additional splice-site MO designed to
target each gene (see Methods). (B)Simplified schematic of gene-copper interactions in a zebrafish melanocyte. Partial reduction of AP3 complex activity (such
as in the ap3s2 morphant; represented by a dotted line) retains sufficient AP3 activity for melanosome pigmentation in optimal-copper nutrient conditions, and
the melanocyte is darkly pigmented. Likewise, melanocytes with normal AP3 activity in suboptimal-copper nutrient conditions retain the ability to generate
pigment. By contrast, in low-copper nutrient conditions, reduced AP3 function is no longer sufficient for promoting proper melanosome maturation, and the
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Figure 4.7: Identification of gene-nutrient interactions in melanocyte pigmenta-
tion. (A) Represe tative zebrafish embryos that were injected with morp olino
oligonucleotides (1-3 pg) direct d against ap1s1 and ap3s2 as well as cont ol m-
bryos were treated with increasing concentrations of neocuproine (0, 1, 2 and 5
µM, rows 1-4). In the last row, the effect of neocuproine treatment is rescued by
the addition of 15 µM copper chloride. Exper ments were r pe ted ore than
three times for each morpholine with n > 20 for each treatment. (B) Schematic
of gene-copper interactions in the zebrafish melanocyte. Effect of copper condi-
tions and AP-3 activity on melanocyte pigmentation is visualised. Cu, copper;
E, endosomal bodies; G, trans-Golgi network; M, melanosomes. This figure was
taken from Ishizaki, Spitzer et al., 2010.
designed against ap3s2 (ap3s2-MO1) and a translation-blocking MO designed
against ap1s1 (ap1s2-MO1) (Montpetit et al., 2008) were injected separately into
single-celled zebrafish embryos and development was monitored. With low O
concentrations (1-3 g), the ap1s1 and ap3s2 morphan s u derwen normal devel-
opment until at least two days pf (Figure 4.7A, top row). Without the addition of
neocuproine, neither the controls nor the morphants displayed any of the charac-
teristics of developmental copper deficiency which include reduced pigmentation,
a buckling notochord or an expanded hindbrain. Partial reduction of ap1s1 or
ap3s2 function did not affect development of the zebrafish embryo in optimal
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nutrient conditions. To mimic low copper conditions, 4-6 hpf morphants were
treated with a range of neocuproine concentrations (1 µM, 2 µM and 5 µM) and
zebrafish embryo development was observed over two days. At low neocuproine
concentrations, the control embryos exhibited only a mild (at 1 µM) to moderate
(at 2 µM) reduction in melanocyte pigmentation (n > 100) whereas many ap3s2
and ap1s1 morphants showed severe hypopigmentation (n = 37/71 embryos and
n = 13/39, respectively). Addition of a higher concentration of neocuproine (5
µM), caused both wild-type and morphant embryos to exhibit features of develop-
mental copper-metabolism deficiency. This could be prevented with the addition
of 15 µM exogenous copper (Figure 4.7A). At least two of the intracellular trans-
port pathways that were identified in the budding yeast showed physiological
relevance in the developing vertebrate.
4.2.4 Investigation of off-target effects of nitrofurans with
zebrafish and yeast
Of the melanocyte-specific drugs, BTB 05727 was investigated in more detail for
two reasons. It is not a tyrosinase-dependent pro-drug (Figure 4.2B) and it con-
tains a 5-NO2 moiety. BTB 05727 has therefore been named NFN1. 5-nitrofurans
are widely used to treat parasitic trypanosome infections. The unicellular para-
site Trypanosoma causes diseases in Africa and in Central and South America.
Trypanosoma brucei causes sleeping sickness in parts of sub-saharan Africa where
50,000-70,000 people are infected. In Central and South America, Trypanosoma
cruzi causes Chagaz disease. It is a tropical parasitic disease and affects 8-11
million people. Both infections are fatal if they are not treated. Nifurtimox is
a drug that is used against both diseases, but treatment is discontinued in 30%
of patients due to severe side-effects. Nifurtimox is a nitrofuran pro-drug that is
activated by parasitic nitroreductases. Recently it has been suggested that it is
converted into an unsaturated open chain nitrile (Hall et al., 2011). The fact that
NFN1 is melanocytotoxic in zebrafish provides a highly visible assay to study the





























Figure 4.8: 5-NO2 moiety is required for nitrofuran activity in zebrafish and
yeast. (A) Effect of NFN1 and NFN1.1 on zebrafish melanocytes.(B) Yeast was
grown in the presence of increasing concentrations of NFN1 (blue) and NFN1.1
(red). OD values were normalised against DMSO controls. The mean of two
independent experiments with three replicates each was calculated; error bars
represent standard deviation. Images in (A) were taken by the Patton lab.
5-Nitrofuran activity in zebrafish and yeast requires the 5-NO2 moiety
5-nitrofurans are pro-drugs and for these drugs to be active against parasites, the
5-NO2 moiety is essential for bioactivation by bacterial nitroreductases (Wilkinson
et al., 2008). S. cerevisiae has at least two nitroreductase-like proteins, but they
share little similarity with the bacterial nitroreductases that activate 5-nitrofurans
in Trypanosoma.
Removing the NO2 moiety from NFN1 resulted in compound NFN1.1 (Fig-
ure 4.2A) which was used to investigate the role of the 5-NO2 moiety in NFN1
bioactivity. Figure 4.8A shows that NFN1.1 did not have any effect on zebrafish
melanocytes, confirming that nitrofuran activity in zebrafish is dependent on the
5-NO2 moiety. In the budding yeast, treatment with NFN1 reduces yeast growth
by 50% at 12.5 µM whereas NFN1.1 did not show any effect on growth, even
at concentrations up to 100 µM (Figure 4.8B). This confirmed that the 5-NO2
moiety is required for NFN1 bioactivation in zebrafish and budding yeast.
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Aldh2 activity is required for NFN1 activity in zebrafish and yeast
Affinity purifications were performed with zebrafish extracts (from three day pf
embryos) to identify NFN1-interacting proteins (Ishizaki, Zhou et al., submitted).
A 56 kD protein was identified as aldehyde dehydrogenase 2 (Aldh2) and validated
on a Western blot with anti-Aldh2 zebrafish antibodies (raised against Aldh2a
and b forms). Purified human Aldh2 was also shown to bind to NFN1, indicating
that the data obtained with the zebrafish model may also be applicable to humans
(Zhou L, Westwood N, Patton E, unpublished data). Aldh2 fulfils several roles
in the human body. After alcohol consumption it catabolises toxic aldehydes in
the liver. It also catabolises toxic metabolites after heart ischemia and acts in
dopamine metabolism.
Aldh2 inhibitors were used to test if Aldh2 activity is required for 5-nitrofuran
toxicity in zebrafish and yeast. Zebrafish Aldh2 a and b are closely related to
human Aldh2. Two chemically different Aldh2-inhibitors were used: daidzin and
disulfiram. Both compounds did not affect melanocyte integrity on their own in
three day pf embryos. Treatment of three day pf zebrafish with combinations
of NFN1 with daidzin or disulfiram however, fully protected melanocytes from
5-nitrofuran activity (Figure 4.9A, Ishizaki, Zhou et al., submitted).
S. cerevisiae has five aldehyde dehydrogenase genes (ALD2-6) (Navarro-Aviño
et al., 1999) and they all share 42-48% similarity with human ALDH2. Ald4 and
Ald5 are mitochondrial aldehyde dehydrogenases and the other three are cytosolic
isoforms. Ald6 is constitutively expressed whereas ALD2 and ALD3 are induced
in response to various stresses and are repressed by glucose.
The two Aldh2-inhibitors were also tested in the budding yeast for interactions
with NFN1. Figure 4.9B shows that daidzin alone had no effect on yeast growth
at concentrations up to 50 µM (blue). Treatment of yeast cultures with increas-
ing concentrations of daidzin in the presence of 50µM NFN1 (black) showed that
daidzin could completely rescue the effects of NFN1. The Aldh2-inhibitor disulfi-
ram was also tested but rescue was not observed with this compound. Disulfiram
is already toxic on its own and has an MIC of 16 µM. Alleviating effects were





























Figure 4.9: Rescue of 5-nitrofuran toxicity by Aldh2 inhibitors. (A) Examples of
three day old zebrafish embryos that were treated with 10 µM Aldh2 inhibitors
(daidzin or disulfiram) for one hour and then treated with 5 µM NFN1 in 0.1%
DMSO or DMSO alone. Zebrafish embryos treated with NFN1 only are shown
as well. (B) Drug interaction between daidzin and NFN1 in the budding yeast
was assessed by combination matrix assays in 96-well plates. Yeast cultures were
treated with increasing concentrations of NFN1 alone (red), increasing concen-
trations of daidzin alone (blue) or in the presence of 50 µM NFN1(black). The
average of three independent experiments was calculated shown; error bars rep-
resent standard deviation. Images in (A) were taken by the Patton lab.
various effects in yeast that are not related to aldehyde dehydrogenase inhibi-
tion. Experiments in zebrafish have shown that disulfiram is a copper chelator
(Ishizaki, Zhou et al., submitted). Disulfiram has been shown to be a multidrug
resistance modulator acting via P-glycoproteins (Loo & Clarke, 2000) as well as
ATP-binding cassette transporters (Shukla et al., 2004; Sauna et al., 2004). This
effect even has therapeutic relevance since disulfiram has been shown to have
activity against clinical isolates of the fungal pathogens Aspergilus and Candida,
some of which were drug resistant (Khan et al., 2007). Recently, disulfiram has
also been identified as an inhibitor of V-ATPase pumps (Johnson et al., 2010).
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Figure 4.10: Effect of NFN1 on aldehyde dehydrogenase gene deletions in S. cere-
visiae. The growth inhibitory effect of 50 µM NFN1 was measured in wild type
haploid yeast, single deletion strains for each of the five aldehyde dehydrogenase
genes ALD2-6 and two different isolates of the ald2∆ald3∆ strain. Normalised
growth at the time of saturation of the corresponding control culture (1% DMSO,
dark grey) is compared to growth of the NFN1-treated cultures (light grey). The
mean of three replicates is shown for each strain; error bars represent standard
deviation.
Deletion of aldehyde dehydrogenase genes renders S. cerevisiae resistant
to 5-nitrofurans
As described in detail in Section 1.2.5, mutations that confer resistance to a
compound can directly point to drug targets or target pathways. This concept
was the basis for the following experiments that were devised to confirm aldehyde
dehydrogenase as the drug target of NFN1 in the budding yeast.
Figure 4.10 shows the effect of single deletions in each of the aldehyde dehy-
drogenase genes on NFN1 sensitivity. Growth of ald2∆, ald3∆, ald4∆, ald5∆,
ald6∆ strains was inhibited by 30-40% upon treatment with 50 µM NFN1. This
level of growth inhibition was similar to the one observed for the wild type strain.
















































Figure 4.11: Rescue of 5-nitrofuran toxicity by aldehyde dehydrogenase deletions
in S. cerevisiae. (A) ALD6 deletion partially rescues the growth-inhibitory effect
of NFN1 in yeast cultures. MATa wild type (blue) and the ald6∆ strain (red)
were treated with increasing concentrations of NFN1 (up to 100 µM). Normalised
growth is plotted. Data points represent the mean of four replicates; error bars
represent standard error. (B) Deletion of the yeast genes ALD2, ALD3 and
ALD6 has additive effects on rescue of NFN1 cytotoxicity in yeast. Dose response
curves for WT budding yeast (blue), ald2∆ald3∆ (red) and the ald2∆ald3∆ald6∆
(black) strains were generated. OD readings were normalised against DMSO
controls. The average of three replicates is plotted; error bars represent standard
error.
same dose of NFN1. ald2∆ald3∆ double deletion mutants were also found to be
less sensitive to 50 µM NFN1 (about 20% growth inhibition). To confirm the
resistance of the ald6∆ and the ald2∆ald3∆ strains, dose response curves were
generated. Again, ald6∆ was found to confer resistance to NFN1 by decreasing
the observed growth inhibition from 60% to just over 20% (Figure 4.11A). The
ald2∆ald3∆ strains alleviated growth inhibition by about 10% compared to wild
type (Figure 4.11B). Finally, the triple deletion strain ald2∆ald3∆ald6∆ was con-
structed and was slightly more resistant than the ald6∆ strain. It showed less
than 20% inhibition when growth of wild type yeast was inhibited by over 60%.
These results indicate a strong genetic dependence on aldehyde dehydrogenase























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.2.5 Mode of action of a compound that selectively kills
melanocytes in D. rerio
Early work has shown that nifurtimox causes DNA damage in trypanosoma (Goi-
jman et al., 1985). The 5-nitrofuran nifurtimox has recently been shown to be
converted to cytotoxic nitrile metabolites (Hall et al., 2011). Work by Hironori
Ishizaki revealed that NFN1 causes cell cycle arrest and DNA damage, increases
levels of reactive oxygen species (ROS) and triggers apoptosis in melanocytes. To
investigate the mode of action of NFN1 further, genome-wide chemical-genetic
profiles were generated in the budding yeast S. cerevisiae. Three different con-
centrations of NFN1 were screened against the haploid deletion pool to identify
deletion strains sensitive to NFN1 treatment. Figure 4.12 shows the Z-scores of
the log2 ratios of all haploid deletion strains in the presence of 20, 40 and 60 µM
of NFN1. A group of the deletion strains that were sensitive to NFN1 treatment
were the RAD genes that are sensitive to radiation and involved in DNA damage
repair. The most sensitive deletion strain in two of the screens were RAD5 and
RAD18. RAD5 is a DNA helicase and it is thought that it promotes replication
fork regression during post-replication repair by template switching. It is a RING
finger containing ubiquitin ligase that stimulates the synthesis of free and PCNA-
bound polyubiquitin chains by Ubc13p-Mms2p. RAD18 is an E3 ubiquitin ligase
that forms a heterodimer with Rad6p to mono-ubiquitinate PCNA-K164. The
heterodimer binds single-stranded DNA and has single-stranded DNA dependent
ATPase activity. RAD18 is required for post-replication repair.
Analysis of the most sensitive deletion strains reveals that many of the genes
that overlap between the screens at different concentrations are involved in DNA
damage. In fact, of the 23 deletion strains that are sensitive in all three drug
screens, 13 function in DNA damage repair (Figure 4.13).
The hits from the NFN1 chemical-genetic profiles were further characterised
using GO annotations. For each GO category, the average Z-score across all
genes that are associated with the GO category was calculated. GO categories
with an average Z-score of ±2 or more significant in at least one of the three
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Figure 4.13: Haploid deletion strains sensitive to NFN1 treatment. The haploid
deletion pool was screened against three different concentrations of NFN1: 20,
40 and 60 µM. Deletion strains with a Z-score smaller than -2 in at least two of
the screens are shown. The total numbers of sensitive deletion strains in the 20,
40 and 60 µM screens were 100, 65 and 94, respectively.
DNA damage repair pathways like single and double strand break repair as well
as repair via recombination and nucleotide excision. However, just based on this
data it is not possible to determine if NFN1 causes a specific type of DNA damage.
There were no GO categories with positive average Z-scores greater than 2.
The sensitivity of 14 deletion strains to NFN1 was assessed by spot dilution
assays (Figure 4.15). The following genes caused increased sensitivity to NFN1
when deleted: RAD5, RAD54, RAD55, RAD57 and TOP3. A subset of eight
deletion strains, containing strains deleted for the five genes that caused sensi-
tivity in the spot dilution assay, was selected for confirmation of the gene-drug
interaction (Figure 4.16) in liquid cultures. All five strains identified as sensitive
before also showed sensitivity in this assay. rad5∆ was the most sensitive deletion
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Genes in GO category GO category
Figure 4.14: GO categories of deletion mutants affected by NFN1 treatment. For
each of the three NFN1 chemical-genetic screens, average Z-scores were calculated
for each GO category. The most significantly affected GO categories are shown
(Z-score < -2; there were no categories with a Z-score > 2). Heatmap represents
log2 sensitivity Z-score. Genes annotated with each GO category are listed on the



















Control NFN1 (40 µM)
Figure 4.15: Spot dilution assay of S. cerevisiae strains deleted for genes involved
in DNA damage repair pathways. Yeast strain dilutions were spotted onto XY
plates as well as XY plates containing 40 µM NFN1.
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WT rad4Ä rad5Ä rad10Ä rad54Ä rad55Ä rad57Ä shu1Ä top3Ä
Figure 4.16: Confirmation of a subset of drug-gene interactions for NFN1. (A)
Spot dilution assay of 14 deletion strains on plates with and without NFN1. (B)
A set of eight deletion strains was tested for their sensitivity to NFN1. OD600
values after 12 hours are shown. The mean of triplicate measurements are shown;
error bars represent standard deviation.
assays. rad4∆, rad10∆ and shu1∆ did not have a significant effect on NFN1
susceptibility in either assay.
Among the 75 compounds that were profiled in Parsons et al. (2006) are four
drugs that are known to cause DNA damage. These compounds are cisplatin,
hydroxyurea, methanesulfonic acid methyl ester (MMS) and mitomycin C. Cis-
platin is a chemotherapeutic agent that is used against different types cancers.
It cross-links to DNA leading to apoptosis of affected cells.. Hydroxyurea is used
against a variety of diseases including sickle-cell disease and AIDS. It is thought
to scavenge tyrosyl free radicals and therefore inhibits ribonucleotide reductase
which leads to DNA damage. MMS is an alkylating agent and is considered a
carcinogen. It is used to treat cancer. Mitomycin C is a natural product that is
used as a chemotherapeutic agent. It is a potent DNA crosslinker. Comparison of
the chemical-genetic profiles of these compounds from the Parsons et al. (2006)
dataset with the NFN1 profile (60 µM) revealed that quite a few of the deletion
strains most sensitive to NFN1 are also sensitive to each of these four drugs (Fig-
ure 4.17). The majority of these shared sensitive deletion strains are involved in
130























































































Figure 4.17: Comparison of chemical-genetic profile of NFN1 with that of DNA
damaging drugs. The chemical-genetic profile of NFN1 was compared with those
of (A) cisplatin, (B) hydroxyurea, (C) MMS and (D) mitomycin C from Parsons et
al., 2006. Note that for scores along the y-axis, positive scores indicate sensitivity
of a deletion strain.
DNA damage repair. These results strengthen the argument that NFN1 causes
DNA damage in the budding yeast S. cerevisiae.
4.2.6 Summary of Results
Using chemical-genetic screens in S.cerevisiae it was shown that compounds af-
fecting melanocyte pigmentation do so by interfering with copper metabolism.
Defects in intracellular AP1 and AP3 trafficking pathways were shown to cause
sensitivity to low copper conditions in zebrafish embryos. Surprisingly, the MAP-
kinase inhibitor U0126 was found to affect copper metabolism. Further, a ni-
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trofuran compound was found to specifically promote melanocyte cell death in
zebrafish. This enabled the study of off-target effects of nitrofurans that are
used to treat trypanosome infections. Nifurtimox is a nitrofuran prodrug that is
activated by pathogen-specific nitroreductases. With yeast and zebrafish it was
shown that nitrofurans are also bioactivated by host-specific aldehyde dehydro-
genases suggesting that a combination therapy with an aldehyde dehydrogenase
inhibitor might reduce side effects associated with nifurtimox.
4.3 Discussion
Combination of zebrafish and yeast screens revealed gene-environment
interactions
Pathways involved in uptake, trafficking and excretion of transition metals are
well conserved between yeast, zebrafish and human (Thiele & Gitlin, 2008; for
copper: Rees & Thiele, 2004). This allows for human diseases related to allelic
variants in genes involved in copper metabolism to be characterised in model
organisms. Compounds that were identified as copper chelators in phenotypic
screens in zebrafish as well as the known copper chelator neocuproine, were
subjected to genome-wide chemical-genetic screens in the budding yeast. These
screens revealed overlap in target pathways of these small molecules. Intracellular
transport pathways were affected in particular and these pathways are essential
for transport of copper to copper-enzymes, for recycling of ATP7a, a copper
transporter, and for detoxification in high copper conditions (Jo et al., 2008). In
melanocytes, the activation of copper-dependent pigmentation enzymes, like ty-
rosinase, is restricted to melanosomes by transport of ATP7A to these specialised
organelles (Setty et al., 2008). The transport of tyrosinase into melanosomes is
mediated by components of the AP1 and AP3 complexes whereas BLOC-1 is
required for selective ATP7A-transport. Rare alleles of the AP3 and the AP1s1
genes have been linked to diseases. The combination of zebrafish and yeast data
suggest that reduced levels of functional AP1 and AP3 do not affect pigmenta-
tion in optimal nutritional conditions but have dramatic effects of pigmentation
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in low-copper conditions (Figure 4.7B). The budding yeast was therefore suc-
cessfully used to identify at least two intracellular transport pathways that are
physiologically relevant in the developing vertebrate.
Unbiased screens detected unexpected drug target(s) for U0126
Characterisation of the in vivo mode of action of a compound is the most impor-
tant and most challenging question in chemical biology. Phenotypic screens and
genome-scale genetic analysis in model organisms have been successfully used to
identify target pathways for known and new compounds. There has been some
success in predicting new molecular targets for known drugs computationally
(Keiser et al., 2009). Cellbased, biochemical and in silico methods are usually
applied to identify molecular targets, but these approaches are quite limited be-
cause they look for specific effects. In addition, a molecular target in specific
experimental conditions does not fully reflect the complex action of a compound
within the developing animal. Indeed, unbiased screens in zebrafish and budding
yeast revealed unexpected copper-dependent effects of the MEK inhibitor U0126
in this study.
Integration of data from different model organisms to investigate off-
target effects of nitrofuran compounds
The beauty of chemical biology is that it is generally possible to investigate the
effect of small molecules in different model organisms or assays. Identification
of the nitrofuran compound NFN1 as melanocyte-specific in a zebrafish pheno-
typic screen provided a model for the study of off-target effects of nitrofuran
compounds independent of trypanosome infections. Nitrofuran compounds are
pro-drugs that are converted to unsaturated open chain nitriles by parasitic ni-
troreductases (Hall et al., 2011). These drugs are widely used even though many
patients suffer severe drug-induced side-effects. Experiments in zebrafish extracts
revealed ALDH2 to be bound by NFN1. Purified human ALDH2 was also shown
to bind to NFN1 (Ishizaki, Zhou et al., submitted). Further experiments in ze-
brafish and yeast showed that the 5-NO2 moiety is indeed required for bioactivity
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of NFN1 in these two organisms. Small molecule inhibitors of aldehyde dehydro-
genase prevented the effects of NFN1 yeast and zebrafish, indicating that NFN1
bioactivation depends on ALDH2 activity. This was also confirmed genetically in
the budding yeast where deletion of ALD2, ALD3 and ALD6 had additive effects
on NFN1 rescue. These results from experiments in zebrafish, yeast and human
supported the hypothesis that nitrofuran compounds can also be activated by
aldehyde dehydrogenase 2 which may cause the side-effects observed in many pa-
tients. Experiments in zebrafish (Ishizaki, unpublished data) and yeast indicate
that nitrofurans cause DNA damage in these organisms which is the mode of
action of nifurtimox against Trypanosoma (Goijman et al., 1985).
Drug combinations as new therapeutic strategy to treat trypanosome
infections
The knowledge that ALDH2 activates nitrofuran compounds in host cells, led
to the hypothesis that inhibition of these enzymes, that are not present in the
genomes of Trypanosoma brucei and Trypanosoma cruzi, could prevent host tox-
icity. Experiments in trypanosome showed that a combination of nifurtimox
and an Aldh2-inhibitor does not affect the trypanocidal potential of nifurtimox
(Ishizaki, Zhou et al., submitted). The observation that Aldh2 inhibitors prevent
5-nitrofuran activity specifically in animals, suggested that combination treat-
ment of 5-nitrofuran compounds together with Aldh2-inhibitors could prevent




Summary and Concluding Remarks
5.1 Summary
Functional genomic approaches in the budding yeast Saccharomyces cerevisiae re-
vealed that membrane-perturbing compounds as well as inhibitors of sphingolipid
biosynthesis synergise with fluconazole in fungal strains. Experiments in zebrafish
and yeast revealed a gene-copper-nutrition interaction. A combined zebrafish-
yeast approach also resulted in a combination treatment for Trypanosoma infec-
tions with reduced side effects.
5.2 Concluding Remarks
I think that drug discovery, especially for neglected diseases, will greatly bene-
fit from the approaches applied in the context of this thesis. Known drugs are
a valuable resource and there is already a variety of applications and screening
approaches. Drug combination screens using a well chosen known drug as an
“anchor drug” seem to be a fruitful approach to discover effective drug combina-
tions against different diseases. The idea of the vast combinatorial chemical space
is daunting, especially when more than two compounds are combined. Progress
135
in systems biology will be necessary to guide drug discovery because biological
systems are much more complex than we are currently able to handle. Organism-
based screening will probably soon be applied to across-species profiling of small
molecule collections. The effects of drugs in different species will inform about
the compounds as well as the species.
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Development and implementation of methods for the
analysis of chemogenomic profiles of small molecules
Genome-wide chemical-genetic profiles can provide a lot of information. This
section will give a short overview of different methods that can be used to analyse
these profiles. The methods were developed and implemented while I worked with
various data sets and they will eventually be implemented as an analysis pipeline.
The Gene Ontology (GO) contains a lot of information about protein function
and is widely used to analyse genome-wide data sets. I used the GO annotations
of proteins and I will therefore briefly introduce it in Section A.1. Sections A2
to A11 give an overview of analysis methods that I have applied to various data
sets.
A.1 Gene Ontology
The GO Consortium is a bioinformatics initiative that aims to develop a dynamic,
yet controlled vocabulary to describe the role of genes and proteins across different
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Species Databases/Organisations
Yeast Saccharomyces Genome Database, SGD;
S. pombe via GeneDB
Bacteria EcoliWiki
Slime mold dictyBase
Flies Berkeley Drosophila Genome Project; FlyBase
Mice Mouse Genome Informatics, MGI
Plants Maize Genetics and Genomics Database, MaizeGDB;
The Arabidopsis Information Resource, TAIR;
Gramene, a comparative mapping resource for grains
Rats Rat Genome Database RGD
Worms WormBase
Zebrafish The Zebrafish Information Network, ZFIN
Humans British Heart Foundation, Cardiovascular GO Annotation Initiative
Table A.1: List of species databases that are members of the GO consortium
(from www.geneontology.org).
species (Ashburner et al., 2000; www.geneontology.org). The consortium is made
up of the model organism and protein databases as well as the biological research
community and has the aim to develop, maintain and actively use GO. The GO
consortium was founded 10 years ago by the three model organism databases
for mouse, yeast and fly. Today, a wide range organisations are GO consortium
members, including species-specific databases for microbial, plant and animal
genomes (Table A.1). Several databases (UniProtKB-Gene Ontology Annotation,
GeneDB, Reactome) as well as the Institute of Genome Sciences at the University
of Maryland and the J Craig Venter Institute are also members of the consortium.
To capture different aspects of protein function three independent ontologies
have been developed: biological process, molecular function and cellular compo-
nent. These ontologies describe the context of action, elemental activities and
subcellular location(s) of gene products, respectively. Normally, annotations in
any of these three ontologies are based on the scientific literature. In 2008, SGD






Speices with annotation 197,439
Annotated gene products
Total 44.5 Mio
Electronic (IEA) 43.7 Mio
Manual 890,094
Table A.2: Status of Gene Ontology as of September 4, 2009 (adapted from The
Gene Ontology Consortium, 2010).
fer GO annotations based on high-throughput data (Hong et al., 2008, Christie
et al., 2009). Another source of GO annotation are computationally predicted
annotations for UniProt proteins based on sequence similarity. The evidence
code ’Inferred from Electronic Annotation’ is associated with all computationally
derived GO annotations.
One of the key motivations behind GO is that GO annotations in one species
can be transferred to other species, enabling a fast initial functional annota-
tion of newly sequenced genomes. The results of this concept can be seen in
Table A.2: only 52 species are actively curated, but there are nearly 200,000
species with GO annotations. It is also important to note that less than one
million manual annotations give rise to over 44 million annotations in total. The
GO Reference Genome Project is committed to the comprehensive annotation
of the 12 GO Reference Genomes: human, Arabidopsis thaliana, Caenorhab-
ditis elegans, Danio rerio, Dictyostelium discoideum, Drosophila melanogaster,
Escherichia coli, Gallus gallus, Mus musculus, Rattus norvegicus, Saccharomyces
cerevisiae, and Schizosaccharomyces pombe (The Reference Genome Group of the
Gene Ontology Consortium, 2009).
As of 2009, about 5000 protein-coding genes of the budding yeast were an-
notated with information from the biological process and molecular function on-
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tologies.
There are also cut-down versions of GO that are called GO Slims. They give
a broad overview of the terms, but I did not find GO SLIM useful in the context
of chemical-genetic profiles.
A.1.1 GO annotation data files
The Saccharomyces Genome Database (www.yeastgenome.org) is one of the model
organism databases that contribute to GO. Annotation files for the budding yeast
can be downloaded from http://downloads.yeastgenome.org/literature curation.
I used the following data files for my GO analyses:
• gene association.tab (version from April 23, 2011) - all GO annotations for
S. cerevisiae genes
• go slim mapping.tab (version from April 23, 2011) - maps all yeast gene
products to GO SLIM terms
• go terms (version from April 23, 2011) - contains the definitions of all GO
terms
• SGD features (from http:downloads.yeastgenome.orgchromosomal feature,
version from April 23, 2011) - contains all chromosomal features in SGD.
These include all ORFs and RNAs (snRNAs, tRNAs, ncRNAs, rRNAs,
snoRNAs), but also annotations for chromosome features like centromeres
and telomeres.
A.2 Optimisation of chemical-genetic screens
Chemical-genetic screens are competitive growth assays during which pools of
deletion strains are grown in the presence of a compound. Compound is added
to cultures with a starting OD of 0.025 and growth inhibition is assessed after
12 hours. To identify deletion strains that are sensitive or resistant to com-
pound treatment, the compound should be added at a concentration that in-
hibits growth at a moderate level. The optimal level of growth inhibition to ob-
serve compound-specific hypersensitivity phenotypes varies between compounds.
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Figure A.1: Scatter plots of green versus red intensities of barcode array data.
(A) Profile with specific hits. (B) Profile with many sensitive deletion strains.
(C) Barcode array where one of the labelling PCRs did not work properly.
Generally, 20-30% growth inhibition compared to solvent control results in good
profiles where most deletion strains are not differentially affected by compound
treatment. Therefore, most data points fall along the diagonal, as is the case in
Figure A.1A. Some compounds give very informative profiles with only 5% growth
inhibition. However, there are compounds that affect growth of many deletion
strains even at very low levels of growth inhibition. Neocuproine is a compound
that affects growth of many deletion strains even at concentrations that only
cause 8% growth inhibition (Figure A.1B). Neocuproine is a very strong copper
chelator which probably explains the observed effect.
To identify the optimal concentration range for a compound, a 2 fold dilution
series from 1 µM to 128 µM is set up for each new compound and growth inhibition
assessed at 12 hours. Typically, cell pellets are frozen down for concentrations
that show 5-40% growth inhibition. Chemical-genetic profiles are then generated
with samples that showed 20-30% growth inhibition. Depending on the profiles,
lower or higher concentrations are also tested.
I observed that levels of growth inhibition can be very different between cul-
tures grown in glass tube and cultures grown in a plate reader in 96-well plates,
even if the cultures in the plate reader are aliquots taken from the glass tube
cultures. There were several instances where a culture would grow with little
164
inhibition in the plate reader, but there was no growth at all in the glass tube.
This could be due to the compound interacting with the polystyrene plates or
precipitation of the compounds because the shaking of the plates is different from
rotating the glass tubes on a wheel. It is therefore advisable to determine levels
of growth inhibition directly on the cultures in glass tubes that will be used for
the chemical-genetic screens.
A.3 Quality control
Quality control is an important step to assess quality and reliability of the
chemical-genetic profiles. A simple scatter plot of red versus green intensities
from the microarray gives a first impression of the data. Three examples are
given in Figure A.1. These plots give an idea about how many deletion strains
are affected by compound treatment (Figure A.1A & B). They can also reveal
problems that occurred during the barcode microarray experiment. The plot in
Figure A.1C for example shows that the red signal is very low for about half the
data points. This probably means that the Cy5-labelling PCR for one of the
barcode tags (UP or DOWN) did not work properly. This microarray will have
to be repeated.
To identify deletion mutants affected by compound treatment, two different
samples (drug treated and control) are hybridised competitively to the barcode
arrays. To ensure that the resulting fold changes are reliable, the red and green
data points should have similar intensity distributions. In the second column of
Figure A.2 the intensities of the red and the green channel are summarised in a
histogram. The first peak corresponds to empty and control spots, the second
peak, that is lower and wider than the first one, contains the barcodes of deletion
strains that are present in the pool. In Figure A.2A, the distributions of red
and green are very similar. A problem that occurred in Toronto as well as in
Edinburgh was oxidation of the Cy5 dye, probably caused by ozone in the air.
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Figure A.2: Quality control plots for barcode microarrays.(A) Barcode array with
similar red and green intensities. (B) Barcode array where the Cy5 dye (red)
has low intensity due to oxidation caused by ozone. (C) Barcode microarray
treated with stabilising solution from Agilent. In (A), (B) and (C) the first panel
is a scatter plot of green vs red intensities, the second panel shows frequency
histograms for red and green intensities and in the third panel the cumulative
frequencies are plotted for red and green intensities.
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This was usually only a problem during the summer months. In the histogram in
Figure A.2B, the oxidation of the red dye can clearly be seen. The red channel
has been scanned with higher laser power as indicated by the shift of the first
peak to the right, but the second peak is nevertheless clearly below the green
one. The problem was eventually solved by treating the barcode microarrays
with stabilising solution from Agilent which protects the Cy5 dye from oxidation.
The array in Figure A.2C has been treated with this solution and in the histogram
the second peak has similar shapes for the green and red channel. The shift to the
right of the green first peak indicates that the solution increases the background
noise in the green channel. All these effects can also be visualised with cumulative
frequencies of the intensities (Figure A.2A-C, last column).
A.4 Data analysis procedure to calculate Z-scores
First, low quality spots are identified and excluded from further analysis. An
intensity cut-off is determined based on the data from the control spots that are
present in each block of the barcode microarray. For each microarray, a cut-off
is chosen such that 95% of all empty spots are classified as such. Application
of this cut-off to all spots on the microarray usually means that for about 4200
deletion strains at least one barcode has a good signal. Each barcode is present
in replicate on the barcode microarray. If the two replicates have very different
intensities, then these barcodes are excluded from further analysis.
Next, the red and green intensities of the two replicates are averaged for all
barcodes that were found to have high quality data. Log2 fold changes are calcu-
lated (drug treatment/solvent-only control) for UP and DOWN tags separately.
Z-scores are calculated from the fold changes as follows: Z = (x− µ)/σ where µ
is the mean log2 fold change for the whole array and σ the standard deviation.
For each strain, the two Z-scores for UP and DOWN barcode tags are averaged
to obtain the final Z-score.
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Figure A.3: Correlation between profiles of one compound screened at different
concentrations. The concentrations plotted are (A) medium versus high, (B) low
versus high and (C) low versus medium.
A.5 Correlation between chemical-genetic screens
It can be very informative to plot the Z-scores of chemical-genetic profiles of the
same compound screened at different concentrations against each other. Figure
A.3 shows correlation plots between three different concentrations of the same
compound. The screens done with high and medium concentrations share many
strong hits (Figure A.3A) whereas the low concentration screen does not share
these hits (Figure A.3B & C).
For larger datasets it can be very informative to cluster all screens based on the
correlation between the chemical-genetic profiles. Replicate screens and screens
conducted with different concentrations of the same drug should cluster together.
The clusters can also inform about mode of action of the compounds because
compounds with similar profiles have similar effects on the deletion pool. In
Figure A.4 the correlation coefficients for a set of 60 chemical-genetic profiles are
represented as a heatmap. The compound profiles were clustered using complete
linkage to find clusters based on the correlation coefficients. Most replicates of
different compounds clustered together.
Large data sets are normally generated in batches. It is advisable to check
if the clusters obtained are in any way biased towards these batches. If that is











































































































































































































































































































































































































































































































































































































































































































Figure A.4: Correlation coefficients for 60 profiles for 30 different compounds. As
indicated in the colour key, white indicates high correlation coefficients and red
indicates low correlation coefficients. The tree on the left hand side shows how
similar the profiles are.
deletion strains and only working with these.
A.6 Overview plots
For single screens, the chemical-genetic profiles can be visualised by plotting the
Z-scores of all deletion strains. Sorting the strains by gene name can already
reveal trends if they are present because the gene names contain some functional
information. For example, ribosomal protein gene names all start with RP or
genes for proteins involved in vacuolar protein sorting start with VPS. Strong
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hits in the profile are also visible in these plots. This is especially interesting for
the set of heterozygous deletion mutants in essential genes because single strong
hits might represent the drug target as seen with ERG11 in the fluconazole screen
and LCB1/2 for L-cycloserine in Figure 3.13. A good example for haploid deletion
pools can be seen in Figure 4.12. The RAD genes are an obvious group of genes
that are sensitive to different concentrations of NFN1.
For larger data sets it is useful to generate a heatmap with the most sensi-
tive/resistant deletion strains to get an overview of the strongest hits for each
screen as well as deletion strains that are affected in more than one screen. Fig-
ure 3.18A, for example, shows the most affected deletion strains for 6 different
compounds.
A.7 Testing for GO enrichment
The standard analysis of high-throughput screens that yield genome-wide data, is
the test for enrichment of specific GO categories among the set of genes that are
defined as hits. There are different methods to define hits from a screen. Three
different methods are shown in Figure A.5. Each method will results in a different
number of hits and the various sets of genes might show differences in their GO
enrichment. In addition, the selection of a subset of the thousands of genes is a
serious limitation because the majority of the data points is excluded from further
analysis. I therefore developed and implemented a method that makes use of all
data generated by determining average Z-scores for each GO category and for












































































































































































Figure A.5: Different methods to determine deletion strains sensitive or resistant
to drug treatment. (A) Using the top hits from both ends of the distribution of
scores. (B) Application of a predefined cut-off to identify hits. (C) Quantile-based
selection of hits.
A.8 Z-scores for GO categories
Calculation of average Z-scores for each GO category is a much more compre-
hensive analysis of chemical-genetic profiles because the data for all genes that
are annotated with GO categories is used. This method has been used to anal-
yse the chemical-genetic profiles of the copper-metabolism compounds (Figure
4.4B) and for the screens with different concentrations of NFN1 (Figure 4.14). A
larger data set of 60 screens for 30 different compounds is shown in Figure A.6.
Screens conducted with the same compound at different concentrations generally
have very similar scores across the GO categories. The heatmap reveals that
some GO categories are sensitive or resistant in response to many compounds,
like ’tryptophane biosynthesis’ at the bottom of the heat map. There are also
many GO categories that only have strong Z-scores in a few profiles, indicating
specific effects of compounds. Since there are many GO categories in Figure A.6,
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Figure A.6: Average Z-scores for GO categories in 60 chemical-genetic screens.
Orange, red and dark red indicate sensitive GO categories (Z-scores smaller than
-1, -1.5 and -2, respectively) and light green, green and dark green indicate resis-
tant GO categories (Z-scores greater than 1, 1.5 and 2, respectively).
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A.9 Evaluation of chemogenomic data on the
level of protein complexes
Similar to the analysis described above, information about protein complexes
can be used to analyse chemical-genetic profiles. The CYC2008 set of protein
complexes (Pu et al., 2008) provides a comprehensive catalogue of heteromeric
protein complexes. 408 protein complexes have been manually curated and are
supported by small-scale experiments in the literature. Figure A.7 shows the
scores for the protein complexes in the same 60 profiles that were analysed for
GO categories in Figure A.6. Similar to the GO category analysis, there are some
protein complexes that have significant scores in response to several drugs and
some protein complexes are only affected by specific compounds.
A.10 Physical and genetic interactions to inter-
pret chemical-genetic interactions
Different data sets are frequently integrated to interrogate the mode of action of
small molecules. For example, Parsons et al. (2004) showed that it is possible to
cluster the chemical-genetic profiles with genetic interaction profiles to identify
target pathways for chemical compounds. Hoon et al. (2008) combined results
from three different experimental approaches to investigate the mode of action
of 188 novel synthetic compounds. I have tried to integrate genetic and physical
interaction data with chemical-genetic profiles. For example, the chemical genetic
profile of benomyl does not point to microtubule-related protein complexes or GO
categories. However, analysis of genetic interactions among the most sensitive
deletion mutants reveals a highly connected cluster of 9 genes most of which
are involved in microtubule-related processes (Figure A.8A). The deletion strains
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Figure A.7: Z-scores for protein complexes in 60 chemical-genetic screens. Or-
ange, red and dark red indicate sensitive protein complexes (Z-scores smaller
then -1, -1.5 and -2, respectively) and light green, green and dark green indicate
resistant protein complexes (Z-scores greater than 1, 1.5 and 2, respectively).
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seem to point to different pathways (Figure A.8B). In addition, integration of
physical interactions reveals three or four potential protein complexes (Figure
A.8C) that have also been identified by calculation of average Z-scores for protein
complexes.
A.11 Follow-up experiments
Confirmation of the most interesting hits from genome-wide chemical-genetic pro-
files improves confidence about these hits and also gives an estimate for the quality
of the screens. It is also a good idea to assess specific chemical-genetic interactions
if a deletion strain does not behave as expected. The chemical-genetic screens
do not directly assess each strain, but rely on microarray read-outs to quantify
abundance of strains. It is possible that deletion strains drop out of the pool or
that mutations occurr in the barcode or the primer regions which will result in
low or no signal for the affected strain.
Follow-up experiments that were conducted in the context of this thesis in-
clude sorbitol rescue and microscopy to assess physiological changes in yeast cells
in response to compound treatment. Different dyes can be used to look at vari-
ous cellular structures. Brenda Andrews’ lab in Toronto, Canada is working on
a set of yeast strains will enable analysis of sub-cellular morphology in response
to compounds. ’The marker project’ aims to assemble a set strains with GFP-
tagged proteins to allow visualisation of these organelles. This set of strains would
provide a rapid means to assess the effect of compounds on cellular physiology.
Depending on the chemical-genetic profiles, various assays can be conducted





Figure A.8: Integration of chemical-genetic profiles and genetic and physical in-
teraction data. Network images were generated with Osprey. (A) Genetic in-
teractions among deletions trains sensitive to benomyl. (B) Genetic interactions
among deletion mutants from a chemical-genetic profile. (C) Physical interactions
among deletion mutants from (B).
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A.12 Concluding remarks
This appendix gives an overview of different data analysis approaches that can
be applied to chemical-genetic profiles. Many approaches are available to analyse
genome-wide data and I have here described the ones that I have used for the
analysis of data presented in this thesis. Some of the described methods are
already available as online tools on our lab website. My goal is to implement a
comprehensive analysis pipeline and make it available as an R package and a web
interface. I am hoping to extend the integration of different data sources with
the chemical-genetic profiles considerably.
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APPENDIX B
Structural clusters of 148 hit compounds
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INTRODUCTION
Melanins are pigment granules that provide the color for human
hair, skin and eyes, and serve to protect surrounding cells from the
DNA-damaging effects of ultraviolet (UV) light. Melanins are
synthesized and stored in the melanosomes, specialized lysosome-
related organelles of the melanocytes that are transferred to
surrounding skin or hair cells or concentrated within the retinal
pigmented epithelium (Raposo and Marks, 2007). The restriction
of melanosome biogenesis to melanocytes results from the cell-
specific expression and production of pigment enzymes coupled
with their trafficking through the Golgi and early endosomal
pathways to the maturing melanosomal organelles. For example,
the melanocyte regulator Mitf promotes expression of the rate-
limiting enzyme tyrosinase, which is directed through the Golgi
and then to the endosome-to-melanosome pathway by the AP1 and
AP3 adaptor complexes. Once at the melanosome, tyrosinase
promotes melanin synthesis and deposition along the Pmel fibrillar
matrix (Chin et al., 2006; Raposo and Marks, 2007).
Copper (Cu2+) is essential for melanin production, and
consequently hypopigmentation is a feature of copper deficiency.
Genetic mutations of the copper transporters ATP7A or ATP7B
lead to Menkes disease or Wilson’s disease, respectively; these
childhood syndromes cause acute clinical symptoms in the bone,
skin, hair, blood and nervous system (Madsen and Gitlin, 2008).
The transporters ATP7A and ATP7B reside in the trans-Golgi
network and shuttle copper from the cytoplasm to copper-
dependent enzymes in the Golgi. Environmental conditions can
also lead to copper deficiency. For example, lambs born to ewes
feeding on copper-deficient grass share many clinical features with
children diagnosed with Menkes disease; this observation
established copper-metabolism deficiencies as an underlying cause
of the pathology of Menkes disease (Danks et al., 1972). Copper
deficiency can also occur in patients undergoing gastric surgery or
after excessive consumption of zinc or iron, all of which can inhibit
absorption of copper through the intestine (Kumar, 2006). However,
as the causes of many cases of copper deficiency remain unknown
(Madsen and Gitlin, 2007b), a more systematic approach to
understanding copper-metabolism deficiency in humans is
required, including the development of robust cell and animal
models (Thiele and Gitlin, 2008).
Melanocytes have a cell-type-specific requirement for copper in
pigmentation because tyrosinase is a copper-dependent enzyme,
and its activity is dependent on ATP7A (Petris et al., 2000).
Transport of ATP7A into melanosomes spatially restricts melanin
synthesis to melanocytes; this process is dependent on the
biogenesis of the lysosome-related organelle complex (BLOC)-1,
which is required for exit of endosomal cargo (Setty et al., 2008).
RESEARCH ARTICLE
Disease Models & Mechanisms 639
Disease Models & Mechanisms 3, 639-651 (2010) doi:10.1242/dmm.005769
© 2010. Published by The Company of Biologists Ltd
1Institute of Genetics and Molecular Medicine, MRC Human Genetics Unit and The
University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4
2XU, UK
2Wellcome Trust Centre for Cell Biology, University of Edinburgh, Michael Swann
Building, King’s Buildings, Mayfield Road, Edinburgh, EH9 3JR, UK
3Center for Systems Biology, Samuel Lunenfeld Research Institute, 600 University
Avenue, Toronto, Ontario, M5G 1X5, Canada
4Sir William Dunn School of Pathology, University of Oxford, South Parks Road,
Oxford, OX1 3RE, UK
5Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN
37232, USA
6The Institute of Cancer Research, Signal Transduction Team, Section of Cell and
Molecular Biology, 237 Fulham Road, London, SW3 6JB, UK
*These authors contributed equally to this work
‡Present address: The Hospital for Sick Children, Developmental Stem Cell Biology,
TMDT Building, 13-601G, 101 College Street, Toronto, Ontario, M5G 1L7, Canada
§Author for correspondence (e.patton@hgu.mrc.ac.uk)
SUMMARY
Hypopigmentation is a feature of copper deficiency in humans, as caused by mutation of the copper (Cu2+) transporter ATP7A in Menkes disease,
or an inability to absorb copper after gastric surgery. However, many causes of copper deficiency are unknown, and genetic polymorphisms might
underlie sensitivity to suboptimal environmental copper conditions. Here, we combined phenotypic screens in zebrafish for compounds that affect
copper metabolism with yeast chemical-genetic profiles to identify pathways that are sensitive to copper depletion. Yeast chemical-genetic interactions
revealed that defects in intracellular trafficking pathways cause sensitivity to low-copper conditions; partial knockdown of the analogous Ap3s1
and Ap1s1 trafficking components in zebrafish sensitized developing melanocytes to hypopigmentation in low-copper environmental conditions.
Because trafficking pathways are essential for copper loading into cuproproteins, our results suggest that hypomorphic alleles of trafficking components
might underlie sensitivity to reduced-copper nutrient conditions. In addition, we used zebrafish-yeast screening to identify a novel target pathway
in copper metabolism for the small-molecule MEK kinase inhibitor U0126. The zebrafish-yeast screening method combines the power of zebrafish
as a disease model with facile genome-scale identification of chemical-genetic interactions in yeast to enable the discovery and dissection of complex
multigenic interactions in disease-gene networks.
Combined zebrafish-yeast chemical-genetic screens
reveal gene–copper-nutrition interactions that
modulate melanocyte pigmentation
Hironori Ishizaki1,*, Michaela Spitzer2,*, Jan Wildenhain2, Corina Anastasaki1, Zhiqiang Zeng1, Sonam Dolma3,‡, Michael Shaw4,
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Excess exogenous copper can restore pigmentation to BLOC-1-
deficient melanocytes in vitro (Setty et al., 2008). Components of
BLOC-1 are mutated in Hermansky-Pudlak syndrome (HPS), a
disorder characterized by defects in lysosome-related organelles,
particularly melanosomes and platelet-dense granules (Wei, 2006).
Aberrant transport of ATP7A might be responsible for the HPS
pathology of melanocytes from BLOC-1-deficient individuals (Setty
et al., 2008). In zebrafish, mutation of atp7a or treatment with the
copper-chelator neocuproine causes a phenotype with features of
Menkes disease, including hypopigmentation, neurological
disorders, and loss of lysyl oxidase cuproenzyme activity in the
developing notochord (Mendelsohn et al., 2006). In zebrafish,
hypomorphic alleles of atp7a and the vacuolar ATPase (v-ATPase)
cause hypopigmentation at low copper concentrations,
demonstrating that genetic mutations can result in copper-
deficiency symptoms in suboptimal nutrient conditions (Madsen
and Gitlin, 2008).
We have developed a coupled zebrafish phenotypic and yeast
chemical-genetic screening approach to identify novel genetic
pathways that underlie copper-nutrient sensitivity in the developing
vertebrate melanocyte (Fig. 1A). Phenotypic chemical screens in
zebrafish enable the identification of novel biological pathways by
virtue of chemically induced phenotypes (Zon and Peterson, 2005).
Such zebrafish screens are typically carried out by treating
developing embryos with libraries of small molecules to identify
compounds that elicit a specific phenotype. The small size and
transparency of the embryo, which can be arrayed in 96-well plates,
coupled with tractable genetic tools for target validation and
disease modelling make the zebrafish a highly effective system for
phenotype-driven small-molecule screens. However, despite its
tractability, identification of the target pathways in zebrafish is
usually arduous (Peterson, 2008). Chemical-genetic approaches in
the budding yeast Saccharomyces cerevisiae can provide rich
functional information on the mechanism of action of compounds
dmm.biologists.org640
Melanocyte gene-environment pathwaysRESEARCH ARTICLE
Fig. 1. A combined zebrafish and yeast approach to probe chemical-genetic interactions in melanocyte pigmentation. (A)Overview of work flow.
Phenotypic screening in zebrafish informs as to the developmental and physiological target pathway. Small molecules that promote similar phenotypes in
zebrafish are then tested in genome-wide chemical-genetic screens in yeast to reveal potential target genetic pathways. Conserved target pathways are then
directly re-tested for chemical-genetic interactions in the zebrafish system using genetic mutant lines, morpholino oligonucleotides or small molecules known to
impinge on the same target. (B)Phenotypic screening of a >1500-compound yeast-bioactive library (S.D., J.W., M. Spitzer and M.T., unpublished data) and the
Sigma LOPAC library for altered pigmentation in zebrafish embryos revealed a copper-metabolism phenotype characterized by hypopigmentation, an expanded
hindbrain and an undulating notochord (Mendelsohn et al., 2006). Representative phenotype caused by 10M JFD00692 was rescued by treatment with
exogenous copper chloride (5M or 15M) during development. (C)Examples of the copper-metabolism phenotype induced by some of the compounds
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(Boone et al., 2007; Hillenmeyer et al., 2008). Mutations that render
yeast sensitive to a particular compound – that is, chemical-genetic
interactions – often establish links to the cellular target pathways
(Hartwell et al., 1997; Parsons et al., 2004; Parsons et al., 2006). The
yeast genome-wide gene-deletion collection, in which each of the
~6000 genes has been individually replaced with a deletion cassette
marked with unique sequence identifiers (barcodes) that can be
quantified in parallel by microarray hybridization, is a powerful
resource for chemical genetics (Winzeler et al., 1999; Giaever et
al., 2002). Chemical-genetic profiling, whereby growth of the
pooled deletion collection is scored for hypersensitivity to a
compound, enables the identification of target and off-target
pathways. This approach has been used to interrogate the
mechanism of action of both novel and clinically approved drugs,
including chemotherapeutics and neuroleptics (Lum et al., 2004;
Parsons et al., 2004; Parsons et al., 2006; Ericson et al., 2008;
Hillenmeyer et al., 2008). Compounds with similar chemical-
genetic profiles can be grouped to reveal similar modes of action
and similar targets (Parsons et al., 2006; Hillenmeyer et al., 2008).
Often the gene networks that confer sensitivity or resistance to a
given compound are conserved from yeast to mammalian cells
(Ericson et al., 2008; Yu et al., 2008).
We identified a novel panel of compounds that affect pathways
of copper metabolism and pigmentation in zebrafish and then
interrogated the mode of action of several of these compounds.
Based on the identification of target genes in yeast encoding
intracellular transport proteins, we show that reduced expression
of the orthologous target genes, ap1s1 and ap3s2, in zebrafish cause
hypopigmentation specifically under conditions of copper
limitation. We also demonstrate that the commonly used MEK
inhibitor U0126 affects copper metabolism in zebrafish, and use
chemical-genetic profiles in yeast to show that U0126 has at least
two target pathways in vivo. This combined zebrafish-yeast
chemical-genetic approach should be applicable to the study of
many other processes associated with disease and development.
RESULTS
A chemical screen identifies small molecules that elicit a copper-
deficiency phenotype in zebrafish
Using phenotypic screening in zebrafish, we identified a panel of
45 small molecules that caused a phenotype characteristic of
copper depletion (Fig. 1; Table 1). We screened the 1280-member
Library of Pharmacologically Active Compounds (LOPAC) and a
collection of 1576 bioactive compounds (S.D., J.W., M. Spitzer and
M.T., unpublished data) for effects on zebrafish pigmentation. Two
embryos at 4 hours post-fertilization (hpf) were placed in each well
of a 96-well plate and treated with 10 M of compound and
observed at multiple time points over 48 hours for a copper-
metabolism phenotype as exemplified by the atp7a-mutant
zebrafish or treatment with neocuproine. These phenotypic
manifestations include hypopigmentation, an expanded hindbrain
and an undulating notochord in a 2- to 3-day-old fish (Fig. 1B).
Active compounds included known copper-binding molecules,
such as 1-phenyl-3-(2-thiazolyl)-2-thiourea (PTT) (Mendelsohn et
al., 2006), as well as the metal-binding thiosemicarbazones, thiourea
derivates, phenanthrolines and pyridin-pyrimidinones (Fig. 1B).
Unexpectedly, the commonly used MEK inhibitor U0126 was also
identified as causing a phenotype consistent with defective copper
metabolism (Table 1); this phenotypic effect of U0126 has been
recently described elsewhere (Hawkins et al., 2008).
Further phenotypic characterization showed the copper-
metabolism phenotype caused by many of the small molecules
could be prevented with the addition of exogenous copper,
indicating that the characteristic zebrafish Menkes phenotypes in
pigmentation, notochord, blood and hindbrain development are
dependent upon the loss of environmental copper availability (Fig.
1B; Table 1). Interestingly, three compounds caused hypersensitivity
to exogenous copper addition (Table 1; supplementary material Fig.
S1). One possibility is that these three compounds interfere with
detoxification of excess copper ions in the cell; elevated copper
levels are highly toxic, and intracellular levels are finely balanced
by copper chaperones and metallothionein levels (Rae et al., 1999).
Genome-wide genetic-sensitivity profiles reveal potential copper-
metabolism pathways
We then used yeast chemical-genetic profiles to identify gene
deletions that resulted in sensitivity to a selected subset of
compounds that affected copper metabolism in our zebrafish
screen: this copper-metabolism subset (CM subset) comprised the
compounds neocuproine, U0126, DP00477, SEW01049, SPB07427,
JFD00692 and RJF01649. Evolutionarily conserved genetic pathways
that are sensitive to copper nutrition in yeast could then be directly
tested in the zebrafish vertebrate system (Fig. 1A). We screened
pools of ~5000 haploid yeast deletion mutants and ~1000
heterozygous diploid mutants for growth after treatment with the
CM subset. Compound concentrations were titrated such that
overall growth of the yeast pool was diminished by 20-30% (Parsons
et al., 2006). Aliquots of the deletion pools were grown for 20
generations in the presence of the different compounds as specified
in supplementary material Table S1 or in the presence of 0.4%
DMSO (control samples). Genomic DNA was isolated from each
pool, the barcodes were amplified with fluorescently labeled
primers, and the PCR products were hybridized to spotted
oligonucleotide microarrays (Cook et al., 2008). Scatter plots
demonstrated that for most chemical-genetic screens, the majority
of deletion mutants were not affected by treatment with compound
(supplementary material Fig. S2). Boxplots and quantile statistics
of z-scores for each microarray allowed identification of sensitive
and resistant mutants (see Methods).
Although all the chemicals in the CM subset produced a similar
developmental atp7a-mutant phenotype in zebrafish, we found
both distinct and common genetic pathways in yeast to be sensitive
or resistant to individual compounds in the CM subset, reflecting
the unique action of each chemical (Fig. 2). First, we examined the
sensitivity of deletions in genes known to be involved in copper
uptake and metabolism. Deletion strains defective in copper
metabolism are in fact rarely affected by chemical treatments in
large-scale surveys (Hillenmeyer et al., 2008), probably because
yeast cultures in these studies are typically grown in rich medium
that contains adequate amounts of available copper. We found the
fitness profiles of strains deleted for known copper-uptake and
-metabolism genes to be unique to each compound (Fig. 2A).
Deletion of genes such as the copper transporter CTR1, the copper
chaperones ATX1 and ATX2, the copper-transporting ATPase
CCC2, the copper-zinc superoxide dismutase SOD1 and the copper-
dependent transcription factor CUP2 all caused sensitivity to
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Table 1. Small molecules and copper-metabolism phenotypes
Moleculea
Maybridge
Code Phenotypeb Copper additionc Compound structure
Neocuproine – Copper metabolism Rescue (5 µM) Phenanthroline
U0126 – Copper metabolism Lethal (5 µM) Sulfanylmethylidene-butanedinitrile
PTT – Copper metabolism not determined 1-Phenyl-3-(2-thiazolyl)-2-thiourea
BIO2A11 DP00477 Copper metabolism Partial rescue (15 µM) Thiocarbamoyl-acetamide derivative
BIO2B11 DP00750 Copper metabolism Rescue (5 µM) Thiosemicarbazone
BIO2F3 CD00707 Copper metabolism Rescue (5 µM) Thio-urea
BIO2G5 CD02745 Copper metabolism Rescue (5 µM) Thiosemicarbazone
BIO2H4 CD02044 Copper metabolism Partial rescue (15 µM) Thiosemicarbazone
BIO3C5 HR 00030 Copper metabolism Rescue (5 µM) Thio-urea derivate
BIO3E2 FM00217 No pigmentation Rescue (5 µM) Thiosemicarbazone
BIO5C9 PD00357 No pigmentation Rescue (5 µM) Thiosemicarbazone
BIO5F10 RDR 00803 Copper metabolism Rescue (15 µM) Thiosemicarbazone
BIO5H4 KM 09752 Copper metabolism Rescue (5 µM) Thio-urea derivate
BIO6C9 RJC 00588 Copper metabolism Rescue (5 µM) Carbamic acid
BIO6D7 RH 01646 Copper metabolism Rescue (5 µM) Thiosemicarbazone
BIO6F7 RH 01676 No pigmentation Rescue (5 µM) Triazole-thiol
BIO7C11 SEW 02973 No pigmentation Rescue (5 µM) Pyridin-pyrimidinone
BIO7C9 SEW 01049 Copper metabolism Lethal (5 µM) Thiosemicarbazone
BIO7D2 RJF01673 Wavy notochord Rescue (5 µM) Pyridin-pyrminidinone
BIO7D3 S 02347 Copper metabolism Partial rescue (15 µM) 2,4-Diphenyl-2,3-dihydro-1,5-benzothiazepine
BIO7F2 RJF 01809 Copper metabolism Rescue (5 µM) Pyridin-pyrimidinone
BIO7G3 S 02850 Copper metabolism Rescue (5 µM) Carbamothioyl benzamide
BIO8A7 SJC 00393 Copper metabolism Rescue (5 µM) Thiosemicarbazone
BIO8C11 SPB 02722 Copper metabolism Partial rescue (15 µM) Benzoxazole derivate
BIO8F8 SPB 00258 Copper metabolism Rescue (5 µM) Thiosemicarbazone
BIO9C3 SPB 05679 Copper metabolism Rescue (5 µM) Pyridin-pyrimidinone
BIO9D5 SPB 07427 Copper metabolism Lethal (5 µM) Thiadiazole derivate
BIO9F4 SPB 07119 No pigmentation Rescue (15 µM) Thiosemicarbazone
CYTO10B10 SEW 06186 Copper metabolism Rescue (5 µM) Urea derivative (carboline-carboxamide)
CYTO10F4 SEW 01792 No pigmentation Rescue (15 µM) N-Hydroxy-benzamidine derivative
CYTO11A5 SPB 01039 Copper metabolism Rescue (5 µM) Triazole-thiol derivate
CYTO11B10 SPB 07027 Copper metabolism Rescue (5 µM) Thiosemicarbazone
CYTO11C10 SPB 07028 Copper metabolism Rescue (5 µM) Thiosemicarbazone
CYTO11D4 SPB 00779 No pigmentation Rescue (5 µM) Triazole-thiol
CYTO2A9 CD 02543 Copper metabolism Rescue (5 µM) Thiosemicarbazone
CYTO2E9 CD 03007 Copper metabolism Rescue (5 µM) Thiosemicarbazone
CYTO3A2 CD 06646 Copper metabolism Rescue (5 µM) Pyridin-pyrimidinone
CYTO3A6 DFP 00275 Copper metabolism Rescue (5 µM) Thio-urea derivate (carbamothioyl benzamide)
CYTO4A11 JFD 00692 Copper metabolism Rescue (5 µM) Phenanthroline (cisplatin analogues)
CYTO7C6 RF01893 Copper metabolism Rescue (5 µM) N-Hydroxy-benzamidine derivative
CYTO7D2 RDR00093 No pigmentation Rescue (5 µM) Thiourea derivate
CYTO7F2 RDR00691 Copper metabolism Rescue (5 µM) Thiosemicarbazone
CYTO8C11 S04201 Copper metabolism Rescue (5 µM) Thio-urea/Quinazolinone derivative
CYTO8C5 RJF01649 Copper metabolism Rescue (5 µM) Pyridin-pyrimidinone
CYTO9C5 S09668 Copper metabolism Partial rescue (15 µM) Thiourea derivates
CYTO9D11 S14458 Copper metabolism Rescue (5 µM) Thiosemicarbazone
aCompounds used in yeast genetic profiling are indicated in a bold font. U0126 and PTT were found in the Sigma LOPAC screening library.
bCopper-metabolism phenotype is defined as having hypopigmentation, a wavy notochord and expanded hindbrain, as described for the copper-transport atp7a-mutant zebrafish
(Mendelsohn et al., 2006) and shown in Fig. 1.
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chemically induced copper deficiency. Copper transport into the
cell by high-affinity transporters requires copper to be in the
reduced Cu(I) state, which is dependent on the ferric and cupric
(ferric/cupric) reductases Fre1 and Fre2 (De Freitas et al., 2003).
In yeast, and in human disease, copper and iron homeostasis are
intimately linked (De Freitas et al., 2003; van Bakel et al., 2005;
Madsen and Gitlin, 2007a). We observed that both fre1 and fre2
strains were highly sensitive to copper starvation caused by different
compounds. Finally, the iron transporters Fet3 and Fet5 are known
copper-dependent enzymes, and we found that a fet3 strain was
also highly sensitive to copper depletion. The effects of the CM
subset on specific gene-deletion strains thus reflected action of
compounds on copper homeostasis, as well as iron homeostasis
(van Bakel et al., 2005; Rustici et al., 2007).
To understand the biological processes affected by the CM
subset, we next assessed the Gene Ontology (GO) biological
processes affected by each compound (Fig. 2B; Table 2;
supplementary material Fig. S3; see Methods). Although each
chemical caused a unique fingerprint of genetic sensitivity, several
core pathways were shared by the different compounds. These
shared processes included mitochondrial translation initiation, the
Swr1 histone-remodeling complex, tubulin-complex assembly,
vacuolar organization and intracellular transport, and peroxisome
formation. Many of these pathways are linked to copper
homeostasis. For example, copper plays a vital role in
mitochondrial function, such as in cytochrome c oxidase activity
(Madsen and Gitlin, 2007b). Expression of the copper
metallothionein gene in yeast is regulated by chromatin
modification (Kuo et al., 2005), such that sensitivity of the Swr1
histone-exchange complex (Zilberman et al., 2008) to low-copper
conditions might reflect inappropriate control of metallothionein
(Kuo et al., 2005). Interestingly, loss of genes involved in threonine
biosynthesis resulted in sensitivity to some CM subset
compounds. Depletion of genes involved in the biosynthesis of
certain amino acids causes sensitivity to multiple treatment
conditions, including high-copper concentrations (Ericson et al.,
2008; Hillenmeyer et al., 2008; Jo et al., 2008). However, genes
involved in the threonine-biosynthesis pathway are not among
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Fig. 2. Yeast chemical-genetic profiles of small molecules that affect copper metabolism. (A)Copper-pathway mutant strains that were specifically sensitive
or resistant to U0126, neocuproine or the CM subset compounds. At least two concentrations for each compound were used for analysis. Genes with copper-
dependent functions were compiled from Saccharomyces Genome Database (SGD, http://www.yeastgenome.org); this list includes copper-containing proteins
and known factors in copper and/or iron transport and homeostasis. Color scale indicates degrees of sensitivity (red) or resistance (green); white indicates no
data available in a given experiment. (B)Yeast chemical-genetic profiles reveal shared and distinct modes of action for CM subset compounds. A heatmap of GO
biological process categories that correlated with sensitivity (red) or resistance (green) to different compounds is shown. Two different concentrations of each
compound were screened. Scores for each GO category that contained at least four genes were calculated as the average z-score of all mutants in the category.
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this known set of pleiotropic genes (Ericson et al., 2008;
Hillenmeyer et al., 2008), suggesting a previously unknown
relationship between threonine biosynthesis and copper
metabolism in yeast.
The identification of strains defective in tubulin binding and
assembly (Geissler et al., 1998) as resistant to copper starvation
revealed an unexpected link between tubulin and copper
homeostasis. Tubulins require post-translation folding, assembly
into heterodimers, and then assembly into microtubules. In vitro
and cell-based studies have shown that microtubules disassemble
in excess copper (Liliom et al., 1999; Liliom et al., 2000; Nawaz et
al., 2005; Pribyl et al., 2008; Liu et al., 2009). Copper might bind
the sulfhydral groups of microtubules and thereby block
microtubule assembly and/or induce disassembly (Wallin et al.,
1977). The GIM (genes involved in microtubule biogenesis) proteins
are highly conserved and form a complex that promotes the
formation of functional tubulins (Geissler et al., 1998). The gim
strains all have a slow-growth phenotype in rich medium, such that
the resistance of gim strains to copper limitation might reflect
reduced activity of a copper-dependent process that normally
inhibits tubulin biogenesis. This effect seems to be specific to the
gim strains because all other strains with a slow-growth phenotype
did not suppress growth defects caused by copper depletion.
Copper transport is highly regulated in the cell and involves
transport into the endoplasmic reticulum, as well as through
secretory and vacuolar pathways for delivery to copper-dependent
enzymes, copper excretion and copper detoxification (Yuan et al.,
1997; Howell et al., 2006; Gonzalez et al., 2008; Jo et al., 2008; Jo
et al., 2009). GO biological process category enrichment for cell
growth in low-copper conditions revealed the importance of the
AP1 adaptor complex, the AP3 adaptor complex, the HOPS
complex, the clathrin adaptor complex and the Golgi-to-vacuole
transport pathway. AP1, AP3 and HOPS complex subunits are
highly conserved and mutated in some human genetic disorders
(Dell’Angelica, 2009). Although disruption of the AP1, AP3 and
HOPS complexes has not previously been shown to cause sensitivity
to low-copper conditions, intracellular transport and vacuolar
pathways share some overlap with sensitivity to iron homeostasis.
For example, disruption of the AP3 adaptor complex in aps3 and
apm3 strains causes sensitivity to both low-iron and low-copper
conditions (Jo et al., 2009) (supplementary material Fig. S3). The
requirement for these pathways in the presence of low levels of
copper might reflect the inability of copper to reach essential
copper-dependent proteins, including the activity of copper-
dependent proteins in iron homeostasis, such as Fet3.
Finally, yeast gene-deletion profiles uncovered an important role
for the peroxisome in coping with copper depletion. We speculate
this dependency arises because the copper-zinc SOD is a
constituent enzyme of the peroxisome matrix, which is essential
for its dismutase and peroxidase function (Titorenko and Mullen,
2006; Islinger et al., 2009). Deletions in other peroxisomal genes
have also recently been shown to sensitize to low-iron conditions,
possibly because of an elevated requirement for peroxisomal -
oxidation in energy production when iron-dependent
mitochondrial energy production is impaired (Jo et al., 2009). A
similar effect might occur upon copper deficiency because copper
is also essential for mitochondrial functions and iron homeostasis.
Notably, human disorders of peroxisome biogenesis such as
Zellweger syndrome are characterized in part by high levels of
copper and iron in blood and tissues (Wanders and Waterham,
2005).
The MEK inhibitor U0126 elicits an unexpected copper-
metabolism phenotype
The identification of U0126 in our zebrafish phenotypic screen is
consistent with a recently suggested role for this MEK inhibitor in
copper metabolism (Hawkins et al., 2008). Although U0126 partially
phenocopies the atp7a-mutant zebrafish, the speculative link
between MEK signaling and copper pathways has not been
investigated (Hawkins et al., 2008). We thus set out to determine
whether the copper-metabolism phenotype induced by U0126 in
zebrafish development and in yeast chemical-genetic profiles was
directly due to inhibition of MEK activity or whether U0126 might
have an additional target in copper homeostasis independent of its
activity as a MEK inhibitor.
We compared the U0126-induced phenotype with those
induced by the selective MEK inhibitor PD0325901 and the known
copper chelator neocuproine (Fig. 3A). In vitro kinase-inhibition
profiles suggest that the MEK inhibitors CI-1040 and PD0325901
are the most highly selective inhibitors of MEK activity, as
compared with U0126 and other commercially available
compounds (Davies et al., 2000; Sebolt-Leopold, 2008). Despite
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Table 2. Genes within Gene Ontology (GO) category biological processes in Fig. 2
GO category Genes
Histone H3-K4 methylation BRE2, SDC1, SHG1, SPP1, SWD1, SWD3
Protein import into
peroxisome matrix
DJP1, PEX10, PEX12, PEX18, PEX2, PEX21, PEX25, PEX13, PEX14, PEX17, PEX5, PEX7, PEX1, PEX15, PEX22, PEX4, PEX6
Tubulin-complex assembly GIM3, GIM4, GIM5, PAC10, RBL2, YKE2
Golgi-to-vacuole transport APL2, APL4, APL5, APL6, APM1, APM2, APM3, APS1, APS3, GGA1, GGA2, PEP12, PEP7, TLG2, VAM3, VAM7, VPS52| VPS53, VTH1, YPT7
Swr1 complex  ARP6, SWC3, SWC5, SWC7, SWR1, VPS71, VPS72, YAF9
GID complex FYV10, GID7, GID8, RMD5, VID24, VID30
-subunit complex
(proteasome core complex)
PRE10, PRE5, PRE6, PRE8, PRE9, PUP2, SCL1
Lid subcomplex (proteasome
regulatory particle)
RPN3, RPN5, RPN6, RPN7, RPN8, RPN9, RPN10, RPN11, RPN12, RPN13, SEM1
Base subcomplex (proteasome
regulatory particle)
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the fact that the RAS-RAF-MEK-ERK signaling pathway plays an
important role in melanoma development in humans, mice and
zebrafish, we found that neither CI-1040 nor PD0325901 affects
melanocyte pigmentation in zebrafish development (Fig. 3A) (see
also Grzmil et al., 2007; Anastasaki et al., 2009). This result
suggests that selective inhibition of MEK activity does not affect
pigmentation in zebrafish melanocytes, and that the similarity
between the U0126-induced phenotype and the atp7a-mutant
phenotype most likely reflects a previously undetected additional
target pathway for U0126 in copper homeostasis. Like
neocuproine, U0126 also causes a loss of blood development in
the embryo and an undulating notochord (Fig. 3A,B). In support
of the hypothesis that U0126 can directly affect copper
metabolism, we found that U0126, but not CI-1040, avidly binds
copper in aqueous solution (Fig. 3C; supplementary material Fig.
S4). Thus, despite its frequent use as a specific inhibitor of MEK
kinase activity, our analysis based on pigment formation in
zebrafish has identified a novel action for U0126 in vivo.
Western blotting of extracts from treated zebrafish embryos with
an anti-phospho-ERK antibody confirmed that PD0325901 and
U0126 both effectively inhibit MEK activity during development,
whereas neocuproine had no obvious inhibitory effect on phospho-
ERK levels in zebrafish (Fig. 3D) or in human cells (supplementary
material Fig. S7). PD0325901 was a substantially more potent
inhibitor than U0126 as a 2-hour treatment was sufficient to
strongly inhibit ERK activity (Fig. 3D). To study the U0126-induced
pigmentation phenotype in more detail, we mapped the timing of
action of U0126 on developing melanocytes (Fig. 3E). In zebrafish
development, melanocytes develop from the neural crest and
become pigmented at about 28 hpf. Treatment with U0126 after
21 hpf did not affect normal melanocyte pigmentation, whereas
treatment before 21 hpf prevented pigmentation; this effect was
not a permanent developmental defect as melanocyte pigmentation
rapidly recovered after U0126 wash-out (Fig. 3E). By electron
microscopy, we also found evidence of fewer and less-dense
melanosomes in melanocytes of embryos treated with 5 M of
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Fig. 3. Phenotype elicited by U0126 treatment in zebrafish embryos. (A)U0126 phenocopy of neocuproine (neo) in 2-day-old zebrafish embryos. As a
control, the more selective MEK inhibitor PD0325901 did not affect pigmentation but instead prevented development of posterior features. (B)U0126 caused
blood loss as detected by o-dianisidine (red) staining. (C)U0126 and neocuproine complex with copper, as indicated by color change upon addition to aqueous
copper chloride solution. (D)Inhibition of MEK activity in vivo. Lysates from 12-hpf zebrafish embryos were assessed for phospho-ERK and phospho-MEK levels
after treatment with PD0325901 (PD) and U0126 (U0). Note inhibitor treatment is known to increase phospho-MEK (Pratilas et al., 2009). A short (2-hour)
treatment (asterisk) with PD0325901 also reduced phospho-ERK levels in zebrafish embryos, demonstrating the elevated potency of PD0325901. (E)U0126
(10M) treatments prevent pigmentation when administered before 21 hpf. When administered at 21 hpf or later, the embryos develop pigment at about
28 hpf, similar to untreated zebrafish embryos. U0126 treatments are each represented by a barline, and the color of the barline represents the color of the
zebrafish melanocytes. The effects on pigmentation are reversible, and pigmentation can rapidly recover from U0126 treatment. For example, U0126-treated
unpigmented 33 hpf zebrafish embryos recover pigmentation 4 hours after shifting to fresh embryo medium (asterisk). These phenotypes are consistent with a
role for U0126 in blocking the copper-dependent pigmentation enzyme, tyrosinase (Rawls and Johnson, 2000). (F)Electron microscopy of 2-day-old untreated
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U0126 (Fig. 3F). The timing of action of U0126 on melanocyte
pigmentation is consistent with the known kinetics of appearance
of the rate-limiting copper-dependent enzyme tyrosinase in
development (Hultman and Johnson, 2010).
We compared the genome-wide chemical-genetic profiles of
U0126, CI-1040 and neocuproine to determine the potential target
pathways of U0126. These profiles revealed that 13 deletion strains
were sensitive to both U0126 and neocuproine, and that 12 deletion
strains exhibited shared sensitivities to U0126 and CI-1040 (Fig.
4A). By contrast, only the pex10 strain was sensitive to both CI-
1040 and neocuproine, and only the yaf9 strain was sensitive to
all three compounds. Therefore, although U0126 has a partially
overlapping chemical-genetic fingerprint with CI-1040 and
neocuproine, CI-1040 and neocuproine have overtly different
activities. These profiles are fully consistent with the shared
molecular phenotype between U0126 and CI-1040 of inhibition of
ERK phosphorylation in zebrafish lysates (Fig. 3D), and the shared
developmental and chemical phenotype between U0126 and
neocuproine (Fig. 3A).
Comparison of GO biological processes (Table 2) affected by the
different inhibitors revealed both shared and distinct processes.
Disruption of the peroxisome and the Swr1 histone-exchange
complexes caused sensitivity to both U0126 and neocuproine (Fig.
4B). Impaired intracellular transport and the function of the
proteasome 19S regulatory particle compromised growth only in
the presence of neocuproine. Loss of the GID ubiquitin ligase
complex reduced growth in the presence of U0126, whereas
disruption of tubulin-binding processes actually led to resistance
in the presence of U0126 (Fig. 4B). A comparison of GO processes
affected by the CM subset compounds and CI-1040 allowed us to
determine whether the U0126 target pathways were due to copper-
dependent pathways, MEK pathways or additional target pathways.
Whereas CI-1040 and neocuproine had no effect on tubulin
binding and tubulin-complex assembly, treatment with SPB07427,
DP00477, JFD00692 and RJF01649 caused resistance of strains
defective in tubulin binding and tubulin-complex assembly. Given
the shared zebrafish and yeast phenotypes between U0126 and
these compounds, it seems that U0126 acts on tubulin-associated
processes via alterations in copper metabolism. Notably, in contrast
to the shared chemical profiles between U0126, neocuproine and
CI-1040, mutations in all six components of the GID complex
resulted in high sensitivity to U0126 (Fig. 3B, Fig. 4B). The GID
complex is an E3 ubiquitin ligase that targets a key enzyme in
gluconeogenesis, fructose 1,6-bisphosphatase (FBPase), for
proteasomal degradation (Santt et al., 2008). With the exception
of neocuproine, the GID complex also showed sensitivity to CM
subset compounds, albeit most strongly with U0126 (Fig. 2;
supplementary material Fig. S3). The GID complex might thus
represent a new target of copper metabolism in yeast. Collectively,
these data reveal new copper-dependent target pathways for U0126,
which have remained cryptic despite the extensive use of U0126
in biochemical and cell biological assays in many different signaling
contexts.
Knockdown of trafficking components sensitizes zebrafish to
copper-dependent hypopigmentation
Intracellular transport pathways, although essential for all cells, have
a specific role in melanosome biogenesis. Pigmentation enzymes
and the copper transporter ATP7A are selectively transported from
the trans-Golgi network to the maturing melanosomes (Raposo and
Marks, 2007; Setty et al., 2008). To test whether the genes that affect
copper sensitivity in yeast might inform about relevant copper
pathways in melanocytes, we selected two genes that had orthologs
in zebrafish for knockdown by morpholino oligonucleotides (MOs)
in the developing embryo. For this purpose we designed MOs
against genes that encode a component of the AP1 transport
complex (APS1 in yeast, ap1s1 in zebrafish) and a component of
the AP3 transport complex (APS3 in yeast, ap3s2 in zebrafish)
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Fig. 4. Novel target pathways for the
MEK inhibtior U0126. (A)Heat map of
deletion strains that are sensitive (red) or
resistant (green) to U0126, neocuproine
and CI-1040. U0126 shares a chemical
profile with neocuproine and with CI-
1040, whereas neocuproine and CI-1040
do not share a common profile.
(B)Neocuproine (yellow), U0126 (green)
and CI-1040 (blue) treatment affect
common and distinct biological
processes. GO categories were examined
for each of the deletion mutants that
were affected by each compound (see
Table 2). The genes in a specific GO
category were compared with the
number of strains actually affected by
each compound and the P values
determined. Only GO categories with
more than four genes were examined and
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(supplementary material Fig. S5). We separately injected a splice-
site MO designed against ap3s2 (ap3s2-MO1) and a translation-
blocking MO designed against ap1s1 (ap1s2-MO1) (Montpetit et
al., 2008) into single-celled zebrafish embryos and monitored
development in low-neocuproine conditions. Splice-site MOs were
verified by PCR analysis (supplementary material Fig. S6). At low
MO concentrations (1-3 pg), the ap1s1 and ap3s2 morphants
developed normally to at least 2 days pf (Fig. 5A). Next, we treated
4-6 hpf morphants with a range of neocuproine concentrations (1
M, 2 M and 5 M) and followed the development of the treated
animals over 2 days. Without neocuproine, neither the uninjected
controls nor the morphant animals displayed any of the principal
features of developmental copper deficiency, including reduced
pigmentation, a buckling notochord or an expanded hindbrain (Fig.
5A). This result suggests that under optimal nutrition conditions,
partial reduction of ap1s1 or ap3s2 function does not affect
development of the zebrafish embryo. At 5 M neocuproine,
developing wild-type and morphant embryos exhibited features of
developmental copper-metabolism deficiency, which could be
prevented with the addition of exogenous copper chloride at a
concentration of 5 M (Fig. 5A). At intermediate neocuproine
concentrations (1 M, 2 M), we often observed severe
hypopigmentation in the ap3s2 morphants (n37/71 embryos),
whereas control animals exhibited only a mild (at 1 M) to
moderate (at 2 M) reduction in melanocyte pigmentation (n>100).
The ap1s1 morphants also displayed melanocyte pigmentation
sensitivity at 1 M neocuproine (n13/39) compared with the
control-treated animals. A similar effect was seen using the splice-
site MOs ap3s2 (ap3s2-MO2) and ap1s1 (ap1s1-MO2) (see
Methods). Thus, at least two of the yeast intracellular transport
pathways that affected sensitivity to the CM subset compounds
proved to be physiologically relevant in the developing vertebrate.
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Fig. 5. Identification of two new gene-nutrient interactions in melanocyte pigmentation. Morpholino oligonucleotides (1-3 pg) directed against ap1s1 and
ap3s2 result in morphants with normal development and pigmentation. Higher concentrations of ap1s1-MO have been reported to cause pigmentation
phenotypes (Montpetit et al., 2008). Treatment with 5M neocuproine caused a copper-deficiency phenotype in all animals that could be rescued with the
addition of 15M copper chloride. At a concentration of 1.0M neocuproine, copper limitation caused a loss of pigmentation in the ap3s2 morphants compared
with control-treated embryos, and a severe loss of pigmentation at 2M neocuproine, compared with mild (1M) to moderate (2M) loss of pigmentation in
control animals. A milder pigmentation phenotype was also visible in the ap1s1 morphants treated with 1M neocuproine. Experiments were repeated multiple
times (more than three times for each morpholino; n>20 per treatment), and similar results could be obtained with an additional splice-site MO designed to
target each gene (see Methods). (B)Simplified schematic of gene-copper interactions in a zebrafish melanocyte. Partial reduction of AP3 complex activity (such
as in the ap3s2 morphant; represented by a dotted line) retains sufficient AP3 activity for melanosome pigmentation in optimal-copper nutrient conditions, and
the melanocyte is darkly pigmented. Likewise, melanocytes with normal AP3 activity in suboptimal-copper nutrient conditions retain the ability to generate
pigment. By contrast, in low-copper nutrient conditions, reduced AP3 function is no longer sufficient for promoting proper melanosome maturation, and the















    




Identification of the allelic variants that underlie gene-nutrient
interactions is important for understanding the genetic differences
between individuals that contribute to disease susceptibility (Thiele
and Gitlin, 2008). We used the zebrafish and yeast model systems
to identify small molecules that affect copper metabolism, to
uncover conserved cognate genetic pathways that sensitize to
copper deficiency and to test physiological relevance of these
pathways in zebrafish (Fig. 1A). The identification of the dual targets
of the commonly used MEK inhibitor U0126 underscores the power
of a combined zebrafish and yeast platform to elucidate multiple
target pathways of small molecules in vivo.
The conservation of copper-metabolism pathways in yeast,
zebrafish and humans suggests that our analysis of genetic
sensitivities to copper limitation can provide insight into the
molecular pathogenesis of hypocupremia. Comparison of the
chemical profiles of the five copper chelators identified by
phenotypic screening, as well as neocuproine and U0126, revealed
a substantial overlap in target pathways, including intracellular
transport pathways. Intracellular trafficking is crucial for transport
of copper to copper-dependent enzymes, recycling of the copper
transporter ATP7a, and also for copper detoxification in
environments of high copper concentrations (Jo et al., 2008). In
melanocytes, ATP7A itself is transported to maturing melanosomes
in order to restrict the activation of copper-dependent pigmentation
enzymes, such as tyrosinase, to this specialized structure (Setty et
al., 2008). Tyrosinase, as well as other pigmentation enzymes, is
selectively transported to the maturing melanosome by components
of the AP1 and AP3 complex; another transporter, the BLOC-1
complex, is required for the selective transport of ATP7A (Wei,
2006; Raposo and Marks, 2007). Known but rare alleles of the AP3
gene give rise to the disorder HPS, and AP1s1 components are
mutated in a neurocutaneous syndrome that is characterized by
mental retardation, enteropathy, deafness, peripheral neuropathy,
ichthyosis and keratodermia, termed MEDNIK. Our yeast and
zebrafish data suggest that reduced but otherwise functional levels
of AP1 and AP3 that have no effect on pigmentation in optimal
nutritional conditions can cause dramatic effects on pigmentation
under reduced-copper nutrition conditions (Fig. 5B). The
combination of zebrafish and yeast screens might be particularly
suited to detection of gene-environment interactions in vertebrates
that are characterized by allelic variants of modest quantitative
effect (Manolio et al., 2009).
Phenotypic and genome-scale genetic analysis in model
organisms is an effective method for identifying new target
pathways for known and novel compounds. A major question in
chemical biology is how a chemically induced phenotype relates
to the in vivo mechanism of compound action and how this
knowledge can be exploited to predict off-target effects.
Biochemical, in silico and cell-based methods are usually applied
in an effort to identify molecular targets, but these approaches can
often fail because of limitations in sensitivity and specificity.
Predicted drug-target associations of 3665 US Food and Drug
Administration (FDA)-approved drugs and other pharmaceutical
agents correctly identified 23 new molecular targets for known
drugs (Keiser et al., 2009). However, a molecular target under a
specific experimental context does not always reflect the action of
the compound within the complexity of the developing animal, as
illustrated by the unexpected copper-dependent effects of the MEK
inhibitor U0126 in our study. Although not all processes or genes
are conserved between yeast, zebrafish and human, we note that
complex disease states often converge on highly conserved gene
networks (Tan et al., 2009), suggesting that the zebrafish-yeast
screening approach might be applicable to many other human
genetic diseases. To our knowledge, our study is the first to
explicitly couple phenotype-based screens in zebrafish to genome-
wide chemical-genetic profiles in yeast in order to identify gene-
environment interactions during animal development. This
approach holds promise for interogating networks of gene-
environment interactions in other complex human genetic diseases.
METHODS
Zebrafish husbandry and phenotypic screening
Zebrafish were raised and maintained in compliance with the
Animals (Scientific Procedures) Act 1986 of the UK. Embryos were
acquired by pair breedings of wild-type AB, AB* and TL zebrafish
lines. For small-molecule screening, two 4-hpf zebrafish embryos
were arrayed in 96-well plates, and 300 l of E3 embryo medium
(Westerfield, 2000) with 10 M of compound in 1% DMSO was
added. Compounds were from the LOPAC (1280) Small Scale
International Version (Sigma-Aldrich) and a subselection of the
Maybridge screening collection (Fisher Scientific International).
Embryos were assessed and imaged for phenotypic changes at 28
hpf, 36 hpf, 48 hpf and 56 hpf. Small molecules that prevented
pigmentation, and caused an expanded hindbrain and a wavy
notochord, were classed as having a copper-metabolism phenotype.
The classification was confirmed by treating developing embryos
with freshly prepared compound in the presence or absence of
excess copper chloride at concentrations of 5 M and 15 M. CI-
1040 was kindly provided by Richard Marais (London, UK) and
PD0325901 was obtained from Hilary McLauchlan (University of
Dundee, UK). Embryos were treated with 10 M or 25 M
neocuproine or U0126 and 1 M or 2.5 M PD0325901 at different
developmental stages. To inhibit pathway activity during
development, 4 hpf embryos were treated with compounds
continuously until 12 hpf; acute effects were assessed using a pulse
of compound from 10 hpf to 12 hpf.
Western blotting
Embryos (12 hpf) were frozen at –80°C after removal of the embryo
buffer. Samples were lysed in RIPA buffer [2 M Tris pH 7.5, 5 M
NaCl, 1% NP40, Na-deoxycholate, 10% SDS, 0.5 M NaF, 1 M -
glycosyl phosphate and protease-inhibitor cocktail tablet (Roche)].
Samples were normalized by protein as measured by Bradford assay,
separated by SDS-PAGE, transferred to Hybond-C Extra
nitrocellulose membrane (Amersham Biosciences), probed with
rabbit [p44/42 MAPK (1:2000) and phospho-MEK1/2 (Ser217/221)
(1:500) (Cell Signaling Technology)] or mouse [phospho-p44/42
MAPK (E10) (1:2000), alpha-tubulin B-5-1-2 (1:50,000) (Santa
Cruz)] antibodies and detected with horseradish-peroxidase-
conjugated secondary antibodies (Roche).
Electron microscopy
Embryos were fixed with 2.5% glutaraldehyde, 2%
paraformaldehyde in 100 mM cacodylate buffer (pH 7.2) with 2
mM MgCl2 and 0.1% picric acid. Following a wash with 200 mM
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cacodylate buffer, samples were fixed with 1% osmium tetroxide
in 100 mM cacodylate buffer (pH 7.0), washed with distilled water,
stained en bloc with 0.5% aqueous uranyl acetate, and dehydrated
with ethanol. Samples were embedded in Agar 100 resin and
sections were cut, stained with lead citrate and viewed on a FEI
Tecnai 12 transmission electron microscope.
Yeast chemical-genetic profiles
The MATahaploid and the essential heterozygous yeast deletion sets
were obtained from Research Genetics (Germany). Chemical-genetic
profiles were generated essentially as described (Giaever et al., 2002).
Briefly, for growth-inhibition screens, 5-ml pool cultures were
seeded at an OD600 of 0.025 and compound (or DMSO for control
samples) was added after a 2-h pre-growth period. Compound
concentrations were selected to inhibit pool growth by 20-30%
compared with DMSO controls at 12 hours; cultures were diluted
back to an OD600 of 0.025 twice with addition of fresh compound
to allow growth for a total of 20 generations. Each compound was
screened at two different concentrations (supplementary material
Table S1). The final concentration of DMSO was 0.4% for all screens.
Genomic DNA was isolated for control and experimental pools,
barcodes were amplified with fluorescently labeled primers, and PCR
products were hybridized to in-house short-oligonucleotide
microarrays (Cook et al., 2008). A GenePix 4200AL was used to scan
the slides, and hybridization intensity for each spot was determined
using GenePix Pro 6.0 software.
Identification of sensitive and resistant mutant strains
The identification of sensitive and resistant strains in the chemical-
genetic screens was performed using R and limma, an R package
for the analysis of gene expression microarray data. Spots with low
intensity and low quality were excluded from further analysis.
Intensities of duplicate spots for each barcode on the array were
averaged. z-scores for up and down barcode tags were calculated
based on log2 fold-change ratios (compound treated vs DMSO
control): z(x-)/s where  is the mean log2-fold change for all up
or down barcodes on an array and s is the standard deviation. The
two barcode scores were averaged for each deletion strain to give
the final z-score. Microarray raw data and z-scores for each mutant
were stored in a custom MySQL database. Standard procedures
for z-score and quantile-based statistics for microarray data were
used to identify sensitive and resistant deletion strains
(Quackenbush, 2002; Cheadle et al., 2003). The microarray data
are available at ArrayExpress (accession number E-TABM-922).
Assignment of GO biological process terms
Instead of relying on arbitrary cut-offs to define enriched sets of
deletion strains that were most affected by treatment with the
compounds, we calculated average z-scores for all GO biological
process categories in each experiment for GO categories that
contained data for at least four genes. Quartile-based statistics were
used to identify significantly affected GO biological processes
(Saccharomyces Genome Database, http://www.yeastgenome.org,
release 02/07/2009).
Morpholino oligonucleotides
The MOs were designed by GeneTools (USA) and prepared as a
1 mM stock solution in water. For Fig. 5A, 1-3 pg was injected into
each one-cell stage embryo. MO sequences were designed to block
splicing for a zebrafish ortholog of the yeast gene APS3, called ap3s2
(Ensembl(Zv8): ENSDARG00000039882) (ap3s2-MO1: 5-
TGCAA AAGCCTCTCCATCACCTTCC-3). Confirmation of
ap3s2-MO1 activity was determined by PCR with primers AP3S2-
F1 [5-TCAACAACCATGGGAAACCC-3 (forward primer)]
and  AP3S2-R1 [5-TGACTGCAGAAACGGCTCG-3 (reverse
primer)]. Inclusion of intron 2 was determined by sequencing of
the longer cDNA product. A translation-block MO for ap1s1
(Ensembl(Zv8): ENSDARG00000056803), an ortholog of APS1, was
directly purchased from GeneTools (ap1s1-MO1: 5-ACAGA -
AGCATAAAGCGCATCATTTC-3), and has been previously
verified by western blotting morphant embryo extracts with an
antibody (Montpetit et al., 2008). Two additional splice-site
MOs  were designed and ordered from GeneTools: ap3s2-MO2
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TRANSLATIONAL IMPACT
Clinical issue
Genetic differences contribute to the variation among individuals in coping
with environmental stresses, such as nutritional deficiency. Copper is an
essential nutrient, and disorders of copper metabolism can lead to severe
neuronal, muscular and pigmentation clinical symptoms. Genetic mutations in
the copper transporter ATP7A lead to a copper-deficiency syndrome called
Menkes disease, and copper deficiency can also develop after intestinal bypass
surgery or an excess intake of iron. However, many causes of copper deficiency
are unknown, and genetic factors might contribute to the sensitivity of some
individuals to reduced nutritional availability of copper. 
Results
Many crucial enzymes require copper as a cofactor, and melanocytes have a
specific requirement for copper in the maturation of pigmented melanosomes.
Here, the authors use a zebrafish- and yeast-based approach to identify
genetic pathways that modulate melanocyte pigmentation in conditions of
copper nutritional deficiency. First, they carry out a chemical screen for small
molecules that affect copper homeostasis in zebrafish on the basis of a
hypopigmentation phenotype. Next, they use budding yeast to systematically
map the genetic pathways that underlie sensitivity to the small molecules
identified in the zebrafish-based chemical screen. They then demonstrate that
two genes encoding intracellular transport proteins identified in the yeast
genetic screen are physiologically relevant, as their zebrafish orthologs, aps1s
and ap3s2, are involved in sensitizing zebrafish melanocytes to
hypopigmentation in conditions of mild copper deficiency. Notably, the
authors also use the zebrafish-yeast approach to identify an off-target effect
for a small molecule commonly used in cell-signaling studies, the MEK
inhibitor U0126, which was previously not known to affect pathways of copper
metabolism.
Implications and future directions
The copper-gene interactions identified in this study illustrate the larger issue
of how disease susceptibility can be underpinned by complex environment-
gene interactions. This zebrafish-yeast approach will be applicable to the
dissection of many complex disease-gene networks, particularly because such
networks are enriched for highly conserved genes. This approach is also well
suited for investigating gene-environment interactions, which are a challenge
to assess given that modest genetic effects can be difficult to identify through
classical quantitative methods. Importantly, the zebrafish-yeast approach
provides a systematic means by which to elucidate the in vivo actions of small
molecules in a vertebrate system, which is a challenge in chemical biology
applications. Finally, the identification of copper-metabolism pathways in
zebrafish is a starting point for exploring the role of analogous pathways in
















    




(5-GACTAGCATACCTACGTAAACACAC-3) (Montpetit et al.,
2008). Confirmation of ap3s2-MO2 activity was determined by PCR
with primers AP3S2-F2 [5-TGCAGCAGCAGATCATCAGGG-3
(forward primer)] and AP3S2-R2 [5-GACTGTCAGTAATGG -
CAAGAGG-3 (reverse primer)]. Results were consistent with both
MOs for each gene, with greater effects seen with increasing
concentration of MO (5-10 pg). All MOs were labeled with a
florescent tag and assessed for even MO distribution throughout
the embryo. Changes in pigmentation were assessed by two or three
individuals who scored the phenotypes blinded to the MO
genotypes.
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Resistance to widely used fungistatic drugs, particularly to the ergosterol biosynthesis inhibitor
fluconazole, threatens millions of immunocompromised patients susceptible to invasive fungal
infections. The dense network structure of synthetic lethal genetic interactions in yeast suggests
that combinatorial network inhibition may afford increased drug efficacy and specificity. We carried
out systematic screens with a bioactive library enriched for off-patent drugs to identify compounds
that potentiate fluconazole action in pathogenic Candida and Cryptococcus strains and the model
yeast Saccharomyces. Many compounds exhibited species- or genus-specific synergism, and often
improved fluconazole from fungistatic to fungicidal activity. Mode of action studies revealed two
classes of synergistic compound, which either perturbed membrane permeability or inhibited
sphingolipid biosynthesis. Synergistic drug interactions were rationalized by global genetic
interaction networks and, notably, higher order drug combinations further potentiated the activity
of fluconazole. Synergistic combinations were active against fluconazole-resistant clinical isolates
and an in vivo model of Cryptococcus infection. The systematic repurposing of approved drugs
against a spectrum of pathogens thus identifies network vulnerabilities that may be exploited to
increase the activity and repertoire of antifungal agents.
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Introduction
The recent increase in fungal infection rates presents a serious
clinical challenge (Arendrup et al, 2009; Gullo, 2009; Shorr et al,
2009). Immune-suppressed individuals, including transplant,
cancer chemotherapy and HIV-infected patients, often succumb
to opportunistic fungal pathogens from the genera Candida,
Cryptococcus, Aspergillus and others (Groll et al, 1996; Baddley
et al, 2001; Clark and Hajjeh, 2002; Richardson and Warnock,
2003). Unlike bacterial infections that can be treated with
multiple antibiotic classes, therapeutic options for fungal
infections are limited. The polyene amphotericin B, discovered
in 1955, remains a front line fungicidal drug; however,
amphotericin B non-specifically disrupts cell membrane integrity,
with concomitant severe patient toxicity. Synthetic azole
antifungals such as fluconazole were introduced 40 years ago
and inhibit lanosterol 14a-demethylase, the gene product of
ERG11, an essential cytochrome P450 enzyme in the ergosterol
biosynthetic pathway (Groll et al, 1998; Revankar et al, 2004).
Fluconazole binds to the heme Fe(III) of Erg11, resulting in
depletion of ergosterol, the accumulation of C-14 methyl sterols
and cell membrane disruption. The crossreactivity of azoles
toward human P450 enzymes also results in toxicity and,
moreover, clinical resistance is prevalent (Cannon et al, 2009;
Marie and White, 2009). Finally, the echinocandins, which
include caspofungin, micafungin and anidulafungin, were
introduced 10 years ago and inhibit the cell wall biosynthesis
enzyme b-(1,3)-D-glucan synthase; however, these agents have a
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restricted antifungal spectrum (Sucher et al, 2009). The dearth of
selective agents and emerging patterns of clinical resistance
demand new antifungal strategies.
A primary challenge in antifungal drug discovery is the
paucity of fungal-specific molecular targets that are essential
for cell growth, due to the conserved biochemical and
molecular biological networks of all eukaryotes. This problem
is exacerbated by the observation that many essential yeast
genes can provide sufficient function at a fraction of wild-type
dosage (Yan et al, 2009). Although only B1100 of the B6000
genes in yeast are essential under nutrient-rich growth
conditions (Winzeler et al, 1999), almost all genes become
essential in specific genetic backgrounds in which another
non-essential gene has been deleted or otherwise attenuated,
an effect termed synthetic lethality (Tong et al, 2001). Genome-
scale surveys suggest that over 200 000 binary synthetic lethal
gene combinations dominate the yeast genetic landscape
(Costanzo et al, 2010). The genetic buffering phenomenon is
also manifest as a phalanx of differential chemical–genetic
interactions in the presence of sublethal doses of bioactive
compounds (Hillenmeyer et al, 2008). These observations
illuminate the inherent redundancy of genetic networks, and
frame the problem of interdicting network functions with
single agent therapeutics (Hopkins, 2008).
This genetic network organization suggests that judicious
combinations of small molecule inhibitors of both essential
and non-essential targets may elicit additive or synergistic
effects on cell growth (Sharom et al, 2004; Agoston et al, 2005;
Fitzgerald et al, 2006; Lehar et al, 2007, 2008; Hopkins, 2008).
Indeed, ad hoc combinations of anti-infective drugs are
frequently used to treat fungal infections (Eliopoulos and
Moellering, 1991; Johnson and Perfect, 2010). However, this
chance approach fails to exploit richness of the chemical–
genetic landscape (Sharom et al, 2004; Hopkins, 2008;
Lehar et al, 2008). Instead, unbiased screens for synergistic
enhancers of a specific bioactivity that are not themselves
active, sometimes termed syncretic combinations, are needed
to fully explore chemical space (Keith et al, 2005). Compounds
that enhance the activity of known agents in model yeast and
cancer cell line systems have been identified both by focused
small molecule library screens (Borisy et al, 2003; Zhang et al,
2007; Zhai et al, 2010) and by computational methods (Lehar
et al, 2007; Nelander et al, 2008; Jansen et al, 2009; Zinner
et al, 2009). Furthermore, direct tests of synergistic com-
pounds have successfully yielded combinations that are active
against pathogenic fungi, including the combination of
fluconazole with chemical inhibitors of Hsp90, calcineurin or
ARF (Cowen et al, 2009; Singh et al, 2009; Epp et al, 2010) and
the antibiotic polymyxin B (Zhai et al, 2010).
To extend the strategy of chemical synthetic lethality to
clinically relevant fungal pathogens, we interrogated a focused
bioactive library of known drugs for synergistic enhancers of
the fungistatic drug fluconazole in systematic screens against
Candida albicans, Cryptococcus neoformans and Cryptococcus
gattii, as well as the genetically tractable budding yeast
Saccharomyces cerevisiae. Compounds not previously recognized
in the clinic as antifungal agents caused potent growth inhibition
in conjunction with fluconazole, often in a genus- or species-
specific manner. Selected combinations were characterized for
mechanism of action and shown to be active against fluconazole-
resistant isolates and efficacious in an in vivo infection model.
The combinatorial redeployment of known drugs defines a
powerful antifungal strategy and establishes a number of
potential lead combinations for future clinical assessment.
Results
Systematic antifungal potentiation screens
in model and pathogenic fungi
Cell-based high-throughput screens were performed on a
panel of four fungal strains to identify small molecules that
potentiate fluconazole across a range of genera and species.
The human pathogens C. neoformans (H99), C. gattii (R265)
and C. albicans (Caf2-1) as well as the model fungus S.
cerevisiae (BY4741) were screened in duplicate against the
Prestwick library, which consists of 1120 off-patent drugs and
other bioactive agents (http://www.prestwickchemical.com).
To identify compounds that potentiate the effect of flucona-
zole, yet have minimal antifungal activity on their own, each
screen was performed in the presence and absence of 0.5
minimal inhibitory concentration (MIC) of fluconazole at a
single compound concentration of 30mM. Residual activity
was calculated for each compound and all data were normal-
ized for plate- and row/column-specific effects (Supplemen-
tary Figure S1; see Supplementary Table S1 for screen data).
Hits were determined using median absolute deviation (MAD)
statistics. By this criterion, 43 compounds were active against
S. cerevisiae, 30 against C. albicans, 70 against C. neoformans
and 91 against C. gattii (Figure 1A and B).
The set of 148 compounds that potentiated the antifungal
action of fluconazole in one or more of the screens
(Supplementary Figure S2) was structurally diverse and
represented a broad range of different therapeutic activities,
including antiparasitics, cardiovascular protectives, dermato-
logicals, genitourinary tract anti-infectives, hormone modula-
tors and a variety of neuroleptic drugs. Notably, 15 of the 17
tricyclic phenothiazine/thioxanthene antipsychotics present
in the Prestwick library exhibited strong interactions with
fluconazole against C. gattii and C. neoformans (Figure 1C).
Derivatives of tricyclic phenothiazines inhibit fatty acid
synthesis and disrupt lipid trafficking (Li et al, 2008).
A striking number of hits were species or genus specific
(Figure 1B). Six compounds were hits in all screens: (i)
the antidepressant sertraline (Zolofts); (ii) the monoamine
oxygenase inhibitor pirlindole, also known to have antide-
pressant activity; (iii) the allylamine antifungal naftifine; (iv)
the antibiotic prodrug pivampicillin; (v) the antinausea drug
thiethylperazine (Torecans); and (vi) the antipsychotic drug
zuclopenthixol. The latter two compounds are members of the
large family of phenothiazines that have antipsychotic and
other central nervous system (CNS) activities.
Synergy assessment and fungicidal activity
To determine whether hit compounds acted in a synergistic
or additive manner with fluconazole, we selected 12 of the
148 hits (albendazole, azaperone, clofazimine, clomiphene,
L-cycloserine, kawain, lynestrenol, mitoxantrone, sertraline,
suloctidil, tamoxifen and trifluoperazine) for detailed studies
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in all four fungal species. We based this selection on an
analysis of distinct chemical class, with one or two represen-
tative structures from families of similar agents that emerged
in the screen, commercial availability of compound, thera-
peutic importance, and known mode of action (Supplementary
Figure S3). These criteria yielded a tractable number of hit
compounds for detailed downstream analysis. We also tested
five known antifungal drugs, both as positive controls and to
explore other potential interactions with fluconazole: ampho-
tericin B, the ergosterol biosynthesis inhibitors ketoconazole,
terbinafine (an allylamine analog of naftifine used in the
clinic) and fenpropidin (an agricultural fungicide), and the
echinocandin caspofungin. Dose-dependent MIC values for
these 17 compounds were determined for each of the four
species (Supplementary Table S2). The interaction of each
compound with fluconazole was assessed by standard con-
C. gattii
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Figure 1 Unbiased screens for bioactive compounds that potentiate the antifungal activity of fluconazole. (A) Scatter plots for Prestwick library screens for four fungal
species. Growth inhibition caused by compounds in the absence (x axis) and presence of fluconazole (y axis) is represented by residual activity after treatment. Yellow
and red filled circles indicate compounds that were classified as active (2 median absolute deviations below the diagonal). Compounds that inhibited growth in the
presence of fluconazole by at least 80% compared with the effect of that compound alone are highlighted in red; FLC, fluconazole. (B) Overlap of hits between different
fungal species. (C) Activity of 17 phenothiazine/thioxathene compounds in different fungal species.
Syncretic antifungal compound combinations
M Spitzer et al
& 2011 EMBO and Macmillan Publishers Limited Molecular Systems Biology 2011 3
centration matrix (checkerboard) analysis (Figure 2A; Supple-
mentary Table S3). Data were quantified by calculation of the
fractional inhibitory concentration index (FICI), the accepted
method for drug interactions in infectious disease (Eliopoulos
and Moellering, 1991; Odds, 2003). Only two compounds,
sertraline and trifluoperazine, exhibited synergy with fluco-
nazole against all four fungal species. A number of synergizers
exerted effects exclusively on a particular species: S. cerevisiae
was uniquely susceptible to four different compounds in
the presence of fluconazole (clofazimine, clomiphene,
L-cycloserine and mitoxantrone), while only C. albicans was
susceptible to ketoconazole or caspofungin in combination
with fluconazole. Neither Cryptococcus species exhibited any
unique synergistic susceptibilities. Most hits from the screens
were confirmed as synergistic with fluconazole, except for
albendazole, azoperone and kawain in S. cerevisiae, and
azaperone, L-cycloserine and lynestrenol in C. albicans
(Supplementary Figure S4). Quantification of interactions at
different drug concentrations revealed some additional syner-
gies with fluconazole: trifluoperazine exhibited synergy
against C. albicans, tamoxifen against C. gattii and C. neofor-
mans, and suloctidil against C. neoformans and S. cerevisiae
(Supplementary Figure S4). Based on the detailed analysis of
these 12 compounds, the high-throughput screens proved a
reliable means to identify synergistic drug interactions, with
an estimated false positive rate of 0.20 and a false negative rate
of 0.28. Importantly, and in contrast to the merely fungistatic
effect of fluconazole alone, several combinations of flucona-
zole and different synergistic compounds were fungicidal,
often in a species-dependent manner (Figure 2A). For example,
trifluoperazine exhibited synergy with fluconazole and was
fungicidal in all species with the exception of C. albicans.
Chemical–genetic profiles of synergistic
combinations
We explored the molecular basis for the synergy of trifluoperazine,
tamoxifen, clomiphene, sertraline, suloctidil and L-cycloserine with
fluconazole (Figure 2B), using established genome-wide methods
in S. cerevisiae to identify gene deletion strains that are sensitive to
drug treatment (Giaever et al, 1999;Parsons et al, 2006;Hillenmeyer
et al, 2008). Genome-wide pools of deletion strains were grown in
the presence of drugs, genomic DNA isolated from drug-treated and
control cultures, and barcode sequence tags amplified and
hybridized to barcode microarrays (Cook et al, 2008).
First, we profiled compound action in haplo-insufficiency
screens, in which the B1000 deletion strains heterozygous for
essential genes were tested for drug sensitivity to identify
candidate drug targets (Giaever et al, 1999). As expected,
deletion of one copy of ERG11 conferred sensitivity to fluconazole
(Figure 3A; Supplementary Figure S5). Deletion of one copy of
either LCB1 or LCB2, which encode subunits of the enzyme
serine palmitoyltransferase that catalyzes the committed step of
sphingolipid biosynthesis, caused sensitivity to L-cycloserine
(Figure 3A; Supplementary Figure S5). In yeast membrane
extracts, high concentrations of L-cycloserine (1 mM) partially
inhibit serine palmitoyltransferase (Pinto et al, 1992). All five
remaining compounds—trifluoperazine, tamoxifen, clomiphene,
sertraline and suloctidil (referred to as the membrane active
group)—conferred sensitivity to loss of one copy of the NEO1
gene (Figure 3A; Supplementary Figure S5), which encodes an
essential aminophospholipid translocase required for membrane
trafficking and vacuolar biogenesis. Deletion of the ortholog of
NEO1 in C. neoformans (APT1) has recently been shown to result















































Figure 2 Synergistic drug interactions with fluconazole. (A) Heat map of drug interactions with fluconazole in each species. Dark blue indicates additive effects (FICI of
0.5–1); lighter shades of blue represent synergy (FICI o0.5). Orange triangles indicate fungicidal drug combinations; yellow triangles indicate fungistatic drug
combinations. (B) Chemical structures of the six drugs chosen for detailed mode of action studies. Source data is available for this figure at www.nature.com/msb.
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attenuated virulence (Hu and Kronstad, 2010). In addition,
deletion of one copy of TIM54, a translocase of the inner
mitochondrial membrane, confers sensitivity to tamoxifen and
trifluoperazine (Figure 3A), consistent with the potential
membrane targets of these drugs.
We then generated haploid chemical–genetic profiles for the
syncretic compounds individually and in combination with
fluconazole (Supplementary Figure S6). This profiling method
reveals genes that buffer against drug toxicity and can identify
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Figure 3 Chemical–genetic interactions of six syncretic synergizers. (A) Sensitivity of heterozygous essential deletion strains to five different syncretic drugs and
fluconazole, as assessed by barcode microarray hybridization. (B) Core set of haploid deletion strains that are sensitive to fluconazole, as assessed by barcode
microarray hybridization. Several concentrations of fluconazole were tested to correlate the signature with MIC. The effect of the six syncretic drugs on the core
fluconazole profile was examined in the presence or absence of a threshold concentration of fluconazole (6 mg/ml). Genes implicated in membrane organization and
vesicle-mediated transport are indicated. (C) Main cluster of haploid deletion strain sensitivities to the six syncretic drugs in the absence of fluconazole, as assessed by
barcode microarray hybridization. Strains that have a Z-score more significant than ±3 for at least one of the drugs in duplicate profiles are shown. Gene names in red
indicate deletion strains that were chosen for verification by quantitative growth curve assays. (D) Log-ratio scores calculated from individual growth curve assays to
confirm chemical–genetic interactions of the six syncretic drugs. Gene names in bold indicate heterozygous deletion strains for essential genes. Values in parentheses
indicate drug concentration in mg/ml. Negative Z-scores and log-ratios indicate sensitivity of a strain to a given drug, whereas positive scores represent resistance. Asterisks
indicate 14 deletion strains that comprise the core signature set for membrane active compounds. Source data is available for this figure at www.nature.com/msb.
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genetic interaction profiles (Hillenmeyer et al, 2008). Strains
deleted for genes that function in vesicle-mediated transport and
membrane organization were sensitive to fluconazole alone
(Figure 3B). For drug combinations, we chose a concentration of
fluconazole (6mg/ml) that caused B20% growth inhibition
compared with control and thereby minimized the selection
against fluconazole-sensitive strains. Importantly, the syncretic
drugs alone did not impair the growth of fluconazole-sensitive
deletion strains (Figure 3B; Supplementary Figure S5), but
significantly sensitized cells to low doses of fluconazole
(Supplementary Table S4). To explore the potential mechanism
of this sensitization further, we examined the chemical–genetic
profiles of single compounds (Figure 3C; Supplementary Figure
S7; Supplementary Table S5). The membrane active group of
trifluoperazine, tamoxifen, clomiphene, sertraline and suloctidil
caused growth inhibition of a core set of deletion strains that
included genes that encode the post-Golgi-associated aminopho-
spholipid translocase (flippase) Drs2 and its activating subunit
Cdc50, the ergosterol biosynthesis enzyme Erg6, the protein
trafficking factors Sac1 and Vps74, the mitochondrial outer
membrane import factors Mdm10 and Mdm12, and the cell wall
integrity MAPK kinase Slt2 and its upstream activating kinase
Bck1. A number of genes implicated in downstream steps of
sphingolipid metabolism, including IPT1, SUR1, SKN1, YPK1
and SWH1, were also required for cell survival in the presence of
the membrane active compounds. Notably, strains disrupted
for non-essential genes implicated in uncoating of clathrin
vesicles (SWA2) and retrograde transport to the cis-Golgi net-
work (YPT6, RGP1, RIC1 and VPS52) were resistant to all six
fluconazole synergizers, suggesting that altered vesicle traffick-
ing may compensate for membrane perturbation and/or Erg11
inhibition.
We confirmed the chemical–genetic interactions between
these haploid deletion strains and each drug using quanti-
tative growth curve assays (Figure 3D). We also assessed
strains that were heterozygous for ERG11, NEO1, LCB1
and LCB2 as well as TIM18 and TIM22, which function in a
complex with TIM54. In addition, we included haploid
deletion strains for DNF1/2/3, the other three flippases in
S. cerevisiae, and LCB3/4/5, which function downstream
of LCB1/2. The quantitative growth curves corroborated
the barcode microarray results, with the exception of the
dubious ORF YOR072W. The range of drug concentrations
tested in the growth curve assays revealed additional
chemical–genetic interactions, such as TIM18, which were
not recovered at the single drug concentrations used in the
barcode profiles.
The results of these genome-wide chemical–genetic screens
point to two related modes of action for the syncretic
combinations tested. Trifluoperazine, tamoxifen, clomiphene,
sertraline and suloctidil appear to cause general perturbation
of membrane, vesicle trafficking and lipid biosynthesis
functions, whereas L-cycloserine preferentially interferes with
an early step in sphingolipid biosynthesis, consistent with its
proposed mechanism of action (Pinto et al, 1992). To test the
latter hypothesis, we examined the effects of myriocin, another
known inhibitor of the first step of the sphingolipid biosynth-
esis pathway (Miyake et al, 1995), and found that it also
potentiated the inhibition of cell growth by fluconazole
(FICI¼0.625).
Cell biological effects of synergistic combinations
We assessed the effects of trifluoperazine, tamoxifen, sertra-
line and L-cycloserine alone and in combination with
fluconazole on S. cerevisiae cell physiology. The diagnostic
fluorescent dyes Calcofluor White, FM4-64 and Mitotracker
Green were used to visualize cell wall and bud scars, vacuolar
membranes and mitochondria, respectively. For each reporter
dye, fluconazole produced staining patterns that were similar
to solvent controls. In contrast, treatment with trifluoperazine,
tamoxifen, clomiphene and sertraline caused a drastic loss
of localization and strong intracellular accumulation of each
dye (Figure 4A; Supplementary Figure S8). In particular, the
disruption of vacuolar structure revealed by FM4-64 staining
suggested severe loss of cell membrane integrity. Consistent
with its different genetic target profile, treatment with L-
cycloserine had no observable effects on the localization of
any of the dyes (Figure 4B).
Lethal perturbation of the membrane and/or cell wall can often
be rescued by osmotic stabilization. Sorbitol (1M) effectively
suppressed the syncretic growth inhibitory effects of trifluoper-
azine, tamoxifen, clomiphene, sertraline and suloctidil, again
supporting a common membrane perturbation mechanism for
these compounds, but had no such protective effect on cells
treated with L-cycloserine and fluconazole (Figure 4C). These cell
biological results affirm the different mechanisms of action of the
two compound classes.
Integration of chemical–gene interactions with
genetic interaction networks
A primary challenge in the discovery of synergistic drug
combinations is the vast number of possible combinations of
drug pairs (Sharom et al, 2004; Hopkins, 2008; Lehar et al,
2008). Integration of drug-induced gene expression profiles
(Lum et al, 2004) and chemical–genetic profiles (Hillenmeyer
et al, 2008) with comprehensive genetic interaction networks
(Costanzo et al, 2010) can allow computational prediction of
synergistic drug pairs (Lehar et al, 2007; Nelander et al, 2008;
Jansen et al, 2009). To assess whether the individual profiles of
fluconazole and each of the syncretic drugs could rationalize
drug interactions, we integrated the chemical–genetic profiles
generated above for each syncretic compound with a global
genetic interaction network composed of both high-through-
put (HTP) and low-throughput (LTP) data compiled from the
primary literature (Breitkreutz et al, 2008; Costanzo et al,
2010). Deletion strains that were sensitive to treatment with
single drugs were used to assess the number of genetic
interactions linked to the chemical–genetic space (CGS) of
fluconazole and each of the synergizers. A core set of haploid
deletion strains affected by the membrane active group of
compounds, referred to as the signature strain set (Figure 3D),
exhibited many genetic interactions with the top 50 flucona-
zole-sensitive strains (Figure 5A). The top 50 most sensitive
deletion strains for each individual drug (Z-scores above
B2.0) also showed many genetic interactions with the
fluconazole profile. We tested the significance of the genetic
connections between the profiles using simulations of genetic
interactions shared between randomly chosen gene sets of a
specific size, based on the known chemical sensitivities of 1143
Syncretic antifungal compound combinations
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Figure 4 Effects of syncretic drugs on membrane integrity. A wild-type S. cerevisiae strain was grown in the presence of the indicated drugs and stained with
(i) Calcofluor White M2R, (ii) FM4-64 and (iii) Mitotracker Green FM, and imaged by fluorescence microscopy. (A) Sertraline (128 mg/ml) in the presence and absence
of fluconazole (64 mg/ml). (B) L-Cycloserine (128 mg/ml) in the presence and absence of fluconazole (128 mg/ml). (C) Growth of wild-type S. cerevisiae compared
with control wells in the presence of the indicated drugs with and without 1 M sorbitol. The mean of four independent measurements is shown; error bars represent
standard error. Source data is available for this figure at www.nature.com/msb.
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non-essential deletion strains that respond to various drug
treatments (Hillenmeyer et al, 2008). The signature deletion
set shared by the membrane active group was significantly
enriched for genetic interactions with fluconazole-sensitive
deletion strains (P-value o107). The individual profiles for
tamoxifen, trifluoperazine, clomiphene, sertraline and suloc-
tidil also showed a significant enrichment of genetic inter-
actions with the fluconazole-sensitive strain profile (all
P-values o0.05), whereas L-cycloserine did not (Figure 5B;
Supplementary Table S6). As a more conservative measure
of pathway separation (Kelley and Ideker, 2005), we applied
a parallel pathway permutation (PPP) test, in which the
chemical–genetic interactors of fluconazole and each of the
synergistic drugs were pooled and randomly assigned to two
groups (Supplementary Figure S9). By this stringent method,
the signature deletion set and the top 50 most sensitive
deletion strains from the trifluoperazine profile also exhibited
significant enrichment (both P-values o0.05; Supplementary
Figure S9; Supplementary Table S6). The genetic interactions
that link the chemogenomic profiles of synergistic compound
pairs thus provide a rational basis for synergism.
To assess the predictive power of the signature deletion
set derived from the membrane active compounds, we
retrospectively analyzed chemical–genetic profiles for 81
psychoactive drugs known to impair yeast growth (Ericson
et al, 2008). Of this set, 16 compounds were represented in the
Prestwick library, 7 of which were predicted to synergize with
fluconazole based on their effect on deletion strains in the
signature set. In our primary screens against the four fungal
species, four of these seven compounds were indeed hits in our
screen, while the other three compounds showed weak
activity (Figure 5C; Supplementary Table S1). These results
demonstrate that chemical–genetic interaction profiles can
predict synergistic drug combinations.
Species-specific effects of ergosterol pathway
inhibition
As the psychiatric drugs trifluoperazine and sertraline
exhibited synergy with fluconazole against each fungal

























































































Figure 5 Rationalization of synergistic interactions by integration of chemical–genetic and genetic interaction networks. (A) Bipartite graph of genetic interactions
between top 50 chemical–genetic interactors of fluconazole and the signature deletion strains sensitive to the five membrane active compounds. As PDR5 was a
member of both sets, it is positioned midway between the two sets. Enriched Gene Ontology (GO) SLIM biological processes are indicated (adjusted P-value o0.05).
GO enrichment was calculated and visualized using GOlorize (Garcia et al, 2007). (B) Chemical–genetic space (CGS) simulation with the 50 most sensitive deletion
strains for each of the synergistic drugs as well as the signature deletion strain set. Arrows indicate the number of actual genetic interactions for the different drugs; black
curve represents the background distribution of genetic interactions between two random sample sets of 50 non-essential deletion strains chosen from 1143 strains that
respond to a variety of different chemicals and drugs (Hillenmeyer et al, 2008); dark red curve depicts the same background distribution except that the second sample
set size was chosen to match the size of signature deletion set. Asterisks indicate a P-value o0.05. (C) Drug sensitivity of 11 of the 14 signature deletion strains
identified in this study for 16 previously profiled psychiatric drugs present in the Prestwick library (Ericson et al, 2008). Strong activity refers to compounds that were hits in
the primary screens, that is, at least 2 MAD away from the diagonal, whereas weak activity refers to compounds that showed at least 20% growth inhibition and were 41
MAD away from the diagonal. Source data is available for this figure at www.nature.com/msb.
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inhibitors might exhibit synergy with these compounds.
We assessed interactions with ketoconazole, an imidazole
inhibitor of ERG11, and terbinafine, an inhibitor of the Erg1
squalene epoxidase in Cryptococcus, Candida and Saccharo-
myces. Ketoconazole was synergistic with both psychiatric
drugs in all fungal species, whereas terbinafine showed
synergies with sertraline in Candida and Saccharomyces but
not in Cryptococcus, and synergized with trifluoperazine
only in Saccharomyces (Table IA). These findings suggest that
while mechanisms of synergy are conserved between different
inhibitors of the same enzymes/pathways, species-specific
differences readily emerge with different compounds, likely
due to subtle differences in genetic network structure (Kuo
et al, 2010).
Higher order combinations of synergizers
Compounds that act in an identical manner are in principle
expected not to exhibit synergy but instead should show only
additive dosage effects. We examined pairwise combinations
within four members of the membrane active group (sertra-
line, trifluoperazine, suloctidil and tamoxifen), as well as with
the sphingolipid-selective synergizer L-cycloserine (Table IB).
Despite their partially overlapping genetic profiles, synergistic
interactions in S. cerevisiae were observed between tamoxifen
and trifluoperazine (FICI¼0.5), sertraline and trifluoperazine
(FICI¼0.4) and sertraline and tamoxifen (FICI¼0.5). These
synergies suggested that in addition to the core effects on
membrane permeability, each compound likely elicits one or
more specific effects that contribute to overall mechanism
of action, and that combining these effects results in further
synergism. This observation predicted that higher order
combinations between synergizers might lead to even stronger
growth inhibition. When compound pairs were tested in the
presence of fluconazole in three-way combinations, fungal
growth was often potently inhibited (Table IB). Titration of
fluconazole concentrations revealed exquisite sensitivity
to the suloctidil/trifluoperazine, L-cycloserine/suloctidil and
L-cycloserine/tamoxifen combinations in the presence of just
1/8 MIC fluconazole (Table IB). The L-cycloserine/suloctidil
pair exhibited the most potent synergy with fluconazole
with an FICI of 0.31. These results demonstrate that it is
possible to incrementally build higher order synergistic
combinations based on the subtly different properties of
individual synergizers, even within in the same class.
In vivo synergy in an insect model of infection
The caterpillar of the greater wax moth Galleria mellonella is a
validated in vivo infection model for study of Cryptococcal
virulence, host immune responses to infection and the effects of
antifungal compounds (Mylonakis et al, 2005; Scully and
Bidochka, 2006; Cowen et al, 2009). We assessed the effect of a
synergistic drug combination on the survival rate of G. mellonella
infected with C. neoformans because of the prevalence of this
virulent pathogen in immune-suppressed individuals. G. mello-
nella was inoculated with C. neoformans H99 and subsequently
treated with fluconazole and sertraline, individually and in
combination. The synergistic action of fluconazole and sertraline
was evident in G. mellonella survival rates when compared with
either drug alone (Figure 6A and B). Survival increased by 40%
when treated with fluconazole and sertraline in combination,
with an overall 60% survival rate after seven days of infection
(Po0.02 for fluconazole versus fluconazole/sertraline). These
results demonstrate that potentiators of fluconazole activity
identified in vitro exhibit comparable activity in an animal model
of infection.
Synergistic activity against fluconazole-resistant
Candida isolates
To address whether syncretic compounds can act on clinically
resistant strains, we investigated whether the combination of
fluconazole and sertraline is effective against fluconazole-
resistant clinical isolates of C. albicans (F-07-2007, F-01-2008),
C. glabrata and a resistant control strain C. parapsilosis (ATCC
22019). Sertraline increased the susceptibility of resistant
strains to fluconazole by up to 32-fold (Figure 6C and D;
Supplementary Table S7). In the presence of sertraline, flucona-
zole MIC values ranged from 2 to 8mg/ml, comparable to
wild-type (Caf2-1, MIC¼8mg/ml) and drug pump-deficient
Table I Combinations of syncretic drugs exhibit species-specific synergism and higher order interactions with fluconazole
Terbinafine Terbinafine Ketoconazole Ketoconazole
Trifluoperazine Sertraline Trifluoperazine Sertraline
(A) FICI values for drug combinations in different fungal species
C. neoformans (H99) 2 0.75 0.25 0.38
C. albicans (Caf2-1) 2 0.5 0.38 0.16
S. cerevisiae (BY4741) 0.38 0.52 0.38 0.31
Sert (32) Sert (64) Tri Tri+FLC (4) Tam Tam+FLC (4) Suloc Suloc+FLC (4)
(B) FICI values for double and triple drug combinations in S. cerevisiae
Trifluoperazine 0.38 0.50
Tamoxifen 0.50 0.63 0.50 0.75
Suloctidil 1.25 1.50 2.00 0.56 1.00 0.75
L-Cycloserine 1.25 0.63 1.00 2.00 1.00 0.52 2.00 0.31
(A) FICIs from combination matrix analysis of sertraline, trifluoperazine, with the ergosterol inhibitors terbinafine and ketoconazole in different species. (B) FICIs from
combination matrix analysis of syncretic drugs and higher order combinations. Trifluoperazine (Tri), tamoxifen (Tam), suloctidil (Suloc) and L-cycloserine were
combined as indicated, in the presence or absence of 1/8 MIC fluconazole (4 mg/ml) and assayed for growth inhibition of a S. cerevisiae strain (BY4741). FICI values
o0.5 indicate synergy, values between 0.5 and 1 indicate additivity and values 41 indicate no interaction. Drug concentrations are given in mg/ml.
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(MIC¼2mg/ml) strains of C. albicans. The sertraline/fluconazole
combination was synergistic in both C. albicans clinical isolates
as well as the C. parapsilosis reference strain, but not in the
C. glabrata strain. As noted above, this differential sensitivity
may indicate strain-specific drug effects, or different mechanisms
of drug resistance (Kuo et al, 2010). We conclude that syncretic
activities in reference laboratory strains can be transposed to
drug-resistant pathogens derived from clinical environments.
Discussion
Systematic screens for syncretic combinations
reveal new antifungal chemical space
The combination of known antifungal agents is an established
therapeutic tactic in infectious disease control (Johnson and
Perfect, 2010). Here, we show that antifungal chemical space
can be systematically expanded through the combination of
a known antifungal drug with other bioactive compounds
that do not have antifungal activity per se, including off-patent
drugs previously approved for other indications. Novel
syncretic drug combinations were readily identified in
systematic screens against different fungal pathogens in the
presence of subtherapeutic concentrations of fluconazole.
These chemically diverse drug hits derive from a broad
spectrum of human therapeutic areas that otherwise would
not have been explored by infectious disease clinicians.
Although hits from screens for fluconazole potentiation in
the S. cerevisiae model system can be transposed to pathogenic
fungi (Borisy et al, 2003; Zhang et al, 2007; Jansen et al, 2009;
Epp et al, 2010), our primary screen data reveals considerable
species specificity that by definition cannot be predicted from
model organism drug-gene interactions. Indeed, in our
primary screen, while 58% (25/43) of hits against S. cerevisiae
exhibited synergistic activity against one or more fungal
pathogens, only 19% (25/130) of the total hits against


































































































































































Figure 6 Synergistic activity of sertraline and fluconazole in an in vivo infection model and against clinical isolates. (A) G. mellonella caterpillars were injected with
8 103 cfu C. neoformans H99 on day 0 and drugs alone or in combination (1 mg fluconazole; 26 mg sertraline) on the first day and incubated for 1 week at 371C. Values
are mean of three independent experiments; error bars indicate standard deviation of the mean. (B) Uninfected G. mellonella caterpillars (top); melanization of infected
G. mellonella caterpillars without drug treatment (bottom). (C) Combination matrix assays against drug-resistant Candida strains. Residual growth was plotted as a
function of combinations of two-fold dilutions of each drug. (D) Bliss synergy analysis for combination assays shown in panel (C). The apparent absence of synergy at
the highest fluconazole concentrations for C. albicans and C. parapsilosis is due to growth inhibition caused by fluconazole alone. Drug concentrations are in mg/ml.
Source data is available for this figure at www.nature.com/msb.
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pathogenic species were detected in S. cerevisiae. This
observation underscores the need to undertake primary
screens in the pathogen of interest.
Many syncretic combinations exhibited fungicidal activity, a
highly desirable feature for neutropenic or otherwise immune-
compromised patients. The fungicidal combination of fluco-
nazole and the antidepressant sertraline (Zolofts) was
effective against all species tested, including drug-resistant
clinical isolates of Candida, and in an in vivo insect model of
C. neoformans infection. Therapeutic intervention for fungal
infections of the CNS is a particular clinical challenge because
of the stringent requirement to breach the blood brain barrier.
The fact that sertraline targets serotonin receptors in the CNS
suggests that the sertraline-fluconazole combination may be
effective in the treatment of fungal meningitis.
Molecular mechanisms and prediction of drug
synergism
Genome-wide chemical–genetic profiles of a selected set of
six fungicidal synergizers revealed two different patterns of
synergy. Five compounds—trifluoperazine, tamoxifen, clomi-
phene, sertraline and suloctidil—elicited genetic sensitivities and
cell biological phenotypes associated with a loss of membrane
integrity. The membrane perturbation caused by these com-
pounds may increase susceptibility to accumulation of ergosterol
pathway intermediates, impair fluconazole export by drug efflux
pumps and/or impair import of exogenous ergosterol (Kuo et al,
2010). It is also possible that the synergizers affect active import
of azoles through altered localization of drug transporters or
general membrane perturbation (Mansfield et al, 2010). Notably,
all five membrane active compounds are cationic amphiphilic
drugs (CADs) that intercalate preferentially into one side of the
lipid bilayer, thereby causing membrane expansion and cell wall
stress (Sheetz and Singer, 1974), consistent with the observed
chemical–genetic interactions with NEO1, DRS2, SLT2 and BCK1.
Moreover, genetic resistance to CADs is conferred by perturba-
tion of vesicular membrane biogenesis and/or trafficking (Rainey
et al, 2010). The synthetic lethal genetic interactions that occur
between strains in the fluconazole and membrane active
chemical–genetic profiles retrospectively predicted the synergis-
tic effects of other hits in our primary screens. Moreover, when
combined with another source of chemical–genetic interaction
data (Ericson et al, 2008), the membrane active signature strain
set correctly identified further synergistic hits in our primary
screen data. In addition, the genetic interaction profile of
L-cycloserine correctly predicted a novel synergistic interaction
between the sphingolipid biosynthesis inhibitor myriocin and
fluconazole. The potentiation of fluconazole activity by CADs
and/or inhibition of sphingolipid biosynthesis may allow new
general approaches to antifungal therapy in the clinic. As genetic
and chemical–genetic space is elaborated, mechanism-based
predictive approaches should become a powerful means of
identifying new synergistic combinations.
Species-specific syncretic effects
We observed many genus- and species-specific syncretic
interactions, which reflects differences in the genetic networks
that dictate cellular responses to each compound (Perlstein
et al, 2007). Since divergence from a common ancestor over
100 million years ago, different pathogenic species have
adapted to particular host environments. For example, genetic
plasticity of the fungal mating-type locus affects survival in
mammalian hosts (Nielsen and Heitman, 2007). Develop-
mental system drift (True and Haag, 2001) can also affect drug
susceptibility, as shown by the differential effects of nikkomy-
cin Z on chitin synthase paralogs in Saccharomyces and
Candida (Gaughran et al, 1994; Sudoh et al, 2000). Marked
differences in the transcriptional response of Saccharomyces,
Candida and Kluyveromyces to fluconazole treatment under-
score the quite distinct mechanisms whereby different species
can respond to the same drug (Kuo et al, 2010). More generally,
species differences in the response to chemical perturbation
may reflect the evolutionary plasticity of genetic interaction
networks (Kapitzky et al, 2010). Species-selective antifungal
combinations may afford a means to both increase efficacy and
decrease host toxicity. Systematic analysis of drug–drug
interactions may also provide a means to classify and predict
drug mechanism of action (Yeh et al, 2006; Hopkins, 2008).
Higher order drug–drug interactions
The densely connected structure of genetic networks predicts
that it should be possible to devise higher order drug
combinations with greater selectivity and potency (Sharom
et al, 2004; Agoston et al, 2005; Lehar et al, 2007). That is,
compounds that target multiple genetically redundant parallel
pathways may exhibit n-way synergies. In an initial elabora-
tion of this concept, we found that the combination of a non-
synergistic pair (suloctidil and L-cycloserine, drawn from the
membrane active and sphingolipid target classes, respectively)
with a low dose of fluconazole resulted in a highly potent
three-way synergism. Somewhat unexpectedly given their
shared core genetic profiles, pairwise tests of four compounds
in the membrane active class also revealed synergistic
interactions in the absence of fluconazole. This type of drug–
drug interaction, which has been observed previously with
bacteria and yeast (Yeh et al, 2006; Jansen et al, 2009),
suggests that, aside from the common core profile, each drug
must have additional specific targets that contribute to overall
synergism. The complex genetic profiles of each drug reflect
effects on primary and secondary targets in the cell, drug
metabolism and detoxification, and genetic feedback between
different network elements (Sharom et al, 2004; Kitano, 2007;
Lehar et al, 2008). Other documented interactions between
fluconazole, reactive oxygen species, Hsp90, calcium metabo-
lism and vesicle trafficking may contribute to these complex
interactions (Cowen et al, 2009; Xu et al, 2009; Epp et al,
2010; Gamarra et al, 2010). We note that although shared drug
profiles have been suggested to be predictive of synergistic
interactions (Jansen et al, 2009), in many instances this is not
the case (Yeh et al, 2006). Even drugs with well-documented
mechanisms of action can have substantially different genetic
interaction profiles compared with their presumptive targets.
For example, although the genetic interaction profiles of
fluconazole and its known target ERG11 exhibit significant
overlap, more than half of the interactions are not shared
(Parsons et al, 2004). Recently, it has been shown that drug
combinations can exhibit remarkably selective but unpredict-
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able effects on the abundance of many different proteins
(Geva-Zatorsky et al, 2010).
Therapeutic implications
The benefits of combinatorial anti-infective therapies include
a decrease in the rate of selection of resistant strains, a lower
required dosage of individual drugs, a decrease in host
toxicity and enhanced antimicrobial activity (Sharom et al,
2004; Hopkins, 2008; Lehar et al, 2008). As shown in this study
and elsewhere (Zhang et al, 2007; Jansen et al, 2009; Epp et al,
2010), syncretic combinations of drugs with improved
antifungal properties can be readily identified in both
model fungal species and highly pathogenic clinical isolates.
Importantly, while it is a potential concern that undesirable
side effects may arise from drug combinations, as occurs for
example with known contraindicated drugs, it has recently
been shown that synergistic combinations usually yield
enhanced selectivity without adverse side effects (Lehar
et al, 2009). As noted above, these benefits may include
improved activity in therapeutically recalcitrant tissues,
such as the CNS. These combinatorial principles apply equally
to viral and bacterial pathogens, cancer and other genetic
diseases (Borisy et al, 2003; Fitzgerald et al, 2006; Hopkins,
2008; Lehar et al, 2009).
Materials and methods
Chemicals, high-throughput screens and MIC
determination
Fluconazole was purchased from Sandoz (Quebec, Canada). All other
compounds were obtained from Sigma (St Louis) or Prestwick
Chemicals (Illkirch, France). The Prestwick Chemical library was
screened in duplicate in the presence and absence of 1/2 MIC
fluconazole at a final concentration of 30mM in 384-well flat bottom
microtitre plates. OD600 was determined after 48 h at 30 or 371C. MIC
determinations were based on Clinical and Laboratory Standards
Institute (CLSI) protocols (Eliopoulos and Moellering, 1991; Odds,
2003), with the exception that yeast SC medium was used instead of
mammalian cell RPMI 1640 medium. Overnight cultures in synthetic
complete media (SC: 0.67% Difcot yeast nitrogen base w/o amino
acids, 0.08% amino acid add back and 2% glucose) were diluted in
0.85% NaCl to an OD530 of 0.11, followed by a 1:100 dilution in 0.85%
NaCl, and a final 1:20 dilution in SC media. Two-fold dilution series
(0–128mg/ml) of fluconazole and other antifungal drugs were added to
200 ml of diluted culture in 96-well plates and OD600 determined after
48 h at 30 or 371C. For fluconazole, MIC was set at the lowest
concentration that caused 80% reduction in growth, corresponding to
two on the azole MIC numerical scale. For other drugs, MIC was set as
the lowest concentration that yielded no growth.
Time kill MIC assays were performed at six different concentrations
of compound and fluconazole (fluconazole at MIC, fluconazole at 1/4
MIC, compound at MIC, compound at 1/4 MIC, both fluconazole and
compound at MIC, and both fluconazole and compound at 1/4 MIC).
At 0, 24 and 48 h dilutions from each well were spotted on an SC agar
plate, incubated for 48 h and colony counts determined. A fungicidal
effect was defined as 43log10 (99.9% killing) reduction in CFU/ml at
synergistic concentrations after 24 h incubation.
Synergy matrix assays
Fluconazole and syncretic compounds were two-fold serially diluted
across the rows and columns of a 96-well plate (0–128 mg/ml; for
daunorubicin HCl, terbinafine, trifluoroperazine dihydrochloride and
ellipticine dilutions were from 0–64mg/ml), incubated with fungal
cultures and OD600 determined after 48 h. The FIC index of each drug
combination was determined by adding the individual FIC values, as
calculated by standard CLSI protocols (Eliopoulos and Moellering,
1991; Odds, 2003). To probe chemical interactions between sertraline,
trifluoperazine, L-cycloserine, suloctidil and tamoxifen, checkerboard
assays were carried out between these five compounds in the absence
and presence of 1/2 and 1/8 MIC fluconazole (16 and 4mg/ml,
respectively).
Chemical–genetic profiles and secondary assays
S. cerevisiae deletion collections (MATa haploid and heterozygous
essential deletion strains) were obtained from Research Genetics
(Germany). Compounds were screened at a concentration that caused
B30% growth inhibition at a final DMSO concentration of 0.2%
(Giaever et al, 1999). Deletion pools were grown for 10 generations,
gDNA extracted and barcode tags amplified with fluorescently labeled
UP and DN primers, followed by hybridization of PCR products to
spotted barcode microarrays (Cook et al, 2008). Arrays were scanned
on a GenePix 4200AL and analyzed with GenePix Pro 6.0 software.
Data sets are available at ArrayExpress (E-MTAB-394). Chemical–ge-
netic interactions were confirmed in quantitative growth assays at
301C with continuous shaking at 564 r.p.m. on a Sunrise shaker/reader
(Tecan); OD600 readings were taken every 15 min and values at the end
of logarithmic phase used to calculate the log ratio between deletion
and wild-type strains. For sorbitol rescue, wild-type strains were grown
in the presence of indicated compounds and 1 M sorbitol. For
microscopy, cells were embedded in 1% low melt agarose and stained
with Calcofluor White M2R (Sigma), Mitotracker Green FM (Molecular
Probes) or FM4-64 (Molecular Probes) and imaged at  100 on a Leica
DMI 6000 B microscope with a Hamamatsu Orca ER-AG camera and
Volocity 4 software. Images were deconvolved using AutoDeblur Gold
CWF using 2-D blind deconvolution and 10 iterations per image.
Computational analysis of gene-drug network
interactions
The 50 most sensitive deletion strains from duplicate chemical–genetic
profiles for clomiphene, L-cycloserine, sertraline, suloctidil, tamoxifen
and trifluoperazine were tested against the top 50 fluconazole-
sensitive deletion strains (from replicate arrays at 8 mM). Shared
genetic interactions between the sets of deletion strains were
determined based on genetic interaction data obtained from
BioGRID (Breitkreutz et al, 2008; BIOGRID release 2.62, http://www.
thebiogrid.org). Visualization of bipartite graphs and simulations was
performed with an online tool available at http://tyerslab.bio.ed.
ac.uk/tools/genelookup_bipartite.php. Simulations based on CGS
were derived from 1143 non-essential deletion strains that respond
to various drug treatments (Hillenmeyer et al, 2008). For each drug
pair, control gene sets of the same size were picked at random and the
number of genetic interactions counted to generate a background
distribution of the number of interactions that would occur by chance,
based on the compiled genetic interaction data. This distribution was
used to calculate the P-value for each drug pair. For PPP, the chemical–
genetic interactors of fluconazole and each of the synergistic drugs
were pooled, randomly assigned to two groups and genetic interac-
tions counted to obtain a background distribution for each drug pair.
The definition of the signature deletion strain set was based on
confirmatory quantitative growth curve assays (Figure 3D). For both
the CGS and PPP methods, 10 000 simulations were conducted for each
drug pair. To predict potential synergistic candidates based on overlap
with published chemical–genetic profiles (Ericson et al, 2008), we
used a binary data matrix based on a Z-score cutoff of ±3. The
significance of enrichment was calculated based on the number of
genes that overlapped with the signature strain set; a subset of 4 out of
11 genes was significant with a P-value o0.05.
Insect larvae assays
Ten weight matched (250–400 mg/worm) G. mellonella caterpillars
per dish were inoculated with C. neoformans H99 and subsequently
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injected with different combinations of compound, fluconazole and/or
control solutions (Mylonakis et al, 2005). Over a 7-day period,
caterpillars were examined visually for discoloration due to melaniza-
tion and for failure to respond to touch as an inviability end point.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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